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DNA methylation is a key epigenetic mark which undergoes global reprogramming 
during early mammalian embryonic development, resulting in almost complete erasure 
of the mark after fertilisation of the zygote. Genome-wide patterns of DNA 
methylation are subsequently re-established in the implanting blastocyst by de novo 
DNA methyltransferases Dnmt3a and Dnmt3b along with their catalytically inactive 
co-factor Dnmt3l, while these DNA methylation patterns are maintained through cell 
divisions by maintenance methyltransferase Dnmt1. The exact mechanisms by which 
these DNA methyltransferase enzymes are targeted to specific genomic regions remain 
unclear, but may involve interaction with modified histones and/or the participation of 
co-factors. Lsh (lymphoid specific helicase), a putative chromatin remodelling 
helicase, has been implicated in facilitating de novo methylation, as Lsh knockout 
embryos and derived somatic cell lines display substantial but specific DNA 
methylation losses at repetitive elements and single copy genes.  
This study aims to define the requirement for Lsh in establishing de novo DNA 
methylation and gene expression patterns during the early stages of mouse embryonic 
development. The ‘2i’ culture system using two small molecule kinase inhibitors was 
harnessed to convert lsh-/- mouse embryonic stem cells (mESCs) to a hypomethylated 
‘ground state’ of pluripotency. Culture conditions were then altered to transition these 
ground state mESCs to cells representing later, more methylated stages of development 
(‘serum’ mESCs, epiblast stem cells and embryoid bodies). Implementation of this 
model system suggests that Lsh does not contribute to DNA methylation establishment 
in a pluripotent context, but rather is important for facilitating de novo DNA 
methylation during differentiation to culture models representing later developmental 
stages. These investigations also reveal that Lsh differentially regulates DNA 
methylation at major and minor satellite repeats depending on cellular context, and 





DNA methylation is an essential biological function in which a chemical tag (a methyl 
group) is added to DNA, affecting many important processes such as how genes are turned 
off/on and mammalian embryo development. During the early stages after an embryo is 
fertilised, DNA methylation undergoes dramatic changes during which it is erased then 
re-established in precise patterns throughout the genome. This process controls what genes 
are turned on and off in highly tuneable stem cells of the embryo to form specific tissues 
such as brain, skin and kidney. However, it is not fully understood how DNA methylation 
alterations are regulated and exactly what proteins are involved.  
A protein called LSH is proposed to be involved in re-establishing methylation during 
mammalian development, as previous gene knockout studies have shown that Lsh is 
important for normal development and for establishment of DNA methylation. The exact 
mechanism by which Lsh contributes to these processes is unknown. During my PhD, I 
aimed to determine the requirement for Lsh in re-establishing DNA methylation patterns 
in cell culture models equivalent to the early stages of mouse embryonic development. 
Technology to examine embryo development in real-time remains lacking, therefore I 
used in vitro mouse embryonic stem cells lacking a functional Lsh gene to observe the 
impact of its absence upon DNA methylation and gene expression. I then altered cell 
growth conditions to mimic the stages of embryo development before and after which 
DNA methylation re-establishment occurs. This revealed that LSH is required to establish 
full DNA methylation in stem cells just before they begin to form specific tissues. 
This work has contributed to a better understanding of the proteins involved in establishing 
DNA methylation during the early stages of embryonic development. Since starting my 
PhD, mutations in Lsh have been identified to cause the rare immune disorder ICF 
syndrome (Immunodeficiency, Centromere instability and Facial anomalies syndrome), a 
key feature of which is reduced DNA methylation at certain regions in the DNA of affected 
individuals. Therefore, my research has implications for genetic disease by providing 
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Chapter 1. Introduction 
1.1 Epigenetics 
The development of a complex, multi-cellular adult organism from a single cell is a 
highly ordered, reproducible process involving coordination between an array of 
cellular systems. One of the key cellular systems that is hypothesised to direct 
developmental decisions during this highly-organised process is the heritable, covalent 
modification of DNA and histones, now collectively termed as “epigenetics”. The 
embryologist Conrad Waddington introduced the term “epigenetics” in 1942, 
combining the concepts of “epigenesis” (the development of an organism) and 
“genetics” (the study of heredity and variation). Waddington defined epigenetics as 
“the whole complex of developmental processes” connecting genotype to phenotype, 
and further went on to use the word “epigenotype” to describe the biological networks 
linking disturbances in genotype to observable abnormal phenotypes (Waddington, 
1942). As an embryologist, Waddington’s definition of epigenetics was focused 
around the process of development. The definition of epigenetics has itself developed 
and been extended over time to give us the generally accepted modern definition that 
epigenetics is the study of stable changes in gene expression that are not explained by 
changes in DNA sequence (Bird, 2007). Although epigenetic mechanisms also 
contribute to genome regulation in a somatic cell context, it could be argued that the 
most impressive example of epigenetics in action is during embryogenesis – where 
epigenetic modifications are dramatically remodelled to orchestrate the differentiation 
of a fertilised zygote into an array of highly-specialised cells that constitute the whole 
adult organism. This concept is illustrated in Waddington’s often-cited model of the 
“epigenetic landscape” (Figure 1.1 A), which depicts the apparently irreversible fate 
decisions that a cell is required to make during development. These decisions are 
underpinned by the role of genes, with complex networks of expression acting to 
determine the pathway the cell will take during progression through development 




Figure 1.1 Waddington's ‘epigenetic landscape’, illustrating the concept of 
epigenetic restriction of developmental potential. A. Cellular development is 
represented by a ball rolling down a landscape with branching valleys and ridges, 
signifying the apparently irreversible fate decisions of a developing cell, and the 
progressive restriction of cellular potential. B. A visual representation of the complex 
network of underlying genes that act to structure this epigenetic landscape, influencing 
cell fate decisions and developmental progression. Figures taken from Waddington 
(1957). 
There are now known to be an array of molecular mechanisms involved in epigenetic 
regulation of the genome. The best studied of these are the direct covalent modification 
of DNA and of histones, the proteins which DNA are wrapped around to organise and 
package genetic information in the cell. Research into these two epigenetic 
mechanisms progressed separately throughout the 1970s and 80s, with the term 
epigenetics only being adopted to describe research of these modifications in the 
1990s, with a rapid increase in research under this term ensuing from the year 2000 
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(Deichmann, 2016). In recent years, there has also been increasing evidence 
uncovering the importance of non-coding RNAs (ncRNAs) in epigenetic regulation of 
gene expression, highlighting the interplay between the functional roles of ncRNAs 
and the covalent modification of DNA and histones (reviewed by Costa, 2008).  
My PhD has involved studying the early stages of development, with a primary focus 
on the establishment of DNA methylation - the covalent addition of a methyl group to 
the fifth position of cytosine - and the factors involved in orchestrating its deposition. 
In particular, I explored the contribution of a DNA methylation co-factor and putative 
chromatin remodeller Lsh (lymphoid specific helicase) to DNA methylation 
establishment in culture systems representing early embryonic development. This 
introduction will provide an in-depth discussion of DNA methylation, along with the 
current knowledge and proposed mechanisms of Lsh involvement in its establishment, 
touching on its potential role in regulation of chromatin structure. I will also summarise 
the dynamic reprogramming of DNA methylation during the early stages of 
development, outlining the culture models utilised throughout my PhD to investigate 
the role of Lsh in DNA methylation establishment in a developmental context. 
1.2 Chromatin structure and function 
The mammalian genome is organised and packaged into chromatin, the structure of 
which assists regulation of transcription through stable, precise control of a vast array 
of regulatory elements across the genome. However, the structure of chromatin must 
retain the ability to undergo dynamic remodelling during periods where extensive 
changes in gene expression are required, such as those observed in cellular transitions 
during embryonic development.  
The organisation of chromatin is hierarchical, from ‘higher-order’ structures where 
chromatin is packaged into distinct compact chromosomes, down to lower-level 
organisation where DNA is wrapped around histone proteins to form ‘nucleosomes’. 
Nucleosomes are the fundamental repeating units of chromatin and comprise an 
octamer of the four core histone proteins – H2A, H2B, H3 and H4 – around which 147 
base pairs (bp) of DNA are wrapped (Kornberg and Thomas, 1974; Burlingame et al., 
1985; Luger et al., 1997). The core histones are predominantly globular, apart from an 
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unstructured N-terminal ‘tail’ which extends out from the nucleosome (Luger et al., 
1997). ‘Linker’ histones – members of the histone H1 family - are structurally distinct 
from nucleosomal histones and interact with the DNA between nucleosomes and core 
histone H2A, stabilising both the nucleosome and condensed higher-order chromatin 
structures (F., Koller and Klug, 1979; reviewed by Robinson and Rhodes, 2006). A 
fundamental functional feature of histones, and in particular their flexible N-terminal 
tails, is that they can be adorned with a vast array of post translational modifications, 
influencing chromatin structure and gene expression (Strahl and Allis, 2000). In terms 
of epigenetic regulation of transcription, the two main functionally pertinent histone 
modifications are methylation and acetylation of particular residues, although other 
modifications such as ubiquitylation also have functional relevance in selected 
contexts. These histone modifications act to regulate transcription primarily through 
directly disrupting chromatin contacts or influencing the recruitment of functional 
non-histone proteins (reviewed by Kouzarides, 2007). Some of the key histone 
modifications and their contribution to establishment and maintenance of chromatin 
structure are outlined in the following sections.  
1.2.1 Classes of chromatin 
Chromatin in mammals can be structurally and functionally partitioned into two 
categories: ‘euchromatin’, which has a relatively open structure, permissive for high 
rates of gene expression, and ‘heterochromatin’, which is much more condensed and 
associated with transcriptional repression. The physically compact state of 
heterochromatin is reflected by its intensely dark staining with 4,6-diamino-
phenylindole (DAPI) and increased resistance to nucleases (Heitz, 1928; Wallrath and 
Elgin, 1995). This compressed structure reduces the accessibility of DNA to regulatory 
proteins and transcriptional machinery, resulting in silencing of genes that reside in 
these heterochromatin regions. Another inherent property of heterochromatin is its 
ability to spread along chromosomes, demonstrated by the condensation and 
subsequent silencing of euchromatic transgenes placed in the vicinity of endogenous 
heterochromatic regions (Wallrath and Elgin, 1995). 
Although heterochromatin is primarily associated with transcriptional repression of 
the genes that it encapsulates, there remains the requirement for dynamic reactivation 
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of some genes in certain cellular contexts. This is exemplified in the further sub-
division of heterochromatin into ‘constitutive’ and ‘facultative’ heterochromatin, both 
with distinct properties and epigenetic signatures. Facultative heterochromatin mostly 
forms at regions that require dynamic regulation of chromatin structure and 
transcription in response to developmental and environmental stimuli, including cell-
type specific genes and regulatory elements such as enhancers (Brown, 1966; Trojer 
and Reinberg, 2007). In contrast, the large proportion of repeat-rich sequences in the 
genome require stable transcriptional silencing across all developmental lineages to 
prevent their retrotransposition and self-duplication, thereby preserving genome 
integrity. This is achieved by packaging them into highly condensed inaccessible 
constitutive heterochromatin, protecting the DNA from contact with the transcriptional 
machinery or regulatory proteins (Saksouk, Simboeck and Déjardin, 2015).  
1.2.2 Heterochromatin formation 
Constitutive heterochromatin is characterised by a distinct profile of histone 
modifications. The most prominent of these is the global absence of histone acetylation 
(generally associated with actively transcribed euchromatic regions). This is usually 
accompanied by an enrichment of trimethylation of lysine 9 on histone H3 
(H3K9me3), a typical mark of constitutive heterochromatin (Noma, Allis and Grewal, 
2001; Martens et al., 2005). This histone modification signature is established through 
the concerted actions of histone deacetylases (HDACs) and histone methyltransferases 
(HMTs), resulting in hypoacetylation of histones and hypermethylation of H3K9. In 
mammals, methylation of H3K9 is catalysed by members of the SET-domain 
containing family of HMTs (chiefly SET domain bifurcated 1, SETDB1) and related 
enzymes Suppressor of Variegation 3-9 Homologs 1 and 2 (SUV39H1 and 
SUV39H2). These enzymes contribute to the majority of H3K9me2 and H3K9me3 
(Rea et al., 2000; Schultz et al., 2002), while GLP and G9a (also referred to as 
euchromatic histone methyltransferase 1 and 2, EHMT1 and EHMT2 respectively) 
catalyse H3K9me1 and H3K9me2 at heterochromatin (Tachibana et al., 2005). These 
histone methylation marks can be self-propagated by a mechanism whereby the HMTs 
bind to existing methylated H3K9 and methylate adjacent nucleosomes, promoting 
spreading of the mark throughout the region (Zhang et al., 2008). H3K9me2/me3 can 
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also be bound by the chromodomain of heterochromatin protein 1 (HP1), which can 
self-oligomerise and form a scaffold to recruit further chromatin modifying proteins 
including H3K9 methyltransferases and HDACs, forming a feedback loop which 
further enhances the spread of compacted heterochromatin (Bannister et al., 2001; 
Canzio et al., 2011). High levels of DNA methylation are a hallmark of this condensed 
heterochromatin and depend on the presence of the SUV39 and G9a enzymes, 
highlighting the interplay between the two repressive epigenetic systems (Lehnertz et 
al., 2003; Epsztejn-Litman et al., 2008). This epigenetically repressed state is stably 
maintained throughout cell divisions to ensure continued suppression of the underlying 
repetitive sequences. This involves the incorporation of parental histones harbouring 
existing modifications into the daughter strands during DNA replication, which in turn 
stimulates recruitment of H3K9 methyltransferases and re-establishment of the 
compacted heterochromatic state (Ragunathan, Jih and Moazed, 2014). 
The formation of facultative heterochromatin involves a different set of proteins to 
establish a condensed repressive chromatin state at specific genes in the appropriate 
developmental context (reviewed by Trojer and Reinberg, 2007). The epigenetic 
signature that defines facultative heterochromatin is less-well characterised, although 
the repressive H3K27me3 mark is prominent at the promoters of lineage-specifying 
genes such as the homeobox (Hox) family and correlates with transcriptional silencing. 
This mark is catalysed by the Polycomb repressive complex 2 (PRC2), which plays a 
key role in chromatin compaction and heterochromatin assembly at its target genomic 
loci (Boyer et al., 2006; Margueron et al., 2008; Margueron and Reinberg, 2011). 
Interestingly, genome-wide H3K27me3 distribution is dependent on global DNA 
methylation levels (Lynch et al., 2012; Reddington et al., 2013). 
1.2.3 Bivalent chromatin 
A combination of both ‘active’ and ‘repressive’ histone marks in the same genomic 
region defines a unique chromatin state referred to as ‘bivalent’ chromatin (Bernstein 
et al., 2006; reviewed by Voigt, Tee and Reinberg, 2013). Bivalent chromatin contains 
active H3K4me3 imposed by the SET/mixed lineage leukaemia (MLL) HMT and 
repressive H3K27me3 catalysed by PRC2. This specific chromatin signature is present 
primarily at the promoters of developmentally-regulated genes in embryonic stem cells 
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(ESCs; Mikkelsen et al., 2007). It is thought that these genes that are involved in cell 
fate decisions are repressed by H3K27me3 in pluripotent cells, but remain ‘poised’ for 
timely activation in response to differentiation signals due to the presence of H3K4me3 
(Bernstein et al., 2006). This represents another level on which histone modifications 
contribute to dynamic regulation of chromatin structure and gene expression during 
development and differentiation. 
1.2.4 Nucleosome remodelling 
The organisation of the genome into nucleosomes and higher-order chromatin 
structures is necessary to condense more than 2 metres of DNA into a single nucleus 
less than 10 microns in length. However, the compaction and association of DNA with 
many histone and non-histone chromatin components can obstruct access and 
interpretation of the DNA sequence. The ability to dynamically alter chromatin 
structure in response to environmental, metabolic and developmental stimuli is critical 
for quick modification of transcriptional programmes. This alteration of chromatin 
structure is primarily achieved through the action of a family of adenosine triphosphate 
(ATP)-dependent chromatin remodelling enzymes. These ATPases can be recruited to 
specific genomic loci through recognition of histone modifications, allowing targeted 
regulation of chromatin structure. Once recruited, these chromatin remodellers 
interrupt histone-DNA interactions in an ATP-dependent manner through disrupting, 
assembling, exchanging or mobilising nucleosomes (Becker and Hörz, 2002; Clapier 
and Cairns, 2009). These ATP-dependent chromatin remodelling enzymes are part of 
large, highly-conserved multi-subunit complexes, of which there are 4 main families 
of chromatin remodelling complexes in eukaryotes, the best characterised being the 
switch/sucrose non-fermentable (SWI/SNF) complex first described in yeast (Winston 
and Carlson, 1992). 
1.2.5 Repetitive elements 
Sophisticated chromatin organisation mechanisms such as those described above are 
required to regulate access to the diverse array of sequences present in the mammalian 
genome. The accumulation of large numbers of repetitive and noncoding sequences 
contributes to the high complexity of the mammalian genome and the need for multiple 
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interacting regulatory systems (Franke et al., 2017). In mice in particular, repetitive 
and noncoding sequences comprise the majority of the genome – 44% repetitive and 
52% noncoding – while only around 4% of the genome is accounted for by protein 
coding genes (Waterston et al., 2002).  
The repetitive sequences in the mouse genome are also diverse, ranging from large 
arrays of repeats associated with centromeres and telomeres, to shorter transposable 
elements interspersed throughout the genome, sometimes interrupting protein coding 
genes (outlined in Figure 1.2, Waterston et al., 2002). The role of the clustered arrays 
of repeat elements in the formation of constitutive heterochromatin at centromeres and 
telomeres is well-characterised (Almouzni and Probst, 2011). The assembly of 
heterochromatin at these tandem repeats, referred to as major and minor satellites, is 
crucial for maintenance of genome stability and repression of transposable elements 
(Ting et al., 2011; Garcia-Perez, Widmann and Adams, 2016; reviewed by Crichton 
et al., 2014). Shorter interspersed repeats originate largely from intact 
retrotransposons, and most can be defined as long or short interspersed nuclear 
elements (LINEs and SINEs), or endogenous retroviruses (ERVs), a repeat family 
mainly comprised of intracisternal a particle (IAP) elements which contain long 
terminal repeats (LTRs; Stocking and Kozak, 2008). Repression of these interspersed 
repeats is less well defined, although it is equally important to suppress their 
retrotransposition, which can result in genomic instability and mutations affecting 
genes and regulatory elements (Burns and Boeke, 2012). However, despite the many 
detrimental effects of repeat element transposition, there is evidence for its 
involvement driving genome evolution, as well more nuanced roles in transcriptional 




Figure 1.2. Overview of the distribution, organisation and abundance of repetitive 
elements in the mouse genome. Top panel - the general distribution of repetitive 
elements is illustrated in the schematic of a mitotic chromosome, highlighting the 
centromeric and pericentromeric localisation of minor and major satellites, respectively. 
Lower panels – summary of the main repeat classes demonstrating repeat organisation, 
copy number and overall abundance in the mouse genome. The numerical values and 
the concept for this figure was taken from Martens et al. (2005). 
1.3 DNA methylation 
DNA methylation is an epigenetic mechanism involving covalent addition of a methyl 
group to cytosine, primarily in the context of CpG dinucleotides in the genome. In 
1975, this modification was described for the first time as an epigenetic mark that 
could be established de novo or stably inherited through somatic cell divisions, in turn 
enabling maintenance of gene expression patterns through mitotic divisions (Holliday 
and Pugh, 1975; Riggs, 1975). These key papers were also the first to associate the 
mark with transcriptional repression. This association was further established by 
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studies showing that in vitro methylated DNA is transcriptionally inactive following 
transfection into Xenopus oocytes (Vardimon et al., 1982) or mammalian cell lines 
(Stein, Razin and Cedar, 1982), functionally linking DNA methylation to 
transcriptional repression. This contribution to gene silencing was found to be enacted 
partly through the formation of transcriptionally inactive chromatin, promoting stable 
maintenance of gene expression signatures (Wolffe and Matzke, 1999). These findings 
uphold the view that the fundamental role of DNA methylation involves transcriptional 
repression and heritable maintenance of a silenced chromatin state (Bird, 1984).  
However, the relationship between DNA methylation and gene silencing has proved 
difficult to decipher. 
1.3.1 DNA methylation – the mark 
DNA methylation is the covalent addition of a methyl group to the fifth carbon of the 
pyrimidine ring of cytosine (5-methylcystosine, 5-mC). This reaction is catalysed by 
DNA methyltransferase (DNMT) enzymes and requires co-substrate S-adenosyl 
methionine (SAM) as a methyl group donor (Figure 1.3). 5-mC is a relatively stable 
mark and is present at similar levels across most adult tissues. However, the levels of 
DNA methylation can also be dynamically regulated, with the clearest example of this 
being during the early stages of embryonic development. The molecular mechanisms 
underlying this dynamic regulation have been further elucidated in recent years due to 
the discovery of a potential de-methylation pathway involving 5-mC derivatives.  
 
Figure 1.3. DNA methylation mechanism. The covalent addition of a methyl group to 
the fifth carbon of cytosine is catalysed by DNMT enzymes, using co-substrate SAM as 
a methyl group donor. 
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1.3.2 DNA de-methylation and 5-hydroxymethylcytosine 
DNA methylation is a potentially reversible epigenetic mechanism. Genomic regions 
can become de-methylated through a passive process, where 5-mC is diluted due to 
DNA replication without maintenance methylation. However, there has been much 
focus on active mechanisms for DNA methylation in recent years due to the 
rediscovery of 5-hydroxymethylcytosine (5-hmC) and further derivatives 5-
formylcytosine (5-fC) and 5-carboxylcytosine (5-caC), which are proposed to 
represent intermediates of an active de-methylation cycle (Kriaucionis and Heintz, 
2009; He et al., 2010; Ito et al., 2011). 5-mC can be oxidised to 5-hmC and further 
converted to 5-fC and 5-caC by the TET (ten eleven translocation) family of 
dioxygenases (Ito et al., 2011). These further derivatives can be specifically recognised 
and excised from the DNA by thymine-DNA glycosylase (TDG) and replaced with an 
unmodified cytosine, thus completing the de-methylation cycle (He et al., 2010). This 
process allows dynamic regulation of DNA methylation without the need for DNA 
replication.  
As well as being an intermediate in a de-methylation pathway, 5-hmC is proposed to 
be a relatively abundant mark with epigenetic functions in its own right. Unlike the 
fairly uniform levels of 5-mC across tissue and cell types, 5-hmC levels have been 
shown to vary with tissue type and are most abundant in neuronal tissues (Globisch et 
al., 2010; Nestor et al., 2012). Furthermore, 5-hmC has been found to be present at 
gene bodies, where it correlates with levels of transcription (Nestor et al., 2012). These 
findings link 5-hmC (and/or the TET enzymes) with regulation of transcription, 
perhaps in particular cellular contexts where the mark is most abundant.  
1.3.3 The roles of DNA methylation 
The fundamental function of DNA methylation is regarded as promoting stable 
epigenetic repression of transcription, although the generality of this function across 
all biological processes is under question. Indeed, genome-wide analysis of promoter 
methylation implies that only a small subset of genes are transcriptionally regulated 
by DNA methylation (Weber et al., 2007; Hackett et al., 2012; reviewed by Weber 
and Schübeler, 2007 and Reddington, Pennings and Meehan, 2013). However, the 
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crucial role of DNA methylation in gene expression regulation is clearly demonstrated 
in a couple of key biological contexts. These include the processes of X-chromosome 
inactivation and imprinting, where the repressive action of DNA methylation is 
demonstrated most strongly and on a large scale, employing similar mechanisms to 
ensure appropriate dosage compensation is established during early embryonic 
development. 
1.3.3.1 X-chromosome inactivation 
X-chromosome inactivation is a dosage compensation mechanism in which one of the 
two X-chromosomes present in female mammalian cells is transcriptionally silenced, 
forming an inactive X-chromosome (Xi). In the early stages of embryogenesis, the 
paternal X-chromosome is preferentially silenced then reactivated in the epiblast of 
the blastocyst, where one X-chromsome is then randomly chosen for inactivation (Mak 
et al., 2004). This inactive Xi established in the cells of the epiblast, is faithfully 
maintained in all the somatic lineages that these cells generate and throughout the 
lifespan of the adult organism. 
The repression of the Xi is mediated by the expression of the functional long non-
coding RNA (lncRNA) Xist. Xist RNA triggers transcriptional silencing in cis by 
coating the chromosome from which it’s expressed, inducing the acquisition of 
repressive histone marks and the subsequent formation of a silent chromatin state 
(Clemson et al., 1996; Kohlmaier et al., 2004). Heterochromatin assembly at the Xi is 
followed by changes in DNA methylation patterns across both X-chromosomes 
(Hellman and Chess, 2007; Sharp et al., 2011). DNA methylation is established at 
many promoters of genes that are silenced on the Xi. Depletion of promoter 
methylation experimentally through 5-aza-2’-deoxycytidine (5-aza dC) treatment or 
Dnmt1 conditional deletion results in transcriptional reactivation of these genes and 
decondensation of the Xi over time (Sado et al., 2000; Csankovszki, Nagy and 
Jaenisch, 2001). This indicates that DNA methylation is required for stable 
maintenance of gene repression and the heterochromatic state on the Xi. On the active 
X-chromosome (Xa), global DNA methylation levels are twice as those of the Xi and 
show a very different distribution of promoter hypomethylation coupled with 
extensive gene body 
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 methylation, which is thought to support expression of active genes on the Xa 
(Hellman and Chess, 2007; Sharp et al., 2011). Finally, DNA methylation contributes 
to the regulation of Xist expression itself, as de novo methylation of the Xist promoter 
acts to repress aberrant Xist expression from the second X-chromosome (Sado et al., 
2004). 
1.3.3.2 Genomic imprinting 
Genomic imprinting is an epigenetically regulated process that results in the mono-
allelic expression of genes in a parental-origin-specific manner. This mono-allelic 
expression relies on DNA methylation to mark, or ‘imprint’, either the maternal or 
paternal allele so that the chromosome homologues can be distinguished from one 
another. These differentially methylated regions (DMRs) at imprinted genes are 
established during gametogenesis in a sex-specific manner and are maintained in the 
resulting offspring (reviewed by Ferguson-Smith, 2011). 
Transcriptional regulation of imprinted genes by DNA methylation is often complex 
and varies depending on the genomic loci and cellular context. The expression of a 
subset of imprinted genes can be directly repressed by methylation at DMRs that 
overlap with the gene promoter. However, many imprinted genes are regulated through 
methylation of a genomic region called the imprinting control region (ICR), which can 
control expression of a gene or a cluster of genes located more than a megabase away 
(Lin et al., 2003; Williamson et al., 2006). The regulation of the Igf2-H19 locus is a 
well-studied example of how differential ICR methylation can affect the mono-allelic 
expression of each gene. The unmethylated ICR on the maternal allele binds chromatin 
insulator CCCTC-binding factor (CTCF), which in turn blocks the interaction of Igf2 
with a shared set of distal enhancers, effectively silencing Igf2 while H19 expression 
is permissible. Reciprocally, CTCF cannot bind to the methylated ICR on the paternal 
allele, allowing expression of Igf2 through interaction with the distal enhancers, while 
H19 expression is blocked (Bell and Felsenfeld, 2000; Hark et al., 2000). Another 
transcriptional silencing mechanism involving DNA methylation of ICRs is the 
regulation of functional lncRNA expression, whose promoters often overlap with 
ICRs. When expressed, these lncRNAs impress a repressive chromatin state in cis that 
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can encompass and silence multiple imprinted genes through acquisition of histone 
modifications and histone modifying enzymes (Nagano et al., 2008).  
These examples of X-inactivation and imprinting both highlight common mechanisms 
employed to initiate and maintain long-term mono-allelic silencing through the 
interplay of DNA methylation, chromatin structure and lncRNA expression. 
1.3.4 Physiological consequences of DNA methylation perturbation 
The selective expression and repression of genes in a developmental stage- and cellular 
context-dependent manner is essential for the correct development and function of an 
organism. The gene mis-expression that is apparent in many human diseases and 
cancer has been linked to perturbations in DNA methylation patterns globally and in 
the vicinity of the mis-expressed genes.  
The importance of the DNA methylation machinery in normal development and 
function is highlighted by the severity of the mouse mutant phenotypes, such as the 
embryonic lethality of Dnmt1 null mice (Table 1.1). In Dnmt1 null ESCs, which show 
a 70% reduction in normal cytosine methylation levels, the rate of mutations that 
involve gene rearrangements is increased ten-fold (Chen et al., 1998). There is also a 
massive upregulation of IAP elements in Dnmt1-/- embryos and somatic cells, which 
has been proposed to play a part in the increased genomic instability (Walsh, Chaillet 
and Bestor, 1998; Dunican et al., 2013). Missense mutations in de novo 
methyltransferase Dnmt3b are also associated with genome instability as they are 
reported to cause immunodeficiency-centromeric instability-facial anomalies (ICF) 
syndrome, a rare autosomal recessive disorder characterised by chromosomal 
rearrangements due to hypomethylation of pericentromeric repeats (Hansen et al., 
1999; Xu et al., 1999; Ehrlich et al., 2008).  
Hypomethylation of transposable and repetitive elements has also been linked to 
genome instability in the context of cancer, and is known to contribute to cell 
transformation and cancer progression (Shukla et al., 2013). The general 
hypomethylation that is observed throughout the genome in cancer is accompanied by 
the striking hypermethylation of many normally unmethylated CpG islands (CGIs). 
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This occurs largely at the promoters of tumour suppressor genes as a result of growth 
selection and acts to promote tumorigenesis (reviewed by Baylin and Jones, 2011 and 
Sproul and Meehan, 2013). However, this view has been challenged by the observation 
that most of the genes associated with affected CGIs are already silenced prior to 
aberrant hypermethylation during cancer development, de-linking transcriptional 
silencing from aberrant methylation (Sproul et al., 2011, 2012). While mutations in 
the DNA methylation machinery resulting in aberrant DNA methylation patterns have 
been linked with acute myeoloid leukaemia and colorectal cancer, aberrant epigenetic 
programs in cancer are more likely a consequence of genetic changes (Kanai et al., 
2003; Ley et al., 2010; Yan et al., 2011). 
The disruption of normal patterns of DNA methylation or its writers are associated 
with many more diseases and disorders, as well as cancer and genomic instability. This 
emphasises the critical role of this epigenetic mechanism in multiple physiological 
processes (reviewed by Timp and Feinberg, 2013; Feinberg, Koldobskiy and Göndör, 
2016). 
1.3.5 DNA methylation distribution across the mammalian genome 
Examination of the distribution of DNA methylation throughout the genome can 
provide insight and understanding into the function of DNA methylation. Techniques 
involving next-generation sequencing to study genome-wide methylation have rapidly 
improved over the past decade, allowing more extensive, in-depth and high-resolution 
characterisation of the methylome than ever before. This has been harnessed to study 
genome-wide methylation patterns across the genomes of a variety of cell types and 
organisms, providing further insight into DNA methylation function at various classes 
of elements throughout the genome.  
1.3.5.1 CpG islands 
DNA methylation in the mammalian genome is widespread, with generally between 
60 and 80% of CpGs being methylated, representing around 4% of all cytosines in the 
genome (Gruenbaum et al., 1981). This widespread methylation is not uniformly 
distributed throughout the genome, but rather exhibits a bimodal pattern of 
distribution. Almost all the CpGs in the mammalian genome (which is itself globally 
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depleted of CpGs) are methylated. However, there is an enrichment of largely 
methylation-resistant CpGs in genomic regions referred to as CpG islands (CGIs). 
These short (approximately 1 kilobases) CG-dense sequences overlap with the 
promoter regions of more than half the genes in the mammalian genome (‘promoter 
CGIs’), and are particularly prevalent at genes involved in housekeeping and 
developmental regulation (Larsen et al., 1992; Deaton and Bird, 2011). There are also 
a large proportion of CGIs that occur in intergenic and intragenic regions not 
associated with a promoter (‘orphan CGIs’). These orphan CGIs share epigenetic 
features with promoter CGIs but are found to be more frequently methylated during 
development (Illingworth et al., 2010).  
The preservation of the CpG-rich status of CGIs in contrast to the rest of the genome 
can be accounted for by the constitutive hypomethylation of these regions, as 
methylated cytosine can be spontaneously or enzymatically converted to thymine by 
deamination, resulting in CpG loss throughout the genome (Deaton and Bird, 2011). 
The maintenance of CGI hypomethylation is thought to be partly accounted for by the 
constitutive methylation of CGIs at H3K4 (predominantly H3K4me2), acting to 
prevent the association of DNA methyltransferases with CGIs (Weber et al., 2007; 
Meissner et al., 2008). This is demonstrated by the action of DNA methyltransferase 
co-factor Dnmt3l, which binds unmodified H3K4 only, initiating de novo DNA 
methylation at its intended targets via Dnmt3a (Jia et al., 2007; Ooi et al., 2007). 
Although most promoter-associated CGIs are hypomethylated in normal tissues, a 
small subset are methylated (< 3%), which correlates with transcriptional repression 
of the gene (Illingworth et al., 2008; Maunakea et al., 2010; Hackett et al., 2012). The 
repressive function of DNA methylation at promoter CGIs is most powerfully 
demonstrated during the processes of X-inactivation and genomic imprinting, where 
their methylation results in robust and long-term silencing of the associated gene (Li, 
Beard and Jaenisch, 1993; Augui, Nora and Heard, 2011). Conversely, the 
consequences of aberrant CGI promoter methylation are clearly demonstrated in the 
context of cancer, where CGI hypermethylation in combination with gene body 
hypomethylation result in the transcriptional silencing of critical growth regulators 
such as tumour suppressor genes. 
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1.3.5.2 DNA methylation at gene bodies and genome-wide 
DNA methylation patterns beyond the well-studied promoters are less well-
characterised, but genome-wide studies have uncovered some intriguing insights into 
potential links between DNA methylation and transcription in the past few years. In 
contrast to the methylation-resistant CpG-rich CGIs described previously, the 
remainder of the mammalian genome is CpG-poor, contains multiple repetitive and 
transposable elements and exhibits high levels of DNA methylation. Most gene bodies 
exhibit these features and display extensive methylation. Unlike in CGI promoter 
regions however, this methylation is not associated with repression. Far from it, gene 
body methylation has been shown to be a feature of transcriptionally active genes 
(Wolf et al., 1984). This was elegantly demonstrated in a study that comparatively 
mapped DNA methylation along the active and inactive X-chromosomes in human 
cells, correlating increased DNA methylation at gene bodies on the more 
transcriptionally active Xa while gene body methylation on the transcriptionally 
inactive Xi was comparatively depleted (Hellman and Chess, 2007). Furthermore, a 
recent study has provided further insight into the relationship between gene body 
methylation and transcriptionally active genes, showing that Dnmt3b methylates 
actively transcribed regions of the genome via its interaction with H3K36me3 (Baubec 
et al., 2015). 
One of the primary proposed functions of hypermethylation at gene bodies is that it 
acts to prevent inappropriate transcription initiation outwith the canonical TSS, whilst 
allowing transcriptional elongation to continue undisturbed (Yoder, Walsh and Bestor, 
1997; Neri et al., 2017; reviewed by Jones, 2012). This potential role was extended to 
propose a more general function of DNA methylation globally, acting as a mechanism 
to block aberrant initiation of transcription at repetitive regions such as retroviruses 
and LINE1 elements (Yoder, Walsh and Bestor, 1997). The concept of suppression of 
transcriptional activation by gene body methylation was exemplified by Maunakea et 
al. (2010). This study demonstrated tissue-specific methylation of an intragenic CGI 
acting as an alternative promoter at the Shank3 locus in mouse and human cells, 
resulting in tissue- and cell type-specific expression of alternative transcripts. Other 
potential roles for DNA methylation at gene bodies have also come to light more 
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recently, including the link between gene body methylation and regulation of splicing. 
Genome-wide high resolution mapping of a variety of human cell lines showed that 
exons are more highly methylated than introns, with a sharp transition at the intron-
exon boundary, suggesting a function for 5-mC in splicing (Laurent et al., 2010). A 
further study demonstrated the effect of gene body DNA methylation on CTCF 
binding, highlighting the consequences for RNA polymerase II pausing and 
subsequent inclusion of alternatively spliced exons (Shukla et al., 2011). These studies 
highlight a previously uncharacterised role for DNA methylation in transcription.  
1.3.5.3 Non-CpG methylation 
Although methylated cytosine is predominantly present in the context of CpG 
dinucleotides, it is not exclusively found in this context. The existence of 5-mC in 
CpT, CpC and particulary CpA contexts has been documented in recent years. It has 
been shown that nearly one quarter of methylated cytosines in human ESCs were 
present in a non-CpG context, whereas nearly all DNA methylation in somatic cells 
occurred within CpG dinucleotides (Lister et al., 2009). This non-CpG methylation 
disappeared following differentiation of these ESCs, and subsequently reappeared 
upon restoration of pluripotency in induced pluripotent stem cells (iPSCs; Lister et al., 
2009; Ziller et al., 2011). This implies the use of alternative methylation mechanisms 
in pluripotent cells for regulation of gene expression. However, knockdown of Dnmt3a 
and Dnmt3b resulted in a global reduction of non-CpG methylation in human ESCs, 
showing that the same DNMTs are responsible for establishment of 5-mC independent 
of the context (Ramsahoye et al., 2000; Ziller et al., 2011). Indeed, high levels of non-
CpG methylation in ESCs may be a by-product of high de novo methyltransferase 
activity in these cells (Lei et al., 1996). Like CpG methylation, non-CpG methylation 
was shown to be enriched in exons of gene bodies compared to introns and depleted 
in protein-binding sites, promoters and enhancers. Additionally, gene ontology 
analysis revealed that gene bodies marked by non-CpG methylation were enriched for 
functions in RNA processing and splicing, suggesting a potentially similar role for 
CpG methylation present in these regions (Lister et al., 2009). 
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1.3.6 The DNA methylation machinery  
A mechanism for inheritance of DNA methylation patterns through somatic cell 
divisions was proposed more than 40 years ago in two key publications predicting the 
existence of an enzyme-mediated mechanism for de novo methylation and subsequent 
maintenance of methylation patterns through recognition of hemimethylated DNA 
(Holliday, R. & Pugh, 1975; Riggs, 1975). These papers led to the concept of 
‘maintenance’ enzymes that could propagate DNA methylation patterns through 
generations of somatic cells, and ‘de novo’ enzymes that establish these methylation 
patterns (Holliday & Pugh, 1975). Three conserved enzymes, collectively termed 
‘DNA methyltransfersases’ (DNMTs), have since been identified and placed into these 
two functional classes. The proposed maintenance methyltransferase, Dnmt1, was 
identified in 1988 followed by the de novo methyltransferases Dnmt3a and Dnmt3b a 
decade later (Bestor et al., 1988; Masaki Okano, Xie and Li, 1998; Okano et al., 1999). 
All three have been shown to be essential for normal development (Table 1.1, Li, 
Bestor and Jaenisch, 1992; Okano et al., 1999). A fourth methyltransferase, Dnmt2, 
has also been identified, and rather than contributing to DNA methylation patterns, it 
has been shown to act as a transfer RNA (tRNA) cytosine methyltransferase with 
possible roles in the regulation of protein translation (Goll et al., 2006; reviewed by 
Jeltsch et al., 2017). Furthermore, a new de novo methyltransferase, Dnmt3c, was 
identified just last year and appears to play a specific role in methylation of 
evolutionarily young transposons in the male germ line (Barau et al., 2016). The key 
features and functions of the main components of the DNA methylation machinery 







Mouse model phenotype Reference(s) 




Embryonic lethal by E8.5; global 
hypomethylation; loss of gene 
repression associated with 
imprinting and X-inactivation; 
transposon activation, ESCs viable 
but apoptose upon differentiation 
Li et al. 
(1992); 





Viable but runted; die postnatally 
(~4weeks); spermatogenesis 
defects; impaired de novo 
methylation particularly at imprints 





Embryonic lethality around E14.5; 
defective de novo methylation at 
minor satellites 





Viable; hypogonadism; male 
sterility; impaired de novo 
methylation at evolutionary young 
retrotransposons 
Barau et al. 
(2016) 




Viable; spermatogenesis defects, 
impaired de novo methylation at 
imprints and retrotransposons in 
germ cells 
Bourc’his et al. 





Early embryonic lethality; 
developmental arrest shortly after 
gastrulation; similar to Dnmt1 
mouse model 





Peri- or post- natal lethality (a few 
hours to a few weeks after birth); 
runted; renal abnormalities; 
skeletal defects; premature ageing 
phenotype; abnormal meiosis in 
gametes 
Geiman et al. 
(2001); Sun et 
al. (2004) 
Table 1.1. Phenotypes associated with mutant mouse models of selected DNA 
methylation mediators and co-factors. 
1.3.6.1 The maintenance methyltransferase – Dnmt1 
The ability for DNA methylation patterns to be stably maintained through generations 
of somatic cells is key to the concept of epigenetic memory, where inheritance of 
epigenetic patterns propagate transcriptional states through cell divisions. This 
requires a mechanism whereby DNA methylation patterns can be copied from the 
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parent strand to the nascent strand during DNA replication in S phase of the cell cycle. 
The first eukaryotic cytosine methyltransferase to be identified, Dnmt1, was shown to 
have a preference for hemimethylated DNA and to interact with components of the 
replication machinery during S phase (Bestor et al., 1988; Chuang et al., 1997; Goyal, 
Reinhardt and Jeltsch, 2006; Schermelleh et al., 2007). Therefore, it is postulated to 
be a maintenance methylatransferase, acting to preserve patterns of DNA methylation 
at each replication cycle.  
Dnmt1 is the most abundant DNA methyltransferase and is widely expressed in 
somatic tissues throughout mammalian development, exhibiting particularly high 
expression levels in dividing cells (Walsh and Bestor, 1999; Goll and Bestor, 2005). 
Dnmt1 is essential for normal embryonic development, as Dnmt1-targeted knockout 
mouse models show embryonic lethality around embryonic day (E)8.5 at the onset of 
gastrulation (Li, Bestor and Jaenisch, 1992; Lei et al., 1996). There is an array of 
reported defects with these embryos (Table 1.1), the most notable being a dramatic 
reduction in global DNA methylation levels, resulting in mis-expression of genes 
associated with imprinting and X-inactivation, as well as elevated IAP element 
transcription (Li, Beard and Jaenisch, 1993; Lei et al., 1996; Walsh, Chaillet and 
Bestor, 1998). Despite the severe embryonic lethal phenotype exhibited by Dnmt1 
deficient mice, ESCs lacking Dnmt1 are viable and divide normally in an 
undifferentiated state, despite exhibiting very low levels of genomic DNA 
methylation. However when these ESCs are induced to differentiate they undergo p53-
mediated apoptosis (Li, Bestor and Jaenisch, 1992; Lei et al., 1996). This highlights 
that the severe DNA hypomethylation present in Dnmt1 null ESCs does not affect cell 
viability before differentiation, but upon initiation of differentiation Dnmt1 activity 
becomes an essential requirement.   
1.3.6.2 The de novo methyltransferases – Dnmt3 proteins 
Two further members of the DNMT family, Dnmt3a and Dnmt3b, were identified by 
Okano et al. (1999) and were proposed to be de novo methyltransferases, responsible 
for establishing DNA methylation patterns during embryonic development. They are 
highly expressed in ESCs but are downregulated upon differentiation, consistent with 
their proposed function in early development (Okano, Xie and Li, 1998; Okano et al., 
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1999; Ramsahoye et al., 2000). A degree of expression is retained in somatic cells 
however, with Dnmt3a expressed ubiquitously at low levels and Dnmt3b exhibiting 
higher expression levels in testes, thyroid and bone marrow (Xie et al., 1999). Further 
differences between these highly homologous proteins were uncovered following their 
targeted disruption in mice. Dnmt3a deficient mice are viable but are runted and die 
within 4 weeks of birth (Table 1.1, Okano et al., 1999). Global DNA methylation 
patterns appear to be unaffected in Dnmt3a null mice, however a progressive loss of 
germ cells in males is apparent, and a role for Dnmt3a in de novo methylation of 
imprints in germ cells was subsequently uncovered (Okano et al., 1999; Kaneda et al., 
2004). The phenotype associated with Dnmt3b deficiency is more severe, as shown by 
the embryonic lethality of Dnmt3b null mice at around E14.5. Notable 
hypomethylation at minor satellites is apparent in Dnmt3b null mice, indicating 
defective de novo DNA methylation at these sequences in the absence of Dnmt3b 
(Okano et al., 1999). The phenotypic differences of these mouse models demonstrate 
the important but distinct roles of Dnmt3a and Dnmt3b in embryonic development. 
Combined deletion of Dnmt3a and Dnmt3b is embryonic lethal at approximately E8.5, 
mimicking the Dnmt1 null phenotype but displaying a lesser degree of 
hypomethylation (Okano et al., 1999). 
In addition to Dnmt3a and Dnmt3b, a new enzymatically active member of the Dnmt3 
family of de novo methyltransferases, Dnmt3c, was identified last year from a 
previously annotated pseudogene downstream of Dnmt3b (Barau et al., 2016). Dnmt3c 
is exclusively expressed in male germ cells where it acts to methylate and silence 
evolutionarily young transposons, an activity that is required to preserve mouse 
fertility. This revelation highlights the complexity and plasticity of the de novo DNA 
methylation system and uncovers further mechanisms involved in retrotransposon 
silencing. 
1.3.6.3 Maintenance vs de novo methylation 
The classic view is that de novo methyltransferases Dnmt3a and Dnmt3b act to 
establish DNA methylation patterns in the early stages of development, which are then 
maintained to later stages of development by the maintenance methyltransferase 
Dnmt1. However, there is evidence to suggest that the functions of enzymes are not so 
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distinct. Dnmt1 has been shown to have some de novo methyltransferase activity 
(Yoder et al., 1997; Pradhan et al., 1999). Futhermore, Dnmt3a-/- Dnmt3b-/- double null 
ESCs which initially retain DNA methylation in early passages progressively lose 
almost all 5-mC during longer-term culture, suggesting an important role for de novo 
methyltransferases in maintenance of global DNA methylation, as well as 
establishment (Jackson et al., 2004). 
1.3.7 DNA methylation readers 
As described previously, DNA methylation patterns are established and maintained by 
DNMTs. However, in mammals a specific set of proteins are employed to interpret 
these DNA methylation patterns, often referred to as DNA methylation ‘readers’. 
These readers are known as methyl-CpG binding proteins (MBPs) of which there are 
three main families: the methyl-CpG binding domain (MBD) proteins (Lewis et al., 
1992; Meehan, Lewis and Bird, 1992; Hendrich and Bird, 1998), the Kaiso protein 
family (Prokhortchouk et al., 2001; Filion et al., 2006), and the SET and RING-finger 
associated (SRA) domain family (Unoki, Nishidate and Nakamura, 2004). The MBD 
family of proteins is the most well-characterised, with the identification of methyl-
CpG binding protein 1 (MeCP1) first indicating the existence of methylation-specific 
binding proteins, followed by the cloning and characterisation of MeCP2 
demonstrating their function in transcriptional repression in vitro (Meehan et al., 1989; 
Lewis et al., 1992; Meehan, Lewis and Bird, 1992). Many further members of the 
MBD protein family have since been identified, including MDB1-6 and SETDB 
proteins 1 and 2, which all contain a MBD domain after which they are named 
(Hendrich and Bird, 1998; Laget et al., 2010). Although each MBD protein has a 
specific function, generally they act to repress transcription, at least in part through 
recruitment and targeting of multiple factors including HDACs, KMTs and chromatin 
remodelling factors, thus inducing heterochromatin formation and an inactive 
chromatin structure (Nan et al., 1998; Ng, Jeppesen and Bird, 2000; reviewed by Du, 
2015). MDB proteins have been shown to localise to pericentromeric heterochromatin, 
and are thought to contribute to constitutive heterochromatin formation and 
transcriptional silencing at these genomic regions (Hendrich and Bird, 1998; Ng, 
Jeppesen and Bird, 2000; Laget et al., 2010). 
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1.3.8 DNA methylation co-factors 
A number of non-methyltransferase proteins have been shown to be required to 
facilitate DNA methylation globally or locally, or in specific cellular contexts. These 
DNA methylation co-factors act to recruit, target or alter the chromatin environment 
to enable establishment or maintenance of DNA methylation. In this section I will 
discuss a few of the key DNA methylation co-factors that have been identified and 
characterised, including the putative chromatin remodelling helicase Lsh on which the 
majority of my PhD project is focussed.  
1.3.8.1 Dnmt3l 
A mammal-specific member of the Dnmt3 family, Dnmt3l (Dnmt3-like) is a 
catalytically inactive co-factor to de novo DNA methylation. It has no known 
methyltransferase activity, but has been shown to bind to Dnmt3a and Dnmt3b to 
stimulate their methyltransferase activity in vitro (Gowher et al., 2005). Dnmt3l is 
highly expressed in germ cells, where it is essential for de novo methylation and 
silencing of maternal and paternal imprinted loci and retrotransposons (Bourc’his et 
al., 2001; Hata et al., 2002; Bourc’his and Bestor, 2004; Kaneda et al., 2004). Indeed, 
male mice lacking Dnmt3l are sterile due to defective spermatogenesis, possibly as a 
result of impaired de novo methylation and silencing of retrotransposons (Bourc’his 
and Bestor, 2004). Dntm3l deficiency in females does not cause sterility, but 
heterozygous offspring die mid-gestation and exhibit biallelic expression of imprinted 
genes due to lack of proper maternal imprint methylation (Bourc’his et al., 2001). The 
phenotype of Dnmt3l null mice is strikingly similar to that of conditional Dnmt3a 
knockout in germ cells, indicating that both factors cooperate in the same mechanism 
to establish methylation at imprinted loci in germ cells (Kaneda et al., 2004).  
A more recent study from Neri et al. (2013) proposed a dual role for Dnmt3l in ESCs, 
where it is also highly expressed. Genome-wide analysis of DNA methylation in 
Dnmt3l knockdown ESCs revealed that Dnmt3l promotes DNA methylation at gene 
bodies while preventing methylation at the promoters of bivalent developmental genes. 
Disturbance of this methylation patterning by knocking down Dnmt3l prevented the 
differentiation of ESCs into primordial germ cells (PGCs), showing that Dnmt3l is 




The mechanism of maintenance methylation by Dnmt1 is dependent on its E3 ubiquitin 
ligase co-factor Uhrf1, which is required to associate Dnmt1 with replication foci and 
to maintain global and local DNA methylation levels following replication (Bostick et 
al., 2007; Sharif et al., 2007). Uhrf1 contains a SRA domain which binds 
hemimethylated CpG dinucleotides, suggesting that Uhrf1 acts to recruit Dnmt1 to 
replication forks by binding hemimethylated CpGs during DNA replication (Sharif et 
al., 2007; Arita et al., 2008). More recently it has been demonstrated that binding 
H3K9me2/3 via the Tandem Tudor Domain (TTD) of Uhrf1 can directly recruit Dnmt1 
to replication foci, linking H3K9 methylation and DNA methylation in the context of 
maintenance methylation (Liu et al., 2013; Zhao et al., 2016; Ferry et al., 2017).  
1.3.8.3 Lsh 
Lsh (lymphoid specific helicase) is another protein that has been implicated as an 
important player in facilitating global DNA methylation. Murine Lsh was first cloned 
in T cell precursors by Jarvis et al. (1996), where it was shown to be highly expressed 
in B and T lymphocytes and associated tissues, which is why it was denoted the term 
Lsh. The human homologue of Lsh was cloned from human leukemic cells and was 
termed PASG (proliferation associated SNF2-like gene, Lee et al., 2000), but Lsh is 
also known as HELLS (helicase, lymphoid specific) and SMARCA6 (SWI/SNF 
related, matrix associated, actin dependent regulator of chromatin, subfamily a, 
member 6). The majority of this thesis is concerned with the murine version of this 
gene, which will be referred to as Lsh and any references to the human homologue will 
use the term HELLS.  
Lsh was identified as a member of the SNF2 subfamily of helicases, many of which 
are involved in chromatin remodelling activities (Geiman et al., 2001). Lsh was shown 
to have a high level of similarity to another SNF2 subfamily member DDM1 (decrease 
in DNA methylation) present in the flowering plant Arabidopsis thaliana. DDM1 was 
previously identified in a forward genetics screen as a modulator of genomic DNA 
methylation in Arabidopsis, as ddm1 mutants displayed a 70% loss in DNA 
methylation, particularly at repeated sequences (Jeddeloh, Stokes and Richards, 1999). 
Analysis of lsh-/- mice revealed a similar pattern of methylation loss, with Lsh-deficient 
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embryos displaying a 40-50% reduction in global DNA methylation levels, 
predominantly at satellite DNA and dispersed repetitive sequences (Dennis et al., 
2001). Throughout this section, I will discuss the function of Lsh as a co-factor to DNA 
methylation, focussing on the effects of Lsh removal on murine development, DNA 
methylation patterns and the transcriptional consequences. I will also discuss the 
potential epigenetic mechanisms of action for Lsh along with its contribution to 
development and disease. 
1.3.8.3.1 Lsh gene structure and expression 
The genomic structure and chromosomal localisation of Lsh was first described by 
Geiman et al. (1998), who showed it to be located on chromosome 19 in mice. Lsh is 
comprised of 21 coding exons and seven helicase domains and, based on the amino 
acid sequence of these helicase motifs, was identified as a member of the SNF2 
subfamily of helicases (Figure 1.4). Lsh appears to be highly conserved in vertebrates, 
with homologues in yeast also apparent, as well as the DDM1 homologue in 
Arabidopsis, of which there is 50% sequence identity with Lsh over the helicase 
domains (Geiman, Durum and Muegge, 1998; Meehan, Pennings and Stancheva, 
2001). These seven helicase domains comprise multiple motifs critical for function 
such as the ATPase domain and DEAH (Asp-Glu-Ala-His) box (Eisen, Sweder and 
Hanawalt, 1995; reviewed by Clapier and Cairns, 2009). 
 
Figure 1.4. Schematic representation of murine Lsh gene. Coding exons are shown 
in black. Seven conserved helicase domains are indicated, as are conserved structural 
domains identified by UniProtKB. Helicase domains targeted by the two Lsh mouse 
models are also shown. 
Lsh was initially identified as being expressed in highly proliferative B and T cells 
(Jarvis et al., 1996). It was since shown to be more ubiquitously expressed across 
multiple mouse foetal tissues, suggesting a more general involvement of Lsh 
throughout the developing embryo outwith the lymphocyte lineages (Geiman et al., 
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2001; Raabe et al., 2001). In adult mice, Lsh is broadly expressed at low levels and 
enriched in tissues with high levels of proliferative and differentiating cells, such as 
the thymus, testis and bone marrow – an expression profile strikingly similar to that  
of Dnmt3b (Xie et al., 1999; Raabe et al., 2001). Furthermore, Lsh and HELLS have 
been shown to be highly expressed in ESCs, suggesting a role for Lsh in a pluripotent 
context (Assou et al., 2007; Xi et al., 2009). 
1.3.8.3.2 Lsh mouse models 
Two separate mouse models targeting Lsh for disruption have demonstrated that Lsh 
is essential for normal murine development and survival. In the first mouse model that 
was generated, helicase domains I, Ia and II were deleted via homologous 
recombination (mouse model 1 in Figure 1.4, Geiman et al., 2001). These domains 
encompass the ATPase and DEAH box motifs, thought to be crucial for Lsh and SNF2 
protein function (Figure 1.4). Western blotting confirmed the absence of any wild-type 
(WT) or truncated forms of LSH protein in lsh-/- mice. Absence of Lsh in developing 
mice resulted in perinatal lethality, with these mice dying a few hours after birth 
exhibiting reduced bodyweight (22% lower compared to WT littermates) and renal 
tubular defects. This demonstrated that Lsh was a non-redundant SNF2 family member 
whose function was critical for normal mouse development (Geiman et al., 2001). 
Further analysis of this lsh-/- mouse model revealed specific defects in the generation 
of male and female germ cells. Lsh is essential for successful completion of meiosis in 
both oocytes and spermatocytes. De La Fuente et al. (2006) showed that while Lsh was 
not required for PGC formation and migration to the differentiating ovary, it was 
essential for the viability of primary oocytes in explanted ovaries. All mutant oocytes 
analysed showed incomplete chromosome synapsis, thus preventing recombination, 
establishment of crossovers and subsequent progression through meiosis. This study 
also revealed the dynamic localisation of Lsh throughout early meiosis, with transient 
localisation of Lsh to heterochromatic regions during synapsis followed by the 
association of Lsh along the length of the synapsed chromosomes in the pachytene 
stage of meiosis. These findings highlighted the crucial role Lsh plays in establishment 
of synapsis and progression of meiosis in female germ cells. This was further 
highlighted in a study demonstrating an essential role for Lsh in spermatogenesis, in 
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which lsh-/- male germ cells arrested in meiosis displaying chromosome synapsis 
abnormalities (Zeng et al., 2011). 
A second mouse model provided further evidence for an essential role for Lsh in 
postnatal development. Exons 10, 11 and 12 containing helicase domains III, IV and 
part of II were deleted, creating a hypomorphic mutation where a truncated version of 
LSH protein was expressed at low levels (mouse model 2 in Figure 1.4, Sun et al., 
2004). These mice display multiple physiological defects, resembling a premature 
ageing phenotype, and die prematurely within a few weeks of birth. Newborn mice 
exhibit a 25% reduction in bodyweight compared to littermates which is first apparent 
at E12.5 in the developing embryo. This reduced bodyweight becomes further 
exaggerated to a 70% difference in two-week-old mice. These mice display attributes 
of a premature ageing phenotype such as greying/loss of hair, reduced skin fat 
deposition, osteoporosis and kidney tubular degeneration. Approximately 60% die 
shortly after or within a few days of birth, while the remaining 40% survive several 
weeks after birth. Furthermore, fibroblasts derived from Lsh mutant embryos display 
a replicative senescence phenotype, with chromosomal abnormalities and karyotypic 
instability apparent in later passage fibroblasts. Characterisation of this mouse model 
provided further evidence for the vital role of Lsh in postnatal development, growth 
and longevity.  
1.3.8.3.3 Lsh function in DNA methylation and transcription 
1.3.8.3.3.1 Globally and at repetitive elements 
Analysis of Lsh mutant mouse models revealed the fundamental role of Lsh in 
modulating genome-wide DNA methylation. Both models exhibited a substantial 
reduction in global DNA methylation levels, an approximate 50-60% decrease in Lsh 
null mice and a 30-40% reduction in hypomorphic Lsh mutant embryos, using methods 
based on the analysis of restriction enzyme sites (Dennis et al., 2001; Sun, David W. 
Lee, et al., 2004). High performance liquid chromatography (HPLC) analysis 
confirmed a 50% reduction in global cytosine methylation levels in Lsh null embryos 
(Tao et al., 2011; Yu, Briones, et al., 2014). DNA methylation levels were shown to 
be particularly reduced at satellite DNA and many dispersed repeat elements. Dennis 
et al. (2001) showed substantial hypomethylation at major and minor satellites as well 
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as IAPs, LINE-1, SINE-B1 and telomeric repeats in Lsh null embryonic tissues by 
Southern blotting. Analysis of lsh-/- oocytes also revealed extensive de-methylation of 
satellite DNA and IAP transposable elements, which was accompanied by reactivation 
of IAP transcription in Lsh deficient ovaries (De La Fuente et al., 2006). Similar to the 
methylation patterns of Lsh null mice, considerable hypomethylation at minor 
satellites and IAPs accompanied by high levels of IAP expression was also apparent 
in hypomorphic Lsh mice (Sun, David W. Lee, et al., 2004). Bisulfite sequencing in 
lsh-/- ESCs also revealed reduced DNA methylation at IAP elements, minor satellites 
and LINE-1 elements compared to WT, and that this hypomethylation was preserved 
during retinoic acid (RA)-induced differentiation (Ren et al., 2015). 
More recently, genome-wide sequencing approaches have defined DNA methylation 
defects at repetitive sequences in more detail. A report from Yu et al. (2014) showed 
a substantial decrease in DNA methylation across nearly all subclasses of repeats 
assayed by whole-genome bisulfite sequencing (WGBS) using WT and lsh-/- mouse 
embryonic fibroblasts (MEFs). A few instances of repeat hypermethylation in lsh-/- 
cells compared to WT were also observed. Transcriptional de-repression of a specific 
subset of the hypomethylated repeats including IAP elements was observed by RNA-
seq, but the extent of hypomethylation did not correlate with the degree of reactivation 
of transcription. This indicates the presence of additional silencing mechanisms that 
act to repress hypomethylated repeats. A further study by Dunican et al. (2013) 
uncovered a more distinct signature of repeat hypomethylation in Lsh-/- fibroblasts 
using HELP-seq, a technique that generates high-resolution DNA methylation profiles 
informative of repeat regions. The largest impact of Lsh deletion on DNA methylation 
patterns was observed at LTR, LINE and satellite repeats, whereas methylation at other 
classes of repeats did not appear to be affected. RNA-seq expression analysis linked 
transcriptional reactivation of certain repeats, particularly IAP elements, to reduced 
DNA methylation levels in lsh-/- fibroblasts, while other hypomethylated repeats such 
as the LINE-1 elements remained largely transcriptionally repressed. This study also 
uncovered hypermethylation of some repeat classes, consistent with findings from Yu 
et al. (2014), suggesting that disruption of Lsh could act in part to redistribute genomic 
DNA methylation.  
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1.3.8.3.3.2 At single copy genes 
As well as modulating DNA methylation at certain repeat elements, there is also 
evidence for Lsh facilitating methylation at selected genomic targets. Initial analysis 
of lsh-/- mice revealed a variable and context-dependent pattern of DNA methylation 
at low copy sequences. The imprinted H19 gene was hypomethylated in lsh-/- mice 
compared to WT, whereas the imprinted Igf2r gene remained methylated. 
Additionally, the β-globin, Pgk1 and Pgk2 genes were hypomethylated in lsh-/- E13.5 
embryos but not in newborn mice, indicating that the modulation of DNA methylation 
by Lsh may differ depending on developmental context (Dennis et al., 2001). Fan et 
al. (2005) also reported hypomethylation of the promoter of the imprinted Cdkn1c 
gene in lsh-/- embryos, resulting in biallelic expression of this gene. Reduced DNA 
methylation was also apparent at the promoters of certain Hox loci in lsh-/- MEFs and 
correlated with transcriptional de-repression of these genes (Xi et al., 2007; Tao et al., 
2010). A role for Lsh in regulation of DNA methylation at pluripotency genes has also 
been demonstrated. Xi et al. (2009) reported impaired establishment of DNA 
methylation at a subset of pluripotency genes including Oct4 and Nanog during 
differentiation of Lsh knockdown embryonal carcinoma cells (ECCs). This resulted in 
incomplete silencing of these genes following differentiation, which was also observed 
in lsh-/- E8.5 embryos. However, this sustained Oct4 expression was not evident in 
E18.5 lsh-/- embryos despite the continued absence of promoter methylation, 
suggesting the involvement of an alternative methylation-independent silencing 
mechanism at a later developmental stage. A further study identified the Rhox gene 
cluster as requiring Lsh for DNA methylation establishment at promoters and 
surrounding regions in lsh-/- MEFs, adding further weight to the idea that Lsh 
contributes to DNA methylation patterns during early developmental stages where 
Rhox genes are de novo methylated during lineage commitment (Myant et al., 2011). 
Genome-wide studies have provided further insight into the methylation status and 
distribution at unique sequences in Lsh mutant embryos and cells. The aforementioned 
study from Myant et al. (2011) utilised methyl-CpG binding affinity purification 
(MAP) combined with promoter-specific microarrays to demonstrate a reduction in 
DNA methylation of at least two-fold at approximately 20% of normally methylated 
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promoters in lsh-/- MEFs compared to WT. A small subset of promoters were also 
found to be hypermethylated in the absence of Lsh. This finding was reinforced by a 
study which produced a comprehensive map of DNA methylation distribution in lsh-/- 
E13.5 embryos using methylated DNA immunoprecipitation (MeDIP) combined with 
a whole-genome tiled array platform (Tao et al., 2011). Lsh disruption resulted in 
changes to the DNA methylation profile at the 5’ end of genes. In particular, a subset 
of single copy genes containing CpG islands at their 5’ ends exhibited 
hypermethylation in lsh-/- embryos. This provided further evidence that Lsh can 
prevent as well as promote DNA methylation, and that Lsh acts to regulate the 
deposition and distribution of methylation at unique sequences. Lastly, WGBS of lsh-
/- MEFs provided high-resolution cytosine methylation maps which revealed a greater 
loss in DNA methylation at low CpG density promoter regions of unique protein-
coding and noncoding RNA genes (Yu, McIntosh, et al., 2014). 
1.3.8.3.3.3 Over large chromosomal domains 
In addition to informing about DNA methylation distribution across genes, the 
genome-wide studies discussed above all provided novel insights into the modulation 
of DNA methylation by Lsh over large chromosomal regions. Tao et al. (2011) 
reported large regions with well-defined boundaries that were differentially 
methylated (hypo- and hyper-methylated) in lsh-/- embryos over chromosomes 8 and 
15. This suggests that distinct chromosomal domains are regulated by Lsh in tandem 
using a common epigenetic mechanism. Myant et al. (2011) also noted clusters of 
promoters on all autosomes whose DNA methylation patterns appear to be regulated 
by Lsh. Moreover, high-resolution WGBS maps generated by Yu et al. (2014) 
demonstrated the extent and diversity of genomic loci differentially methylated in lsh-
/- MEFs compared to WT, suggesting that Lsh targets a nuclear compartment rather 
than specific genomic sequences. These differentially regulated regions consistently 
overlapped with lamin B1 attachment domains (LADs), indicating that Lsh function 
may involve targeting this nuclear compartment for DNA methylation regulation. 
Collectively, these studies highlight complex nature of DNA methylation modulation 
by Lsh. The major targets of Lsh are repetitive elements, particularly satellite DNA 
and LTRs. However, Lsh also participates in regulation of DNA methylation patterns 
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at unique sequences, especially those involved in pluripotency, development and 
lineage-commitment. Furthermore, there is increasing evidence that Lsh targets 
specific nuclear compartments, chromosomal domains and clusters of genes to 
regulate epigenetic patterns over large chromosomal regions rather than at discrete 
genomic loci. The extent and diversity of the sequences affected by Lsh depletion hints 
at a sophisticated mechanism for Lsh function which may include cooperation with 
DNMTs, chromatin and other epigenetic modulators. These potential mechanisms will 
be discussed in a subsequent section. 
1.3.8.3.4 Potential mechanisms of Lsh function 
It is clear that Lsh modulates genome-wide DNA methylation in mice, but the 
molecular mechanisms underlying this process remain unclear. It is still not fully 
understood whether Lsh acts directly or indirectly on genomic loci to regulate DNA 
methylation and whether any chromatin remodelling activities are involved. 
Furthermore, it is still disputed as to whether Lsh acts as a recruitment factor for 
DNMTs or associates with other epigenetic factors as part of a complex or scaffold to 
modify DNA methylation. The potential mechanisms of Lsh function will be 
overviewed in this section. 
1.3.8.3.4.1 Lsh as a co-factor for DNMTs 
The amino acid sequence of Lsh harbours no recognisable methyltransferase domain, 
suggesting that Lsh does not act to directly methylate genomic targets. Rather it is 
hypothesised that Lsh recruits or directs the activity of DNMTs to establish or maintain 
DNA methylation patterns at selected genomic loci (Meehan, Pennings and Stancheva, 
2001; Dunican et al., 2013). Disruption of Lsh in mice resulted in remarkable global 
hypomethylation in the absence of any apparent changes in DNMT expression levels 
or activity (Dennis et al., 2001). However, Lsh has been shown to interact and 
cooperate with Dnmt1, Dnmt3a and Dnmt3b in vitro (Zhu et al., 2006; Myant and 
Stancheva, 2008; Xi et al., 2009; Dunican, Pennings and Meehan, 2015). Much 
evidence supports the current working hypothesis that Lsh predominantly contributes 
to de novo DNA methylation. Lsh was shown to be required for DNA methylation 
establishment on episomal vectors introduced into MEFs, while it was not required for 
methylation maintenance of already methylated episomes (Zhu et al., 2006). This 
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study also demonstrated that Lsh affects both Dnmt3a and Dnmt3b-mediated de novo 
methylation and silencing of a retroviral transgene, and confirmed a direct interaction 
between Lsh and both de novo DNMTs by co-immunoprecipitation. Further studies 
have implied that Lsh primarily acts in concert with Dnmt3b, as Lsh depletion results 
in reduced association of Dnmt3b with specific genomic targets such as Hox and stem 
cell gene promoters (Xi et al., 2007, 2009). Two recent reports have highlighted the 
importance of Dnmt3b for Lsh function. Termanis et al. (2016) demonstrated de novo 
methylation of repeats and gene promoters in lsh-/- MEFs when Lsh was re-introduced 
and that this methylation re-establishment was impaired upon Dnmt3b knockdown. 
Ren et al. (2015) further highlighted the cooperation of Dnmt3b and Lsh, showing that 
Dnmt3b binding to and de novo methylation of specific repeat elements (such as IAPs) 
is dependent on the presence of Lsh. These reports indicate that Lsh and Dnmt3b act 
in concert to target specific genomic regions for de novo DNA methylation. However, 
comparison of lsh-/- and dnmt3b-/- methylomes illustrated that Lsh can also function 
independently of Dnmt3b to facilitate DNA methylation deposition and transcriptional 
silencing of selected repeats, such as LTRs (Dunican et al., 2013).  
Largely, however, it appears that the probable role of Lsh in de novo DNA methylation 
primarily involves Dnmt3b, although the functional requirements for this role remain 
unclear. The crucial function of the ATP binding site and DEAH motifs became 
apparent in the aforementioned studies form Termanis et al. (2016) and Ren et al. 
(2015). These reports demonstrated that de novo methylation of repetitive elements 
and unique sequences in ESCs and MEFs relied on fully functional LSH protein with 
an intact ATP binding site and DEAH motif. Furthermore, the targeting of Dnmt3b to 
repeat loci was shown to be dependent on the presence of WT Lsh, as targeting was 
impaired in ATP and DEAH mutant LSH protein (Ren et al., 2015). These 
observations highlight a critical role for the ATPase activity of Lsh in directing 
Dnmt3b to establish cytosine methylation patterns at selected repeats and single copy 
sequences, hinting towards the involvement of Lsh in chromatin remodelling activities.  
1.3.8.3.4.2 Lsh as a chromatin remodeller 
SNF2 family members are characterised by their ability to disrupt histone-DNA 
interactions. This can act to alter chromatin structure, in part through ATP-dependent 
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nucleosome sliding, influencing the accessibility of enzymes to DNA. Lsh is a putative 
chromatin remodeller based on its amino acid homology to other SNF2 family 
members, yet chromatin remodelling activity by Lsh has yet to be demonstrated. 
However DDM1, the homologue of Lsh in Arabidopsis, has been shown to induce 
nucleosome repositioning on a short DNA fragment in vitro in an ATP-dependent 
manner (Brzeski and Jerzmanowski, 2003). Due to the homology of Lsh to the SNF2 
family, it has been proposed that Lsh may also exert nucleosome remodelling activity 
to promote heterochromatin structure while regulating access of de novo 
methyltransferases to certain genomic loci (Meehan, Pennings and Stancheva, 2001). 
Recent WGBS analysis of DDM1 mutants has reinforced this theory. DNA 
methylation was markedly depleted at linker histone 1 (H1) rich DNA in ddm1 
mutants, demonstrating a specific requirement for DDM1 for methylation at regions 
of densely packed chromatin (Zemach et al., 2013). It has been demonstrated in vitro 
that DNA wrapped around nucleosomes is protected from DNA methylation, and that 
the presence of SNF2 proteins improves de novo methylation in vitro by remodelling 
nucleosomes to provide a better substrate for de novo DNMTs (Felle et al., 2011). 
Therefore it has been proposed that DDM1, and perhaps Lsh, promotes access of 
DNMTs to nucleosomal DNA at H1-rich heterochromatin, incurring DNA 
methylation deposition at these regions (Zemach et al., 2013). 
Heterochromatin is the major target of Lsh. Lsh is known to be required for DNA 
methylation mainly at lowly expressed genes and repetitive sequences which are 
embedded in heterochromatin (Yu, McIntosh, et al., 2014). It has also been referred to 
as an ‘epigenetic guardian’ of repetitive elements due to the multiple epigenetic 
mechanisms Lsh appears to employ to maintain silent chromatin at these repeats 
(Huang et al., 2004). Lsh has been shown to strongly associate with heterochromatin, 
particularly at pericentromeric regions, in an ATP-dependent manner (Yan et al., 2003; 
Lungu et al., 2015). This suggests that the putative chromatin remodelling function of 
Lsh is required for its activity at heterochromatin. A recent study aimed to investigate 
the nucleosome remodelling capabilities of Lsh using the Nucleosome Occupancy and 
Methylome (NOMe) sequencing assay, which provides a high resolution nucleosome 
footprint alongside a DNA methylation profile. This report suggested that Lsh is 
required to maintain nucleosome density at repeat sequences, as nucleosome 
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occupancy was reduced at IAP and LINE-1 elements in lsh-/- ESCs compared to WT 
following RA-induced differentiation (Ren et al., 2015). WT levels of nucleosome 
occupancy were restored upon re-introduction of fully functional LSH protein, but not 
ATPase and DEAH mutants. This led the authors to propose that nucleosome 
remodelling is the principal function of Lsh, acting to influence patterns of DNA 
methylation at repetitive elements. Another very recent study further elucidated a 
potential mechanism for Lsh function in chromatin remodelling using a tethering 
strategy to target a GAL4-LSH fusion protein to an engineered Oct4 locus in ESCs. 
Prior to differentiation, Lsh associates with the Oct4 locus, reducing the active 
H3K4me3 histone mark and chromatin accessibility without any effects on DNA 
methylation or gene expression. Upon differentiation, Lsh association induces 
transcriptional repression along with an increase in repressive H3K9me3 and DNA 
methylation (Ren et al., 2017). Along with the insights into the remodelling capacity 
of DDM1, this sheds light on an exciting and potentially crucial function of Lsh at 
heterochromatin. Indeed, the report from Ren et al. (2017) illustrates a potential 
mechanism for Lsh in priming specific genes in ESCs by changing chromatin 
accessibility. This results in their eventual repression during differentiation due to Lsh 
promoting heterochromatin formation, and subsequent reinforcement of this 
repression through the acquisition of DNA methylation.  
1.3.8.3.4.3 Lsh association with complexes and histone modifications 
There is also evidence that Lsh may interact and cooperate with protein complexes to 
influence histone modifications and chromatin accessibility. Lsh was shown to 
associate with PRC1 components in MEFs and was required for proper establishment 
of PRC1-mediated H2A-K116 patterns at Hox genes, with effects on PRC2-mediated 
H3K27me3 also apparent (Xi et al., 2007). More recent genome-wide reports have 
also noted aberrant patterns of H3K27me3, as well as other marks such as H3K4me3 
and H3K9me3 in lsh-/- MEFs (Dunican et al., 2013; Yu, McIntosh, et al., 2014). Lsh 
is thought to cooperate with H3K9me3 to reinforce heterochromatin formation and 
transcriptional silencing at repeats, and an intact H3K9me3 pathway is required for 
release of Lsh from pericentromeric heterochromatin (Dunican et al., 2013; Yu, 
McIntosh, et al., 2014; Lungu et al., 2015). Lsh has also been proposed to cooperate 
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with the G9a/GLP complex responsible for most H3K9 dimethylation at chromatin. 
The absence of Lsh resulted in impaired recruitment of G9a/GLP to Rhox promoters, 
hampering the establishment of silenced chromatin and transcriptional repression at 
these loci (Myant et al., 2011). Increased H3 acetylation was also evident at these Rhox 
genes, leading to the hypothesis that Lsh may bind and promote deacetylation, 
providing a suitable substrate for H3K9 dimethylation by G9a/GLP. This proposed 
connection of Lsh with H3 deacetylation is backed up by previous studies 
demonstrating cooperation of Lsh with HDACs: Lsh recruits HDACs and DNMTs to 
aid the formation of transcriptionally repressive chromatin and Lsh dissociates from 
pericentromeric heterochromatin following prolonged treatment with HDAC 
inhibitors (Yan et al., 2003; Myant and Stancheva, 2008). Taken together, these reports 
indicate that Lsh functions in concert with an array of proteins and complexes to alter 
histone modifications, chromosome accessibility, gene expression and DNA 
methylation.  
1.3.8.3.5 Lsh in pluripotency and development 
Much of the research that has been undertaken into Lsh function has pointed to a role 
for Lsh in establishment of DNA methylation at genes involved in development and 
pluripotency (Xi et al., 2007, 2009; Myant et al., 2011). There have also been insights 
into the functional requirement for Lsh in preserving proper pathways of lineage 
commitment and differentiation in mice. Lsh has been shown to be necessary for 
normal haematopoesis, spermatogenesis and development of oocytes (De La Fuente et 
al., 2006; Fan et al., 2008; Zeng et al., 2011). Furthermore, the involvement of Lsh in 
pluripotency and differentiation has been investigated, demonstrating the Lsh-
dependent de novo methylation and repression of a subset of stem cell-specific genes 
and the maintenance of stem-cell like characteristics in Lsh-depleted ECCs following 
differentiation (Xi et al., 2009).  
The involvement of Lsh in regulation of stem cell gene expression has been further 
demonstrated in two recent reports from Ren et al. (2015 and 2017) that were discussed 
previously. These revealed an important potential function for Lsh in inducing DNA 
methylation and heterochromatin formation to silence certain genes, such as the 
pluripotency factor Oct4, during ESC differentiation. These indications that Lsh plays 
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a role in influencing pluripotency factor expression, coupled with the high expression 
of Lsh in ESCs compared to somatic cells, makes stem cell systems an attractive model 
in which to study the contribution of Lsh to DNA methylation during development.  
Recently, there have been two in-depth studies into the differentiation capacity of lsh-
/- ESCs, further elucidating the role of Lsh in pluripotency and lineage commitment. 
Yu et al. (2014) observed an appearance of H3K4me1, a mark of putative enhancer 
elements, clustered at neuronal lineage genes that were hypomethylated in lsh-/- MEFs 
compared to WT. These differentially enriched H3K4me1 regions were maintained 
upon reprogramming to iPSCs, where the neuronal genes they marked showed 
increased expression. This resulted in the enhanced propensity of lsh-/- iPSCs to 
differentiate towards the neural lineage pathway, exemplifying the link between Lsh, 
de novo methylation and cellular plasticity via perturbation of H3K4me1 patterns. A 
further study has recently described an apparently contrary effect of Lsh disruption on 
neural differentiation. Han et al. (2017) showed that the absence of Lsh led to defects 
in the differentiation of neural stem progenitor cells (NSPCs), such as delayed lineage 
commitment and reduced neural lineage marker expression in mature cultures. This 
study also demonstrated a critical role for Lsh in regulating the proliferation and self-
renewal of NSPCs via its association with enhancers of key stem cell and cell cycle 
regulators Bmp4 and Cdkn1a. Reports that Lsh interacts with core pluripotency factors 
such as Oct4 adds weight to the idea that Lsh could play a role in regulating self-
renewal through interaction with the pluripotency network (van den Berg et al., 2010). 
However, further studies are required to uncover how this regulation may influence 
lineage commitment and differentiation, with particular focus on the role of Lsh in 
priming and progression of neural differentiation. 
1.3.8.3.6 Lsh in cancer and disease  
Lsh mutant mouse models have demonstrated a crucial role for Lsh in normal murine 
development and survival. Recently, the human homologue of Lsh, HELLS, was found 
to be mutated in the rare autosomal recessive disease ICF syndrome (Thijssen et al., 
2015). This disorder is largely regarded as an immunodeficiency disorder, as the life 
expectancy of ICF patients is significantly reduced due to recurrent, severe respiratory 
and gastrointestinal infections that are often fatal. This is accompanied by a failure to 
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thrive, developmental delay, distinctive facial abnormalities and varying degrees of 
intellectual disability (Hagleitner et al., 2007; Weemaes et al., 2013). Pericentromeric 
chromosomal instability is a hallmark of this disorder, manifesting in characteristic 
rearrangements of chromosomes 1, 9 and 16, regions which exhibit substantial DNA 
methylation loss and chromosome decondensation in ICF patients (Jeanpierre et al., 
1993; Hagleitner et al., 2007). This reinforces the indications from Lsh-deficient 
mouse models that Lsh is required for DNA methylation and heterochromatin 
maintenance at pericentromeric regions, and demonstrates the physiological 
consequences of loss of this function in humans. Missense mutations in Dnmt3b 
account for approximately 50% of ICF cases, providing further support to the proposal 
that Lsh predominantly functions alongside Dnmt3b to facilitate DNA methylation 
deposition, particularly at repetitive regions of the genome (Hansen et al., 1999; Xu et 
al., 1999; Ehrlich et al., 2008). Interestingly, four out of the five mutations in HELLS 
identified in ICF patients were outwith the conserved helicase domains, indicating 
crucial functions for less well-characterised regions of the protein (Thijssen et al., 
2015). 
Aberrant HELLS expression and its epigenetic function has also been associated with 
development and progression of cancer. Increased HELLS expression has been shown 
to be characteristic of a diverse range of cancers and is implicated in playing a critical 
role in tumour growth and metastasis, ultimately driving cancer progression (Keyes et 
al., 2011; von Eyss et al., 2012; Wang et al., 2015; He et al., 2016). HELLS exerts this 
action through association with other epigenetic factors, such as G9a and the lncRNA 
HOTAIR, affecting the expression of key genes and tumour suppressors (Wang et al., 
2015; He et al., 2016). The widespread hypomethylation caused by Lsh deletion in 
mice has also been shown to promote erythroleukemia development and is associated 
with genomic instability (Fan et al., 2003, 2008). Another recent report has provided 
further insight into the contribution of Lsh to genome stability. Litwin et al. (2017) 
found that the Saccharomyces cerevisiae homologue of Lsh, Irc5, interacts with the 
cohesin complex, and that disruption of IRC5 led to reduced accumulation of cohesin 
on chromosomes. This resulted in premature sister chromatid separation, which has 
implications for genomic stability, as well as for accurate DNA replication and 
chromosome segregation during mitosis. These studies highlight physiological roles 
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for Lsh, as well as the critical function in epigenetic regulation of cell growth and 
genomic stability. 
1.4 Epigenetic mechanisms in embryonic development 
Mammalian embryonic development is the process by which a single-cell zygote 
undergoes cell division and differentiation, resulting in a complex and multi-cellular 
mammalian embryo. Development of an embryo from a zygote is a complex process 
requiring co-ordination of multiple global and cell-specific mechanisms to direct 
changes in gene expression, while the underlying DNA sequence remains unchanged. 
These gene expression changes are primarily orchestrated by a network of core 
transcription factors (TFs), Oct4, Sox2 and Nanog (reviewed by Li and Belmonte, 
2017). Epigenetic mechanisms act alongside TF networks to regulate TF binding and 
to reinforce expression changes, directing cell fate decisions and promoting 
developmental progression.  
Establishment of stable, heritable epigenetic marks directs lineage commitment, 
progressively restricting the developmental potential of cells and establishing barriers 
to prevent reversion to preceding cellular states. However, genome-wide epigenetic 
patterns can be extensively reprogrammed to reinstate developmental potency at two 
key stages during mammalian development - in the zygote after fertilisation and in 
PGCs (Smith et al., 2012; reviewed by Hackett and Surani, 2013). Extensive global 
epigenetic remodelling can also be induced in vitro, exemplified by generation of 
iPSCs from somatic cells (Takahashi and Yamanaka, 2006). These systems highlight 
the importance of dynamic epigenetic changes during development in defining cell 
state and developmental plasticity. 
Multiple epigenetic systems including DNA methylation, histone modifications and 
small RNAs co-operate to influence the progression of embryonic development. DNA 
methylation undergoes possibly the most extensive changes during development, and 
its importance in development is highlighted by the relatively early embryonic lethality 
of the DNMTs (Li, Bestor and Jaenisch, 1992; Lei et al., 1996; Okano et al., 1999). 
Specifically, 5-mC has been demonstrated to be critical for directing and maintaining 
cell differentiation in embryonic lineages, as hypomethylated Dnmt1-/- ESCs are viable 
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and proliferate normally, but undergo p53-mediated apoptosis when induced to 
differentiate (Li, Bestor and Jaenisch, 1992). Due to the essential role of DNA 
methylation in influencing and maintaining cellular identity, the mechanisms which 
erase and establish DNA methylation during development and the direct effects of 
these epigenetic events are of particular interest and are still not fully understood.  
1.4.1 Epigenetic dynamics during early embryonic development 
During the early stages of mammalian embryonic development, DNA methylation 
undergoes dramatic global reprogramming.  This ensues in the zygote upon 
fertilisation, where there is rapid and extensive de-methylation of the genome 
(illustrated in Figure 1.5). It has been suggested that the zygotic DNA de-methylation 
is TET enzyme mediated (primarily TET3) and proceeds through oxidation of 5-mC 
to 5-hmC, followed by a passive loss of 5-hmC through DNA replication (reviewed 
by Hill, Amouroux and Hajkova, 2014). However, detailed analysis indicates that 5-
mC is removed from the paternal genome prior to 5-hmC accumulation and that 
inactivation of TET3 does not interfere with this process; implying that the processes 
underlying DNA de-methylation is complex and still to be fully explained (Amouroux 
et al., 2016; reviewed by Nashun, Hill and Hajkova, 2015). This progressive de-
methylation culminates in functionally pluripotent cells of the inner cell mass (ICM) 
of the blastocyst (approximately E3.5 in mice) that display a globally hypomethylated 
genome. It is this stage of development from which ESCs are derived, which will be 
discussed in more detail in section 1.4.3. Some genomic regions retain DNA 
methylation in the hypomethylated ICM, such as IAPs and genomic imprints, however 
some dispersed repeats such as LINEs and selected LTR classes undergo dramatic de-
methylation (Lane et al., 2003; Kim et al., 2004). 
Following genome-wide DNA methylation erasure, global DNA methylation patterns 
are progressively re-established in the ICM in the implanting blastocyst, during the 
morphogenetic transformation of the blastocyst into a cup-shaped epithelium known 
as the egg cylinder (Figure 1.5). This wave of DNA methylation deposition assists in 
directing lineage specification and ultimately maintaining cellular identity and 
genomic stability. De novo DNA methyltransferases Dnmt3a and Dnmt3b and their 
co-factor Dnmt3l direct this global re-methylation of the genome in the implanting 
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blastocyst. These patterns of DNA methylation are then maintained throughout all 
subsequent cell divisions by Dnmt1 and its co-factors. Genome-wide studies using 
reduced representation bisulfite sequencing (RRBS) and meDIP indicated that the vast 
majority of de novo DNA methylation re-establishment is completed prior to the onset 
of gastrulation at E6.5 (Borgel et al., 2010; Smith et al., 2012). A study examining de 
novo DNA methylation during trophoblast differentiation highlighted gains of DNA 
methylation across specific lineage-specific promoters such as Elf5 that act as an early 
epigenetic restriction and a determinant of cell fate (Ng et al., 2008). A further study 
also demonstrated the establishment of 5-mC at specific pluripotency and germ-line 
specific gene promoters during mESC progression to lineage-committed neural 
progenitors (Mohn et al., 2008). This acquisition of DNA methylation early in the 
differentiation process correlated with lineage commitment, suggesting a role for de 
novo DNA methylation in repression of pluripotency and preventing differentiation 
down the germ cell lineage. Accumulation of DNA methylation at key promoters 
exemplifies the idea that progressive DNA methylation acts to influence early 
developmental decisions and ultimately restrict cell fate, reminiscent of Waddington’s 





Figure 1.5. DNA methylation remodelling during embryonic development. Rapid 
DNA de-methylation ensues after fertilisation of the zygote in the paternal genome 
(represented in blue), with DNA de-methylation progressing at a steadier pace in the 
maternal genome (shown in red). This genome-wide erasure of 5-mC culminates in 
globally hypomethylated cells of the ICM in the blastocyst, from which ESCs are derived. 
Genome-wide patterns of DNA methylation are re-established during implantation of the 
blastocyst. The majority of 5-mC patterns are re-established by day E6.5, resulting in a 
hypermethylated genome in the post-implantation epiblast (the stage from which EpiSCs 
are derived). 
A second wave of global de-methylation occurs during PGC specification between 
E8.5 and E12.5. The genome-wide hypomethylation observed in PGCs is more 
extensive than that of pre-implantation ICM, as it includes erasure of genomic imprints 
so that they can be re-established in a sex-specific manner during PGC specialization 
(Hajkova et al., 2002). In contrast to hypomethylated ICM cells, DNA methylation is 
lost at almost all repetitive elements except IAPs were it is partially retained (Lane et 
al., 2003). Re-methylation ensues from E12.5 during differentiation and maturation of 
gametes, although the dynamics of de novo DNA methylation differ between male and 
female germ cells. This results in re-establishment of distinct DNA methylomes 
between the hypermethylated sperm and partially methylated oocyte genomes (Smith 
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et al., 2012). These mature gametes may ultimately go on to fuse, restarting the 
mammalian life cycle from the zygotic stage. 
1.4.2 Pluripotent stem cells as a model for early development 
Pluripotent stem cells are defined as having the potential to generate almost every cell 
type in the body. They possess the ability to generate any of the three primary germ 
layers: ectoderm, mesoderm and endoderm, and can therefore give rise to almost all 
the tissues and organs that make up an adult organism. Pluripotent stem cells do 
however retain a degree of lineage restriction, as they do not efficiently contribute to 
the trophoectoderm or primitive endoderm, unlike totipotent cells which can generate 
all extra-embryonic tissues (Beddington and Robertson, 1989). 
There are several key types of pluripotent stem cells, with the most commonly used 
forms being ESCs derived from the ICM of the blastocyst, embryonic germ cells 
(EGCs) isolated from the primordial germ layer of a developing embryo, and ECCs 
that can be established from teratomas that arise in the ICM. Isolation and culture of 
these pluripotent stem cell models has provided valuable tools in which to study 
development in vitro. More recently, a breakthrough discovery showed that adult 
somatic cells can be directly (genetically) reprogrammed into iPSCs through ectopic 
expression of specific pluripotency factors Oct4, Sox2, Klf4 and c-Myc (Takahashi and 
Yamanaka, 2006). This discovery provided a great deal of promise for the areas of 
developmental biology, regenerative medicine and epigenetics. For this thesis, I 
focussed on the most commonly used and best characterised pluripotent stem cell type, 
ESCs, as an in vitro model for early mammalian embryonic development.  
1.4.3 Isolation and culture of mouse ESCs 
ESCs were originally isolated and cultured from the ICM of the mouse blastocyst in 
1981 by two groups (Evans and Kaufman, 1981; Martin, 1981). These mouse ESCs 
(mESCs) were shown to have the capacity to self-renew, meaning that they could be 
established as progressively growing cultures in vitro. The pluripotent status of these 
mESCs was confirmed when they were shown to be able to differentiate into a wide 
variety of cell types that contribute to all three germ layers. Despite the transiency of 
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the pluripotent state that cells of the ICM occupy in vivo, their in vitro mESC 
counterparts can be maintained indefinitely under the appropriate culture conditions. 
Even after extensive culture, mESCs retain key attributes of ICM cell identity and 
potency and can contribute to all adult tissues in chimeric animals following 
reintroduction into the developing blastocyst (Bradley et al., 1984). The capability of 
mESCs to re-enter the developmental program in chimeric animals to produce 
functional somatic and germ cells was pivotal for the development of techniques to 
produce transgenic mouse models. Combination of these ESC techniques with 
homologous recombination technologies paved the way to targeted transgenesis, 
enabling precise manipulation of the mouse genome, and so the production of knock-
out, knock-in and conditional transgenic mouse and cell lines (Doetschman et al., 
1987; Thomas and Capecchi, 1987; Downing, Battey Jr. and Battey, 2004). The key 
features of self-renewal and developmental potency also make mESCs a valuable tool 
for modelling development and disease mechanisms in vitro. 
Conventionally, mESC cultures are maintained on a layer of mitotically inactivated 
‘feeder’ fibroblasts and in the presence of foetal calf serum, which provide previously 
undefined factors enabling the sustained proliferation of these cultures whilst 
maintaining their pluripotent status. The cytokine leukaemia inhibitory factor (LIF) 
was later identified as the crucial factor secreted by fibroblasts, a discovery which 
enabled the generation of mESC cultures maintained in LIF and serum in the absence 
of feeders (Smith et al., 1988; Williams et al., 1988). LIF promotes pluripotency by 
inducing expression of pluripotency genes, such as Klf4, through binding to the gp130 
receptor to activate transcription factor STAT3 in a JAK kinase-dependent manner 
(Niwa et al., 1998, 2009). Alongside LIF, bone morphogenic protein 4 (BMP4), which 
is present in foetal calf serum, was identified as the other key component that supports 
mESC self-renewal and supresses neural differentiation in culture (Ying et al., 2003; 
Zhang et al., 2010). It achieves this by acting via SMAD signalling pathways to 
stimulate expression of Inhibition of differentiation (Id) genes (Ying et al., 2003). 
Together, LIF and BMP4 (provided by serum) constitute the central components 
required to protect the pluripotent status of mESC cultures through both induction of 
pluripotency networks and suppression of differentiation.  
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The ‘conventional culture’ of mESCs in LIF and serum as described above can lead to 
some issues with the reproducibility of cultures due to the presence of undefined and 
variable factors within and between batches of animal-derived serum. The mechanisms 
by which LIF and serum act to maintain mESCs can also affect the stability of cultures. 
The mode of action of LIF and serum focuses on counteracting the downstream effects 
of differentiation priming. Along with activation of undefined signalling pathways by 
unregulated serum components, this creates an environment comprising numerous and 
often conflicting signals (reviewed by Hackett and Surani, 2014). Although this does 
not affect the functional pluripotency of the culture as a whole, it results in a population 
of cells occupying a spectrum of pluripotent states. This manifests in cultures 
displaying heterogeneity in terms of morphology, gene expression and differentiation 
capacity (Chambers et al., 2007; Hayashi et al., 2008; Toyooka et al., 2008). Some 
cells will resemble a state of ‘naïve’ or ‘ground state’ pluripotency, representative of 
cells in the ICM of the blastocyst, while others may more closely reflect a ‘primed’ 
state, associated with expression of lineage specification markers and are proposed to 
be more developmentally advanced (Hayashi et al., 2008; Canham et al., 2010). 
mESCs cultured in serum and LIF are dynamic, with cells continually cycling between 
these pluripotent phases (Toyooka et al., 2008; Abranches et al., 2013). Thus, these 
mESC cultures can be described as ‘metastable’. This metastability has been proposed 
by some to be a functional property of mESC cultures, allowing preparation for lineage 
commitment whilst preserving the pluripotent status of the population as a whole 
(Torres-Padilla et al., 2014). Others argue that the heterogeneity of mESCs is a result 
of sub-optimal conventional culture conditions and that there is a lack of evidence for 
the existence of transcriptional heterogeneity in the epiblast in vivo (Kalkan and Smith, 
2014). 
Additionally, and crucially, populations of mESCs cultured in the presence of serum 
and LIF exhibit global DNA hypermethylation, despite being isolated from the 
hypomethylated ICM (Meissner et al., 2008; Habibi et al., 2013; Leitch et al., 2013). 
The average CpG methylation of cultured mESCs in serum is approximately 80%, a 
level similar to those of primed or lineage-restricted cells (Stadler et al., 2011). Indeed, 
WGBS indicated that DNA methylation profiles of male mESCs resemble those of 
post-implantation E6.5 epiblast (Habibi et al., 2013). This highlights that the DNA 
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methylomes of cultured mESCs may not faithfully reflect those of the pre-implantation 
ICM from which they are derived, and so may not represent the ideal model for 
investigation of DNA methylation patterns in early development. 
1.4.4 The ground state of pluripotency 
To overcome the issues associated with conventional mESC derivation and culture, 
more well-defined serum-free culture systems were sought. In 2008, Ying et al. 
described the use of two small molecule kinase inhibitors (‘2i’) which simultaneously 
block Fgf/Erk signalling and enhance Wnt signalling, resulting in a population of cells 
occupying a state of naïve pluriopotency. Specifically, small molecule PD0325901 
(PD03) targets Mek for inhibition, blocking the differentiation-inducing consequences 
of Erk signalling, whereas CHIR99021 (CHIRON) promotes pluripotency through 
Gsk3 inhibition, which stabilises β-catenin, mimicking canonical Wnt signalling. 
Collectively, the 2i components stabilise and promote naïve pluripotency by insulating 
mESCs from differentiation signalling and inducing pluripotency and self-renewal 
networks (Ying et al., 2008). This results in a more uniform expression of key 
pluripotency genes such as Nanog, Esrrb and Prdm14 as well as reduced expression 
of lineage-associated factors, resulting in a population of mESCs that are 
transcriptionally and functionally distinct from those cultured in serum and LIF 
(Figure 1.6, Marks et al., 2012).  
Crucially, establishment of naïve pluripotency also coincides with global 
hypomethylation. Analysis of global 5-mC levels using mass spectrometry techniques 
revealed an approximate three-fold reduction in global DNA methylation in mESCs 
cultured in 2i and LIF compared to their serum counterparts (Habibi et al., 2013; Leitch 
et al., 2013). Genome-wide methylome analysis showed that the distribution of DNA 
methylation in 2i/LIF mESCs was comparable to the hypomethylated cells of the ICM 
from which ESCs are derived, indicating that the 5-mC profiles of 2i mESCs may more 
faithfully reflect methylation patterns present in the pre-implantation epiblast (Ficz et 
al., 2013; Habibi et al., 2013; Choi et al., 2017). Some genomic loci were resistant to 
the de-methylation associated with transition to naïve pluripotency, such as IAP 
elements and genomic imprints, consistent with the unchanged expression levels of 
Dnmt1 which are required to maintain methylation at these regions (Ficz et al., 2013; 
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Habibi et al., 2013; Leitch et al., 2013). The retention of 5-mC at these regions 
parallels those which escape the wave of de-methylation in vivo following fertilisation 
of the zygote. Somewhat surprisingly, when 2i/LIF mESCs were returned to 
serum/LIF culture, global 5-mC levels fully recovered and showed appropriate re-
establishment of DNA methylation patterns (Habibi et al., 2013; Leitch et al., 2013). 
This illustrates the interconvertibility between these culture states and the distinct 
DNA methylomes that they confer, highlighting the remarkable plasticity of the 
supposedly relatively stable 5-mC mark in this culture system (illustrated in Figure 
1.6). The interconvertibility of this system also provides opportunities to dynamically 
modify DNA methylation levels in mESC culture models. 
 
Figure 1.6. Schematic depicting the characteristic features of serum and 2i 
cultures and the interconvertibility between these pluripotent states.  ‘Metastable’ 
mESCs cultured in the presence of serum exhibit heterogeneous expression of 
pluripotency and lineage-associated factors and are globally hypermethylated. They can 
be reversibly transitioned to the pluripotent ‘ground state’, where pluripotency factor 
expression becomes more uniform, lineage-associated factor expression is reduced, 
and the genome exhibits global hypomethylation. 
A caveat of using the 2i culture system as a model for the ICM is that perturbation of 
Wnt and Fgf/Erk signalling is linked to genome instability and cellular transformation 
in ESCs (Acevedo et al., 2007; Raggioli et al., 2014; Chen et al., 2015). An increase 
in karyotypic abnormalities has been reported following prolonged culture (more than 
20 passages) of mESCs in 2i (Hassani et al., 2014). A recent study has also 
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demonstrated irreversible epigenetic perturbations, such as progressive de-methylation 
of ICRs at most imprinted genes, alongside chromosomal aberrations after long-term 
2i culture, affecting the developmental potential of these mESCs (Choi et al., 2017). 
Therefore, maintenance of mESCs in the presence of 2i is not advised, and short-term 
(less than 10 passages) culture of mESCs is preferred for modelling DNA methylation 
in pre-implantation development.  
The mechanisms governing the global DNA methylation reprogramming observed 
during transition from primed serum mESCs to naïve pluripotency have remained a 
topic of discussion since its discovery. Ficz et al. (2013) proposed that de-methylation 
occurs through a combination of active and passive mechanisms. Within the first 72 
hours of 2i transition, initial global 5-mC erasure was accompanied by a two-fold 
transient enrichment in 5-hmC, suggesting that active removal of 5-mC through a 5-
hmC intermediate partly accounts for DNA de-methylation in the early stages of 2i 
transition. This initial active DNA de-methylation was followed by replicative loss of 
5-mC and 5-hmC throughout the genome during the remainder of the transition to 
ground state pluripotency. This passive de-methylation was thought to be assisted by 
the disabling of de novo DNA methylation through rapid transcriptional repression of 
Dnmt3a and Dnmt3b and their co-factor Dnmt3l, while expression levels of Dnmt1 
and its co-factor Uhrf1 remained constant (Ficz et al., 2013). Other reports supported 
this model of cooperation between active and passive mechanisms alongside de novo 
methylation suppression, resulting in genome-wide 5-mC erasure associated with 
transition to 2i culture (Habibi et al., 2013; Leitch et al., 2013). Indeed, a critical role 
for PR-domain-containing 14 (Prdm14) in 2i-associated de-methylation was revealed 
by Yamaji et al. (2013), who demonstrated that Prdm14 downregulates the expression 
of de novo DNMTs via recruitment of the repressive complex PRC2, and that the 
presence of Prdm14 is essential for global hypomethylation during the transition to the 
pluripotent ground state. The reversion of ground state mESCs into serum/LIF culture 
results in the upregulation of Dnmt3a, Dnmt3b and Dnmt3l expression, which is 
thought to drive the re-establishment of DNA methylation throughout the genome 
(Habibi et al., 2013; Leitch et al., 2013; Yamaji et al., 2013).   
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A recent report employed mathematical modelling of DNA de-methylation kinetics to 
dissect the contribution of different de-methylation mechanisms to 2i-associated 
genome-wide hypomethylation. This analysis implicated impaired DNA methylation 
maintenance in global 5-mC erasure, rather than active de-methylation or disrupted de 
novo methylation. A reduction in Dnmt1-targeting co-factor Uhrf1 alongside a 
genome-wide loss of H3K9me2, which is thought to be required for association of 
Uhrf1 with chromatin, is proposed to disrupt targeting of Dnmt1 to replicating DNA, 
resulting in impaired 5-mC maintenance and its subsequent reduction throughout the 
genome of ground state mESCs (von Meyenn et al., 2016). These conflicting models 
for 5-mC erasure during transition to naïve pluripotency highlight the further 
investigation that is required to uncover the mechanistic regulation of this DNA de-
methylation pathway. 
Alongside the extensive remodelling of DNA methylation that occurs upon transition 
towards naïve pluripotency, there is a genome-wide reconfiguration in the patterns of 
repressive histone modifications. The histone mark deposited by PRC2, H3K27me3, 
is globally redistributed in ground state mESCs. Unlike in conventional serum mESCs 
where H3K27me3 is enriched over the promoters of PRC target genes, H3K27me3 is 
depleted at promoters in 2i, although this does not coincide with transcriptional 
activation of the associated genes. Total cellular levels H3K27me3 are comparable 
between serum and 2i mESCs, suggesting a redistribution of the mark rather than 
global depletion, which is confirmed by a substantial increase of H3K27me3 apparent 
at major satellite regions (Marks et al., 2012). A report from Walter et al. (2016) that 
utilised 2i in combination with vitamin C to deplete 5-mC even more extensively than 
in 2i/LIF media alone also observed an accumulation of H3K27me3 at repetitive 
elements, suggesting that this repressive mark is sequestered to these regions to 
reinforce silencing of transposons in the absence of DNA methylation. Furthermore, 
the redistribution of H3K27me3 away from promoters results in a marked reduction 
of bivalency in ground state mESCs, implying that fewer genes are poised for 
development in this pluripotent state (Marks et al., 2012). Along with reconfiguration 
of H3K27me3 deposition, there is also evidence of other epigenetic perturbations, such 
as a global reduction in H3K9me3, and particularly H3K9me2, in the pluripotent 
ground state (Leitch et al., 2013; von Meyenn et al., 2016; Walter et al., 2016). 
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1.4.5 Culture models representing later developmental stages 
The cluster of 10-20 cells that are present in the ICM of the blastocyst give rise to more 
than 200 specialised cell types that are present in the adult organism. The biological 
processes of lineage commitment and differentiation that underlie the generation of 
this diverse array of tissues from a relatively small pool of pluripotent cells is an area 
of active research. Over the years, methods involving in vitro differentiation of mESCs 
have been developed and optimised. This has allowed dissection of the molecular and 
epigenetic mechanisms involved in the biological processes of lineage commitment 
and differentiation, as well as providing culture models representing the early stages 
of post-implantation development. 
A key and widely-used differentiation method involves LIF withdrawal and 
aggregation of mESCs in suspension, resulting in the formation of structures called 
embryoid bodies (EBs). The differentiation of mESCs to EBs can generate all three 
germ layers, as well as wide variety of specialised cell types such as those in the 
cardiovascular, hepatic and neural lineages (Doetschman et al., 1985; Burkert U, von 
Rüden T, 1991; Murry and Keller, 2008). Addition of growth factors to mESC cultures 
during transition to EBs can also influence the route of differentiation, with addition 
of specified concentrations of RA promoting formation of neurons (Wichterle et al., 
2002). The process of EB formation is thought to reflect the orderly dynamics of in 
vivo differentiation, as EBs have been reported to exhibit a degree of self-organisation 
and appear to undergo a gastrulation-like process during their generation (ten Berge et 
al., 2008). They have been demonstrated to form a primitive streak-like region, where 
cells undergo an epithelial-to-mesenchymal transition and differentiate into 
mesodermal progenitors, and appear to establish an anteroposterior polarity. This 
renders EBs an effective model in which to study the gastrulation process in vitro, and 
has added advantages over differentiation protocols involving adherence to matrices 
or in monolayers due to the ability of EBs to form gastrulation-like structures and 
polarity.  
More recently, cell lines were derived from post-implantation mouse epiblasts by two 
groups using culture conditions including Fgf and Activin in the absence of LIF, 
conditions also sufficient for long-term propagation of human ESCs (Brons et al., 
51 
 
2007; Tesar et al., 2007). These cultures, termed epiblast stem cells (EpiSCs), express 
the core pluripotency factors Oct4, Sox2 and Nanog, but all other naïve pluripotency 
genes are transcriptionally silent (Guo et al., 2009). Instead, markers of the early post-
implantation epiblast are expressed such as Fgf5, along with lineage-specific genes 
such as endodermal Foxa2 and mesodermal Brachyury. However, EpiSC populations 
are highly heterogeneous, as is the expression of lineage-specific factors, with EpiSC 
populations proposed to occupy a range of states representing the early epiblast to up 
to the late-gastrula-stage embryo (Han et al., 2010; Kojima et al., 2014; Tsakiridis et 
al., 2014). EpiSCs have been proposed to be true in vitro counterparts of the post-
implantation epiblast as they retain functional properties of the epiblast, such as the 
ability to differentiate into somatic lineages in vitro and can generate chimeras when 
grafted into post-implantation embryos in culture (Han et al., 2010; Huang et al., 2012; 
Kojima et al., 2014). 
EpiSCs can also be generated in culture from ESCs propagated in the presence of Fgf2 
and Activin (Guo et al., 2009). This involves multiple passages to stabilise the culture 
after a period of substantial cell death. However, parallels can be drawn between this 
ESC to EpiSC conversion and the in vivo differentiation process as one copy of the X-
chromosome becomes epigenetically silenced in female cells, suggesting that similar 
epigenetic mechanisms are active in both systems. Additionally, EpiSCs generated in 
culture represent a developmentally restricted state as they do not spontaneously revert 
to the pluripotent state without genetic manipulation (Guo et al., 2009). Although these 
EpiSCs can be inefficiently reprogrammed to naïve pluripotency with the introduction 
of a single pluripotency factor Klf4, they are proposed to represent a distinct 
developmental, epigenetic and functional state from naïve ESCs in culture, and 
provide an in vitro model of the pre-gastrulation epiblast (Guo et al., 2009; Nichols 
and Smith, 2009). 
1.5 Thesis aims 
The erasure and re-establishment of DNA methylation during early embryonic 
development in order to acquire then progressively restrict cellular potential remains 
a remarkable example of the power of epigenetics. However, despite the great interest 
in these biological processes, the mechanisms involved in governing these transitions 
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are still not fully understood. It is becoming increasingly clear that the complement of 
factors involved in enacting epigenetic processes in a cell is dependent on cellular 
identity and developmental context. Therefore, I aimed to dissect the contribution of 
selected factors to the epigenetic mechanism of DNA re-methylation during the 
developmental transitions observed in the early stages of cellular potential restriction 
(i.e. differentiation).  
The DNA methylation co-factor and putative chromatin remodelling helicase Lsh has 
been conclusively shown to be essential for normal levels of DNA methylation in 
mouse embryos. Its crucial role in development had also been demonstrated, as Lsh-
depleted mice exhibit multiple physiological defects and die either perinatally or in 
their infancy. However, most previous studies of Lsh function had focussed on the 
effects of Lsh depletion in somatic cells and embryonic tissues, with little insight into 
the requirement for or function of Lsh in the early stages of development, where DNA 
methylation patterns are set in accordance with lineage commitment. I set out to 
decipher the contribution of Lsh to DNA methylation in these developmental stages 
using culture models where establishment of DNA methylation and restriction of 
developmental potential could be assessed. Therefore, the main aims of my thesis were 
specified as follows: 
• To develop and optimise a mESC system in which to dynamically modulate 
DNA methylation levels, allowing observation of DNA methylation 
establishment in a pluripotent context 
• To determine the requirement for Lsh function in DNA methylation 
establishment in this mESC culture system 
• To investigate the contribution of Lsh to DNA methylation deposition in 
culture models representing later developmental stages, during the restriction 




Chapter 2. Materials and Methods 
2.1 Mammalian cell culture 
All mammalian cells were cultured on cell culture grade tissue culture flasks (Corning) 
or plates (nunclon delta surface, Thermo Scientific) in a humidified atmosphere at 
37°C and 5% CO2. 
2.1.1 Cell lines and media 
E14 and CRISPR lsh-/- mESCs generated from E14 mESCs were used throughout this 
project (CRISPR lsh-/- line generated by Dr Donncha Dunican, unpublished). WT and 
dnmt3l-/- mESCs generated using TALEN gene editing were kindly provided by the 
Oliviero group (Neri et al., 2013). WT and HELLS mutant HAP1 cell lines were 
purchased from Horizon Genomics (www.horizondiscovery.com). The media recipes 
for all cell lines used are detailed in Tables 2.1 and 2.2. 
 Serum EB SNLP HAP1 Company 
Media type GMEM DMEM DMEM IMDM Gibco 
FCS 15% 20% 15% 10% In-house 
NEAA 1% 1% 1% - Sigma 
Sodium pyruvate 1% - 1% - Sigma 
L-glutamine 1% 1% 1% 1% In-house 
Pen/strep 1% 1% 1% 1% In-house 
β-mercaptoethanol 50 µM 100 µM - - Invitrogen 
LIF 500 units/ml - - - Millipore 
Table 2.1. Culture media recipes. Companies that reagents were acquired from are 




 2i EpiSC Company 
Basal Media    
Neurobasal 50% 50% Invitrogen 
DMEM-F12 50% 50% Invitrogen 
N2-supplement 0.5x 0.5x Invitrogen 
B27-supplement 0.5x 1x Invitrogen 
7.5% BSA 0.05% - Invitrogen 
Pen/strep 1% 1% In-house 
NEAA - 1% Sigma 
β-mercaptoethanol - 50 µM Invitrogen 
Complete Media    
LIF 1000 units/ml - Millipore 
L-glutamine 1% 1% In-house 
PD0325901 1 µM - Stemgent 
CHIR99021 3 µM - Stemgent 
Monothioglycerol 0.15 mM - Sigma 
FGF2 - 10 ng/ml R&D systems 
Activin A - 20 ng/ml Peprotech 
Table 2.2. Specialised culture media recipes. Basal media recipe is indicated in the 
top portion of the table. Complete media refers to the components that were added 
to 50 ml aliquots of the basal media and used within 3 days of preparation. 
2.1.2 mESC serum and 2i culture 
The ‘serum’ and ‘2i’ media that mESCs were cultured in are detailed in Tables 2.1 and 
2.2. LIF was included in both serum and 2i media. Serum and 2i mESCs were passaged 
every 2-4 days upon reaching ~80-90% confluency. To passage, the media was 
removed and the cells rinsed with 1x PBS (Sigma). The cells were detached from the 
culture surface using 1x trypsin-EDTA v/v (Sigma) and gentle agitation following 
incubation at 37°C for 2-3 minutes. The trypsin was then inactivated by adding media 
containing serum then centrifuging at 1000 rpm for 5 minutes. For 2i cells, an 
additional wash step was performed to remove traces of serum using GMEM only 
medium (Gibco).  Cells were then resuspended in the appropriate medium and seeded 
into new flasks or plates coated with 0.2% gelatin (G1890, Sigma, prepared in 1x 
PBS). Media was changed when required, or every 1-2 days for mESCs cultured in 2i. 
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2.1.3 Transition to epiblast stem cells (EpiSCs) 
E14 and lsh-/- mESCs converted to 2i in the presence of LIF for at least 15 days (treated 
as passage 0) were transitioned to EpiSCs in the absence of LIF using the media 
detailed in Table 2.2. Culture flasks/plate surfaces were prepared by adding 0.75 
µg/cm2 of fibronectin diluted in 1x PBS (Millipore, FC010). This was incubated at 
room temperature for 10 minutes, then removed and surfaces were left to dry in a 
sterile culture hood for at least 30 minutes prior to use. At the start of the transition, 2 
x 105 2i mESCs were seeded per well of a 6-well plate coated with fibronectin in 2i 
medium. The cells were left to attach to the plate for approximately 6 hours before the 
medium was changed to ‘EpiSC’ medium. During the transition, cells were passaged 
upon reaching ~80-90% confluency, which was between every 2-7 days depending on 
the stage of the transition. To dissociate the cells, 1x accutase (StemPro) was added to 
the cells after rinsing with 1x PBS. The cells were carefully collected in EpiSC 
medium and centrifuged at 1000 rpm for 5 minutes, then gently resuspended in EpiSC 
medium and seeded into new plates or flasks coated with fibronectin. Media was 
changed every 1-2 days during the transition to EpiSCs.  
2.1.4 Differentiation to embryoid bodies (EBs)  
E14 and lsh-/- mESCs adapted to 2i in the presence of LIF for 15 days were transitioned 
to EBs using the media detailed in Table 2.1. On day 0 of the protocol, 20 µl droplets 
of ‘EB’ media (without LIF) containing 200 or 400 2i mESCs were plated onto the 
lids of sterile 10 cm2 dishes (Thermo Scientific) using a multichannel pipette. On each 
lid, 48 droplets were plated. The plates were filled with 20 ml 1x PBS to maintain a 
humid environment for the hanging drop EBs to form in. The plates were left 
undisturbed until day 3, when the newly-formed EBs were removed from the lids and 
placed into non-gelatinised 10 cm2 sterile dishes to achieve further growth in 
suspension. EB medium was used to flush the EBs from two plate lids (approximately 
96 EBs) into a 50 ml Falcon tube. The EBs were then left to settle to the bottom of the 
tube at room temperature for 15 minutes. Excess media was aspirated and the EBs 
were resuspended in fresh EB medium and placed into a non-gelatinised 10 cm2 dish. 
Care was taken not to disaggregate the EBs during this process, helped by using 
stripettes with a large opening (25 ml or 50 ml).  The 200- and 400-cell EBs were 
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cultured separately. On day 5, the 200- and 400-cell EBs were collected and excess 
media removed using the same procedure as on day 3. The 400-cell EBs from one dish 
were resuspended in fresh EB medium and seeded into a 10 cm2 culture dish (nunclon 
delta surface, Thermo Scientific) coated with 0.2% gelatin. The 200-cell EBs were 
seeded into gelatinised 12-well culture plates containing one glass coverslip per well, 
aiming to place 4-5 EBs per well. At this stage, RA (Sigma) was added to the media 
of the appropriate wells/plates at a final concentration of 1 µm. The EBs settled and 
attached to these culture surfaces and were incubated a further 7 days. The media was 
carefully changed every 2-3 days. On day 12, the EBs in the 10 cm2 dishes were 
harvested (as described in section 2.1.4.) using trypsin-EDTA to detach them from the 
culture surface. The EBs cultured on coverslips were fixed in situ (as described in 
Section 2.6.1.) for analysis by immunofluorescence. 
2.1.5 Blastocyst derivation and culture 
Blastocysts were isolated from Lsh conditional knockout mice with the aim of deriving 
lsh-/- mESC lines to confirm results obtained using CRISPR-generated lsh-/- lines. Two 
mice conditional for the genetrap construct in the Lsh locus were crossed and E3.5 
blastocysts isolated from the resulting pregnant female. Blastocysts were collected, 
plated and disaggregated (at day 7) as described in Czechanski et al. (2014) in 2i media 
(containing LIF, shown in Table 2.2) on a layer of mitotically inactivated SNLP 
feeders. Established mESC lines were maintained in 2i with LIF and on feeders and 
were passaged using the method described in section 2.1.1., using a seeding density of 
1-3 x 105 cells per cm2. Transgenic mouse lines were maintained and crosses set up by 
David Read. Blastocyst collection, plating and disaggregation was carried out by Dr 
Ian Adams. 
2.1.5.1 Preparation of mitotically inactivated feeders 
A layer of mitotically inactivated SNLP feeders were required to support derivation 
and growth of mESC lines derived from blastocysts. SNLPs were cultured in the media 
described in Table 2.1. They were treated with 10 µg/ml mitomycin C (Sigma) for 2.5 
hours, then washed thoroughly twice with PBS before dissociation with 1x trypsin. 
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These mitotically inactivated SNLPs were then counted and seeded at a density of 1 x 
104 cells per cm2 for use in blastocyst derivation and culture. 
2.1.6 Recovery and cryopreservation of mammalian cell lines 
To recover a cell line, the appropriate vial was retrieved from liquid nitrogen and 
stored in dry ice until thawing in a 37°C water bath. The cell suspension was carefully 
added to 10 ml of the appropriate culture media, then centrifuged at 1000 rpm for 5 
minutes. The resulting cell pellet was resuspended in the required culture media before 
seeding into culture dishes/flasks with the appropriate coating.  
To maintain stocks of cell lines, cells that were surplus to requirements during 
passaging were prepared for cryopreservation in liquid nitrogen. Following 
dissociation and centrifugation, cell pellets were resuspended in CryoStor cell 
cryopreservation media CS10 (Sigma) to obtain cell concentrations of 2-5 x 106 cells 
per ml and added to cryovials. These were subsequently stored at -80°C overnight in 
a Mr Frosty (ThermoFisher Scientific) to facilitate a steady rate of freezing (-1 oC a 
minute) for optimal cell preservation. Following overnight storage at -80 °C, the vials 
were transferred to liquid nitrogen (-140°C) for long-term storage. 
2.1.7 Counting and harvesting of mammalian cell lines 
For cell counting, cultures were dissociated following the appropriate method, 
centrifuged at 1000 rpm for 5 minutes and the resulting pellet thoroughly resuspended 
in 2-5 ml of the appropriate medium to achieve a single-cell suspension, 10 µl of which 
was pipetted into a haemocytometer counting chamber. The number of cells in all four 
quadrants were counted, divided by 4 to give the average number of cells per quadrant, 
then multiplied by 1 x 104 to give the number of cells per ml of suspension. This 
allowed me to seed the correct number of cells at the beginning of the EpiSC and EB 
transition experiments. 
To prepare cell cultures for harvesting, cells were dissociated using the appropriate 
method, collected in media then centrifuged at 1000 rpm for 5 minutes. The resulting 
pellet was resuspended in 1x PBS then centrifuged again at 1000 rpm for 5 minutes. 
All supernatant was removed and pellets for DNA or protein were snap frozen on dry 
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ice and stored at -80°C. Pellets for RNA were resuspended in 1 ml Trizol reagent 
(Invitrogen), snap frozen on dry ice and stored at -80°C. 
2.2 DNA preparation, manipulation and analysis 
2.2.1 DNA extraction from mammalian cell pellets 
Cell pellets were resuspended in 1 ml lysis buffer (100 mM Tris pH 8.5, 5 mM EDTA, 
0.2% SDS, 200 mM NaCl) supplemented with 2 µl RNaseA cocktail (Ambion) and 
incubated for approximately 1 hour at 37 oC. Following this incubation, 5 µl of 20 
mg/ml Proteinase K (ThermoFisher Scientific) was added and the samples were 
incubated at 55oC overnight with shaking at 1000 rpm in a thermomixer. 
The next day an equal volume of UltraPure Phenol:Chloroform:Isoamyl Alcohol (PCI, 
25:24:1 v/v, Invitrogen) was added, the sample was mixed vigorously then centrifuged 
at 4000 rpm for 15 minutes at 4 oC. The upper aqueous phase containing the DNA was 
pipetted off from the lower organic phase containing protein and cell debris. This was 
added to a new tube and a second PCI extraction was performed. A final chloroform 
only (Sigma) extraction was performed and the aqueous phase collected in a new 
eppendorf. One fifth of the sample was transferred to a new eppendorf, 2.5 volumes of 
ice-cold 100% ethanol were added along with 1/10th volume 3 M sodium acetate 
(Sigma). The extractions were then incubated at -20 oC for at least 1 hour to overnight 
to precipitate the DNA. The precipitate was then centrifuged at 13,000 rpm at 4 oC for 
5 minutes to pellet the DNA. The supernatant was discarded and the pellet washed 
with 70% ethanol and centrifuged again at 13,000 rpm at 4 oC for 5 minutes. The 
pelleted DNA was left to air dry for approximately 5 minutes before resuspension in 
30-50 µl mass spectrometry grade water (LC-MS Chromasolv, Sigma). These samples 
were stored at -20 oC for downstream analysis by liquid chromatography mass 
spectrometry to determine methylcytosine content. To the remainder of the PCI 
extracted sample, 2-3 volumes of ice-cold 100% ethanol were added and the sample 
gently inverted to mix. A microbiological loop was used to spool out the precipitated 
DNA. The DNA was washed with 70% ethanol and air dried for 3-5 minutes. The 
DNA was resuspended in 200-300 ul Tris-EDTA (TE, 100 mM Tris pH 8, 10 mM 




2.2.2 Nucleic acid quantification 
The concentration was measured and purity assessed of both dsDNA and ssRNA 
spectrophotometrically using a Nanodrop ND-1000. 1.5 µl of sample was loaded and 
the A260 absorbance measured to calculate the concentration of the sample (as an OD 
of 1 at 260 nm = 50 μg/ml of dsDNA). The A260/280
 and A260/230 ratios were also 
assessed to determine the purity of the nucleic acids.  
2.2.3 Agarose gel electrophoresis  
Nucleic acids were resolved using UltraPure agarose (Invitrogen) gels made using 1x 
TBE (Tris/Borate/EDTA) or 1x TAE (Tris/Acetic acid/EDTA) and supplemented with 
1x SYBR safe (ThermoFisher Scientific) or 1 µg/ml ethidium bromide (EtBr, 
Invitrogen). DNA samples were loaded using orange G loading buffer (50% glycerol 
v/v; 5 mM EDTA pH 8; 0.3% orange G w/v). GeneRuler DNA ladder mix 
(ThermoFisher Scientific) was used to determine the size of DNA fragments. Agarose 
gels were visualised using a UV transilluminator or a FLA-5100 imaging system 
(FujiFilm Life Science). 
2.2.4 Restriction digestion of genomic DNA 
Restriction digestion using methylation-sensitive enzymes was used to assess the 
extent of CpG methylation at their restriction sites, which are enriched in repetitive 
sequences in the genome. Methylation-sensitive restriction endonucleases MaeII 
(HpyCHIV, NEB), HpaII (NEB) were used along with a methylation-insensitive 
isoschizomer of HpaII, MspI (NEB). 1 µg of RNA-free genomic DNA was incubated 
with 10 units of each of these enzymes and 1x CutSmart buffer (NEB) in a total volume 
of 20 µl at 37 oC for 2 hours. Digested DNA was resolved on a 1.5% agarose-TBE gel 
run at 100-150 volts for 1.5-2 hours. The gel was then stained in 1 µg/ml EtBr and 
imaged using the FLA-5100 imaging system. 
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2.2.5 Southern blotting 
Southern blotting in combination with restriction digestion was used to estimate DNA 
methylation levels at major and minor satellite genomic regions. Genomic DNA 
samples restriction digested with MaeII, HpaII or MspI were run on a large 1% 
agarose-TBE gel at 100 volts for approximately 3 hours (for assessment of major 
satellites) or 50 volts for approximately 6 hours (for minor satellites). The gel was 
post-stained with 1 µg/ml EtBr and imaged using the FLA-5100 imaging system. The 
gel was washed 2 x 15 minutes in denaturing solution (0.5M NaOH, 1.5M NaCl) and 
then 2 x 15 minutes in neutralising solution (0.5M Tris pH7.5, 1.5M NaCl) on a 
rocking platform at room temperature. The gel was equilibrated in 20x saline-sodium 
citrate (SSC) for at least 10 minutes before the DNA was transferred onto a Hybond-
N+ membrane (GE Healthcare) overnight by capillary action. The membrane and gel 
were placed between 1 mm Whatman paper saturated with 20x SSC, with the ends of 
the paper dipped in a reservoir of 20x SSC. Dry paper towels and a weight were placed 
on top of the upper Whatman to draw the buffer through the stack, transferring the 
DNA onto the membrane. Following transfer, DNA was crosslinked to the membrane 
using the Stratalinker 1500 UV crosslinker (Stratagene). Hybridisation and probe 
labelling was performed using AlkPhos Direct Labelling and Detection System 
(Amersham). Membranes were pre-hybridised at 55 oC with rotation in 20 ml of the 
provided hybridisation buffer supplemented with 0.8 g of the provided blocking 
reagent (4% w/v) and 2 ml 5M sodium chloride (0.5M final concentration). 50 ng of 
purified probe DNA (detailed in section 2.2.5.1) was denatured in a boiling waterbath 
for 5 minutes, placed on ice for 5 minutes then labelled as follows: 
5 µl 10 ng/µl denatured probe DNA 
5 µl Reaction buffer 
1 µl Labelling reagent 
5 µl Cross-Linker solution (diluted 1 in 4 in water) 
The reaction was incubated at 37 oC for 30 minutes then added to the membrane in the 
hybridisation buffer and incubated overnight at 55 oC with rotation (final probe 
concentration was 2.5 ng/ml). The probed membrane was washed 2 x 10 minutes at 55 
oC with primary wash buffer (2M Urea, 0.1% w/v SDS, 50 mM Na phosphate pH 7, 
150 mM NaCl, 1 mM MgCl2, 0.2% w/v Blocking reagent) then washed 2 x 5 minutes 
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at room temperature in 1x secondary wash buffer (20x = 1M Tris base, 2M NaCl, pH 
10) supplemented with MgCl2 to a final concentration of 2 mM. For detection, 7 ml 
CDP-Star detection reagent (Amersham) was added to the membrane for 5 minutes, 
then developed and imaged using an ImageQuant LAS 4000 (GE Healthcare).  
2.2.5.1 Probe preparation 
Plasmid DNA for major satellite (pSAT, Lewis et al., 1992) and minor satellite (R198, 
Kipling et al., 1994) genomic regions was double restriction digested (EcoRI/BamHI, 
NEB, for major satellite, EcoRI/HindIII, NEB, for minor satellite) to excise the 
fragment to use as a Southern blot probe. 2 µg plasmid DNA was digested at 37 oC for 
2 hours with 20 units of each of the appropriate enzymes in a total reaction volume of 
50 µl with 1x CutSmart buffer (NEB). The fragment for the probe (major satellite 240 
bp, minor satellite 360 bp) and the plasmid DNA were separated on a 1% agarose-
TAE gel and the fragment was gel purified as described in Section 2.5.2. The plasmids 
used to prepare the probes for Southern blotting were kindly provided by Professor 
Nick Gilbert. 
2.2.6 Mass spectrometry analysis of 5-methylcytosine content 
Liquid chromatography mass spectrometry (LC-MS) was used to identify and quantify 
global levels of 5-methylcytosine (5-mC) in DNA samples from mammalian cells. 
Using this technique, genomic DNA was hydrolysed to single nucleotides which were 
then extracted using methanol and acetonitrile and separated on a spectrometry 
column, using the monoisotropic mass in daltons (Da) to identify desired nucleotide. 
Standards for cytosine and 5-mC (Zymo) were prepared in the same way as and run 
alongside the samples for comparison. For results shown in Chapter 3 and Appendix 
Figure A2 the following protocol was used for digestion and LC-MS analysis of 
genomic DNA: 
Degradation of DNA to single nucleotides: 
1 µg genomic DNA (in mass spectrometry grade water) 
2.5 µl DNA degradase buffer (1x, Zymo research) 
1 µl DNA degradase enzyme (10 units, Zymo research) 
Up to 25 µl with mass spectrometry grade water 
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The reaction was incubated at 37 oC for 2 hours followed by 70 oC for 20 minutes to 
heat-inactivate the enzyme. It was then centrifuged at 10,000 rpm for 20 minutes to 
spin down the majority of the enzyme to the bottom of the tube. The upper 10 µl of 
the solution was removed and added to 40 µl of a 5:3 mixture of methanol and 
acetonitrile (mass spectrometry grade, Sigma) to give a 5:3:2 mixture of 
methanol:acetonitrile:sample. This was centrifuged at 10,000 rpm for a further 5 
minutes at room temperature. The upper 40 µl was removed and submitted to the 
IGMM mass spectrometry facility for LC-MS analysis performed by Jimi Wills as 
follows: 10 µl of the provided sample was separated on a SeQuant ZIC-pHILIC 
(150x4.6mm) column using a Thermo UltiMate 3000 BioRS, with a flowrate of 0.3 
mL/min and a gradient from 90% to 5% B in 10 minutes, where B is acetonitrile and 
A is 20 mM ammonium carbonate. Mass spectra were acquired in negative mode on a 
Thermo Q Exactive, scanning from 300 to 350 m/z at resolution 70k. AGC target was 
set to 3 x 106 and maximum ion time 500 ms. LC-MS data were analysed using 
Excalibur software to assess the quality of the mass spectra peaks and to quantify the 
area under the peaks.  
For results shown in Chapter 4, LC-MS analysis methods had been improved and so 
the following protocol was used: 2.5 µg genomic DNA was made up to 44 µl in mass 
spectrometry grade water and incubated at 95 oC for 10 minutes. 5 µl 10x T7 DNA 
polymerase reaction buffer and 1 µl 10 units/µl T7 DNA polymerase (Thermo Fisher 
Scientific) were added and the mixture incubated overnight at 37 oC. The reaction was 
then inactivated by incubation at 75 oC for 10 minutes. The samples were centrifuged 
at 10,000 rpm at room temperature for 45 minutes and then 20 µl extracted in a 5:3:2 
mixture of methanol:acetonitrile:sample, resulting in a final volume of 100 µl. After a 
final centrifugation at 10,000 rpm for 5 minutes, the upper 90 µl of the sample was 
taken and the organic solvent removed using a vacuum centrifuge (Thermo). Analytes 
were reconstituted in 30 µl mass spectrometry grade water by Jimi Wills and 10 µl 
injected onto a 30x1mm HyperCarb column (VWR). A gradient of 0-90% B was run 
over 4 minutes, where B is acetonitrile and A is 20 mM ammonium carbonate. Mass 
spectra were acquired in negative mode on a Thermo Q Exactive, scanning from 300 
to 350 m/z at resolution 70k. AGC target was set to 1 x 106 and maximum ion time 
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100 ms. Data were analysed using an in-house R script, which is in re-submission and 
is available at https://gitlab.com/jimiwills/assay.R.  
2.2.7 Bisulfite sequencing 
The methylation status of genomic CpGs was examined using bisulfite sequencing. 
This involves bisulfite treatment of genomic DNA to distinguish methylated from 
unmethylated CpGs, as unmethylated cytosines are converted to uracil in the presence 
of bisulphite whereas methylated CpGs are protected. DNA Sanger sequencing can 
then be used then identify unmethylated (thymine) and methylated (cytosine) CpGs. 
EZ DNA Methylation-Lightening kit (Zymo) was used to bisulfite treat 500 ng 
genomic DNA using the manufacturer’s instructions. Bisulfite treated and purified 
DNA was PCR amplified using primers specific to the region of interest (detailed in 
Table 2.3). The PCR was set up as follows: 
2 µl bisulfite treated DNA 
1 µl forward and reverse primer mix (10 µm of each primer) 
2 µl 10x PCR buffer (Invitrogen) 
2 µl dNTPs (10 µm of each dNTP, Invitrogen) 
0.6 µl Mg2+ (Invitrogen) 
0.2 µl Taq polymerase (Invitrogen) 
The cycling conditions were as follows (35 cycles): 
94 oC 3 minutes 
94 oC 45 seconds 
58 oC 30 seconds 
72 oC 30 seconds 
72 oC 10 minutes 
PCR products of the expected size (360 bp for major satellites and 210 bp for minor 
satellites) were gel purified, cloned into the pGEM-T Easy vector, transformed into 
DH5α competent cells (described in Section 2.5). Transformed bacterial colonies 
(white colonies) were picked and placed into wells of a 96-well mini-prep block 
containing 1 ml Luria-Bertani (LB) culture broth containing 50 µg/ml ampicillin. The 
96-well blocks were incubated at 37 oC overnight in a shaking incubator and plasmid 
DNA was mini-prepped and sequenced using Sp6 or T7 sequencing primers by the 
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HGU technical services. The resulting sequences were aligned to a reference sequence 
for the region and the methylation status of each CpG assessed using the Bisulfite 
Sequencing DNA Methylation Analysis (BISMA) online tool for repetitive sequences 
(http://services.ibc.uni-stuttgart.de/BDPC/BISMA/index_repetitive.php, Rohde et al., 
2010). Default settings were used except from the sequence identity which was set at 
60%. Clonal sequences were identified by BISMA and removed. The overall CpG 
methylation percentage was calculated for each region. Bisulfite plots were generated 
using the online Quantitative Methylation Analysis tool (QUMA, 
http://quma.cdb.riken.jp/).  













Table 2.3. Details of primers used for bisulfite sequencing. 
2.3 RNA preparation, manipulation and analysis 
2.3.1 RNA extraction from mammalian cells 
Mammalian cell pellets that had been resuspended in 1 ml Trizol and stored at -80 oC 
were thawed at room temperature. 200 µl chloroform was added to the sample 
followed by vigorous mixing by hand and incubation at room temperature for 5 
minutes. Aqueous and organic phases were then separated by centrifugation at 13,000 
rpm for 15 minutes at 4 oC. The upper aqueous phase was removed and added to 1 
volume of 70% ethanol. The remainder of the RNA extraction was then performed 
using the RNeasy mini kit (Qiagen) as per the manufacturer’s instructions. Briefly, the 
aqueous phase/ethanol mixture was added to RNeasy extraction columns and 
centrifuged at 13,000 rpm for 30 seconds. The columns were then washed with the 
appropriate volume of RW1 wash buffer. An on-column DNase step was performed 
using RNase-free DNase (Qiagen), adding 10 µl DNase to 70 µl buffer RDD which 
was subsequently incubated on the column at room temperature for 15 minutes. The 
columns were washed again with buffer RW1, then washed twice with the appropriate 
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volume of RPE. A dry spin at 13,000 rpm for 1 minute was included to eliminate 
residual wash buffer. RNA was eluted in 30 µl of RNase-free water. RNA integrity 
was assessed by electrophoresis on a 1% agarose gel. 2x RNA loading dye (Thermo 
Fisher Scientific) was added to RNA samples which were then incubated at 80 oC for 
2 minutes. RNA samples were loaded onto the gel alongside 2 µl RiboRuler (Thermo 
Fisher Scientific) to distinguish 28S and 18S RNA fragments. RNA was stored at -80 
oC.  
2.3.2 cDNA preparation 
Complementary DNA (cDNA) was synthesised using Superscript III (Invitrogen) as 
per manufacturer’s instructions. Initially, 2.5 µg total RNA was mixed with 100 ng 
random hexamers (Promega), 1 µl of 10 mM dNTP mix (Invitrogen) and distilled 
water up to a volume of 13 µl. This mixture was heated to 65 oC for 5 minutes then 
incubated on ice for at least 1 minute. The following components were then added 
resulting in a final volume of 20 µl: 
4 µl 5x First-Strand buffer 
1 µl 0.1 M DTT 
1 µl RNaseIn ribonuclease inhibitor (Promega) 
1 µl SuperScript III (200 units) 
This reaction was incubated according to the following protocol: 
25 oC for 5 minutes 
50 oC for 1 hour 
70 oC for 15 minutes 
Negative control RT reactions were also set up as shown above without the addition 
of SuperScript III to control for the contribution of genomic DNA and aerosol 
contamination in downstream experiments. The resulting cDNA was diluted to 100 µl 
in distilled water and stored at -20 oC. 
2.3.3 qRT-PCR 
To determine the transcript levels from certain genes, qRT-PCR was performed using 
first-strand cDNA. Primers for qRT-PCR (detailed in Table 2.3) were designed using 
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the ‘Primer3’ program (http://frodo.wi.mit.edu/primer3/), with altered settings to give 
an annealing temperature of 60 oC and a product size of < 300 bp. qRT-PCR primers 
were designed to span a large intron to avoid the detection of any contaminating 
genomic DNA. Reactions were set up with a final volume of 10 µl as follows: 
5 µl 2x SYBR Select Master Mix (Thermo Fisher Scientific) 
2 µl forward and reverse primer mix (2.5 µM of each primer) 
1 µl cDNA 
2 µl sterile water 
The PCR was performed using a LightCycler480 (Roche) with the following cycling 
conditions: 
95 oC for 2 minutes (Initial denaturation) 
95 oC for 15 seconds (Denaturation) 
60 oC for 1 minute (Annealing and elongation)  
Denaturation and annealing/elongation steps were repeated for 50 cycles in total.  
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Target gene Primer sequence (5’-3’) 
Prdm14 F: TAATGCCAAAGCTCACCCGT 
R: GAGGCTCTTTGCCTCTCCAA 
Nanog F: TCGAATTCTGGGAACGCCTC 
R: GTCTTCAGAGGAAGGGCGAG 
Oct4 F: GCCGTGAAGTTGGAGAAGGT 
R: CTTCTGCTTCAGCAGCTTGG 
Dnmt3b F: CTGGGTACAGTGGTTTGGTG 
R: AGTGTGGTACATGGCCTTCC 
Dnmt3l F: TTCTCACGGAGTGGACTGCT 
R: AAAAGGCTCAGTACCCGCA 
Dnmt1 F: CTGGAAGAGGTAACAGCGGG 
R: CTGGTGTGACGTCGAAGACT 
Fgf15 F: CGGTCGCTCTGAAGACGATT 
R: CCTCCGAGTAGCGAATCAGC 
Pax6 F: CTTCAGTACCAGGGCAACCC 
R: GAGTTGGTGTTCTCTCCCCC 
Klf4 F: AGAACAGCCACCCACACTTG 
R: AATTTCCACCCACAGCCGTC 
Fgf5 F: AGTCAATGGCTCCCACGAAG 
R: GGCACTTGCATGGAGTTTTCC 
Foxa2 F: GCCCGAGGGCTACTCTT 
R: CATTCCAGCGCCCACATAG 
TBP F: GAAGAACAATCCAGACTAGCAGCA 
R: CCTTATAGGGAACTTCACATCACAG 
β-actin F: AGAGCTATGAGCTGCCTGACG 
R: TGTGTTGGCATAGAGGTCTTTACG 
Nestin F: AGGACCAGGTGCTTGAGAGA 
R: TTCGAGAGATTCGAGGGAGA 
Gata4 F: GGAAGACACCCCAATCTCGT 
R: ACATGGCCCCACAATTGACA 
Brachury F: TGGCTCTAGCCAGTATCCCA 
R: AAAGAACTGAGCTCCCAGCC 
Table 2.4. Target genes and sequences of primers used for qRT-PCR analysis. 
2.4 Protein preparation and analysis 
2.4.1 Protein extraction 
Whole cell extracts were prepared using Pierce RIPA (Thermo Fisher Scientific) 
buffer supplemented with 1X phosphatase inhibitor cocktail (Thermo Fisher 
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Scientific) and 1x protease inhibitor cocktail (cOmplete mini EDTA-free tablets, 
Sigma). To lyse the cells, 100 µl of supplemented RIPA buffer was added to 
approximately 1 x 106 frozen cells. This mixture was incubated on ice for 10 minutes. 
To degrade the nucleic acids in these extracts, 1 µl benzonase (Sigma) was added and 
the sample incubated for a further 30 minutes on ice. To enhance cell lysis, extracts 
were sonicated in a Bioruptor (Diagenode) for 10 cycles (30 seconds on/30 seconds 
off) on the high setting, then centrifuged for 10 minutes at 13,000 rpm at 4 oC to 
remove cell debris. The supernatant was taken for protein quantification. For storage, 
protein extracts were stored at -80 oC after adding glycerol to a final concentration of 
10%. 
2.4.2 Protein quantification 
Protein concentration of whole cell extracts was measured using the Pierce BCA 
protein assay kit (Thermo Fisher Scientific) as directed by the manufacturer’s 
instructions. Samples were diluted 1 in 4 so that the protein concentration fell within 
the range of the standard curve in the assay. Each sample was measured in duplicate 
in a 96-well flat-bottomed plate and the protein concentration read in a Multiskan GO 
microplate spectrophotometer (Thermo Fisher Scientific) at 562 nm. Protein 
concentrations were calculated using the spectrophotometer readings from the 
standard curve, taking into account the dilution factors of the extracts. Between 20 and 
40 µg of protein was used for Western blotting analysis. 
2.4.3 SDS-PAGE 
Before loading protein samples onto a gel, 4x NuPAGE sample loading buffer and 10x 
NuPAGE sample reducing agent (Invitrogen) were added to the appropriate volume of 
cell extract to give a final concentration of 1x. Samples were boiled at 70 oC for 10 
minutes then incubated on ice prior to loading. Protein was resolved by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using NuPAGE 4-
12% Bis-Tris precast protein gels (Invitrogen). 4 µl PageRuler prestained protein 
ladder (Invitrogen) was also loaded for sizing. Gels were run in a NuPAGE gel tank 
(Invitrogen) in 1x NuPAGE MOPS SDS running buffer (Invitrogen) at approximately 
150 V for 1-1.5 hours.  
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2.4.4 Western blotting 
Following protein separation by SDS-PAGE the proteins were transferred onto a 
nitrocellulose membrane using the iBlot 2 dry transfer system (Invitrogen), The P0 
transfer method was used, which involves transfer at 20 V for 1 minute, 23 V for 4 
minutes and 25 V for 2 minutes. Membranes were stained with Ponceau S solution 
(Sigma) following transfer to assess whether equal transfer had occurred. Blocking 
was performed for approximately 1 hour using 1.25 ml Western blocking reagent 
(Roche), 1x Tris buffered saline (TBS, 50 mM Tris, 150 mM sodium chloride, pH 
adjusted to 7.5) made up to 50 ml with sterile water. Membranes were incubated 
overnight at 4 oC with the appropriate primary antibody (α-HELLS, Proteintech, 
11955-1-AP, 1:1000; α-β-TUBULIN, Abcam, ab6046, 1:1000) in block solution. 
Following overnight incubation, blots were washed with 1x TBS supplemented with 
0.1% Tween-20 (TBST, Sigma) 3 x 5 minutes at room temperature on a shaking 
platform. Secondary antibodies (α-mouse or α-rabbit HRP-conjugate, Cell signalling, 
1:10,000) were incubated with the membranes in block solution for 1-2 hours at room 
temperature, then thoroughly washed 3 x 10 minutes in TBST. Protein detection was 
performed using SuperSignal Western Pico Reagent chemi-luminescence reagent 
(Pierce) for 5 minutes, then developed using ECL Hyperfilm (Amersham) and an x-
ray film processor. 
2.5 Cloning techniques 
2.5.1 PCR amplification 
To amplify fragments for TA cloning, reactions were set up for PCR amplification as 
follows: 
25 µl DreamTaq green 2x PCR master mix (Thermo Fisher Scientific) 
3 µl forward and reverse primer mix (10 µm of each primer) 
250 ng template DNA 
Up to 50 µl with distilled water 
Cycling conditions were as follows (35 cycles): 
95 oC 3 minutes 
95 oC 30 seconds 
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Ta 30 seconds  
72 oC 1 minute 
72 oC 10 minutes 
The primers and annealing temperatures (Ta) used are indicated in Table 2.4. 
2.5.2 DNA fragment extraction from agarose  
Amplified DNA fragments were resolved using 1% agarose-TAE gels supplemented 
with 1x SYBR safe and were viewed using a Safe Imager transilluminator (Invitrogen). 
DNA fragments were purified from agarose gels using the Nucleospin PCR and gel 
extraction kit (Machery-Nagal) as per the manufacturer’s instructions. The DNA 
fragment(s) of interest were cut from the gel using a scalpel blade. Gel slices were 
weighed, 200 µl buffer NT1 per 100 mg agarose was added and then incubated at 50 
oC for 10 minutes in a Thermomixer with shaking at 1000 rpm to dissolve the gel 
slices. The sample was centrifuged at 11,000 rpm through the silica-gel columns 
included in the kit for 1 minute. DNA bound to the column was washed twice with 
buffer NT3 supplemented with 100% ethanol then dried by centrifugation for 1 minute 
at 11,000 rpm. DNA was eluted from the columns in 15 µl elution buffer by 
centrifugation for 1 minute at 11,000 rpm following a 1 minute incubation at room 
temperature. 
2.5.3 pGEM T Easy cloning 
DNA fragments amplified by Taq polymerase often have a 3’ deoxyadenosine (dA) 
which means they can be efficiently ligated into vectors with 5’ deoxythymidine (dT) 
overhangs. Purified DNA fragments were therefore ligated into the linearised pGEM 
T Easy vector (Promega) which contains 5’ dT overhangs. Ligation was performed 
using 50 ng pGEM T Easy vector and the Rapid DNA ligation kit (Roche), with an 
approximate insert to vector ratio of 3:1. Ligation reactions were incubated at room 
temperature for at least an hour or overnight at 4 oC.  
2.5.4 Bacterial transformation 
Library efficiency DH5α chemically competent Escherichia coli cells (Invitrogen) 
were used for bacterial transformation. 50 µl of competent cells were mixed with 1 µl 
71 
 
ligated DNA and incubated on ice for 20-30 minutes. The transformation mixture was 
heat shocked at 42 oC for 45 seconds then immediately cooled on ice for at least 2 
minutes. Room temperature S.O.C media was added to the transformations up to a 
volume of 500 µl. The transformations were subsequently incubated at 37 oC in a 
shaking incubator for 1 hour, then 1/10th and 9/10th of the mixtures were aseptically 
spread onto separate L-agar plates containing 50 µg/ml ampicillin and 200 µg/ml X-
gal (Sigma) for blue-white colony selection. The plates were inverted and incubated at 
37 oC overnight to allow colonies of transformed bacteria to grow.  
2.5.5 Bacterial culture and isolation of plasmid DNA 
For the preparation of plasmid DNA, single white (indicating that they were 
recombinant) colonies were picked and added to 5 ml LB broth containing 50 µg/ml 
ampicillin. They were then incubated at 37 oC overnight in a shaking incubator set at 
225 rpm. Plasmid DNA was extracted using the NucleoSpin Plasmid kit (Machery-
Nagal) as per the manufacturer’s instructions, eluting in 50 µl of the buffer AE 
provided. 
2.5.6 Sanger sequencing 
Isolated plasmid DNA was sequenced by the HGU technical services using Sp6 or T7 
sequencing primers. The BigDye terminator v3.1 sequencing kit was used according 
to manufacturer’s instructions and products run on an ABI Prism 3720 genetic 





































































Table 2.5. Details of primers used for sequence mutation checks, CRISPR off-
target mutation checks and Lsh blastocyst genotyping. 
2.6 Mammalian cell imaging 
2.6.1 Immunofluorescence 
Cells were plated onto glass coverslips coated in 0.2% gelatin in 12-well culture plates 
at a density of approximately 1-2 x 105 cells per well and cultured overnight. Media 
was removed and cells washed with PBS before adding 0.5 ml 4% paraformaldehyde 
(PFA, w/v, Sigma) per well for 10 minutes at room temperature for fixation. PFA was 
removed and fixed cells washed twice with PBS before being blocked with 10% 
donkey serum in 0.1% Triton-X (v/v, both Sigma) for at least 1 hour at room 
temperature. Following blocking, primary antibodies (detailed in Table 2.5) were 
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added to the cells in 400 µl total volume of 1% donkey serum in 0.1% Triton-X and 
incubated at 4 oC overnight. Primary antibody solution was washed off with 3 x 10 
minutes washes in PBS at room temperature. Secondary antibodies (α-mouse or α-goat 
AlexaFluor-555 or -647, Thermo Fisher Scientific, 1:200) were added to cells in the 
same blocking solution as primary antibodies for 45-60 minutes at room temperature 
in the dark. Cells were washed again in PBS for 3 x 10 minutes in the dark at room 
temperature. DAPI (50 µg/ml, 4’,6-diamidino-2-phenylindole) was diluted 1 in 1000 
in PBS then 500 µl added per well for 10 minutes at room temperature in the dark. 
Coverslips were washed 2 x 10 minutes in PBS and once in distilled water then 
mounted onto glass slides using Vectashield (Vector Laboratories) and sealed using 
nail varnish. Secondary-only controls where the primary antibody incubation was 
omitted were also performed assess the presence of any background signal. Images 
were captured using the 40x objective of a Zeiss Axioplan II fluorescence microscope 
and micromanager open source microscopy software. Images were analysed using 
ImageJ software. Signal correlation plots were generated using the Coloc2 plugin 




Company Dilution used 
Secondary 
antibody 
Nanog AF2729 R&D systems 1:75 Goat 







ab7817 Abcam 1:100 Mouse 
Tuj1 ab14545 Abcam 1:1000 Mouse 
Table 2.6. Details of primary antibodies used for immunofluorescence. 
2.6.2 Brightfield imaging 
Phase contrast microscopy was used to capture brightfield images of live mammalian 
cells in culture. The 10x objective of a Nikon Eclipse Ti-S inverted microscope was 
used to capture images along with iVision 4.5 software.  
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2.7 Generation and bioinformatic analysis of next-generation 
sequencing data 
2.7.1 Transcripome analysis by RNA-seq 
2.7.1.1 Library preparation and sequencing 
Genome-wide expression analysis by RNA-seq was performed to analyse the 
transcriptomes of cultured cells. The integrity of the starting total RNA was assessed 
using a Bioanalyzer 6000 nano chip (Agilent, run by HGU technical services). Only 
high quality RNA with a RIN score > 8 was used for downstream analyses.  
For serum and 2i mESCs, library preparation was performed in-house using NEBNext 
Poly(A) mRNA Magnetic Isolation Module (NEB) as per manufacturer’s instructions 
to purify polyadenylated RNA from 1 µg total RNA. Libraries were then generated 
from the poly(A)-purified material using the NEBNext Ultra Directional RNA library 
prep kit for Illumina (NEB) and NEBNext Adaptors for Illumina (NEB) as per 
manufacturer’s instructions. During library preparation, PCR library enrichment was 
performed for 13 cycles. Agencourt AMPure XP beads were used throughout to purify 
samples following each reaction. The quality of the resulting libraries were assessed 
on a Bioanlyzer DNA high sensitivity chip (Agilent, run by HGU technical services). 
This confirmed the absence of smaller fragments representing primers and adaptor-
dimers. For EpiSCs, TruSeq stranded mRNA-seq libraries were prepared by 
Edinburgh Genomics. All libraries were sequenced using Illumina HiSeq 4000 75 bp 
paired-end read sequencing performed by Edinburgh Genomics. 
2.7.1.2 Mapping and normalisation of RNA-seq data 
All RNA-seq datasets were downloaded from Edinburgh Genomics and tested for 
sequencing read quality using FastQC (v0.11.4). Once data quality was confirmed, 
demultiplexed datasets were parsed for NGS adaptor presence, short reads, read 
quality scores and reads falling below our thresholds were filtered out using Trim 
Galore! (v0.4.1.). Paired processed fastq files (Paired End sequencing was employed) 
were mapped to the mouse genome (genome build Mus_musculus.NCBIM37.61.fa 
and the matched transcriptome assembly Mus_musculus.NCBIM37.61.gtf) using 
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TopHat (v2.1.0) using the settings: tophat --no-coverage-search -r {inner mate 
distance} --mate-std-dev {mate distance standard deviation} --library-type fr-
firststrand -G /path/to/transcriptome/assembly -p 8 –o output.file 
/path/to/genome/build a.fastq b.fastq. Inner mate distances and standard deviations 
were computed for each paired set of fastq files using an unpublished python script 
kindly provided by Prof. Ian Adams. Counts over transcripts were counted using 
HTSeq count tool (v0.7.1) and were converted to an edgeR (v3.12.1) objects in the R 
(v3.4.0) programming environment using normalisation based on count depths over 
given datasets with limma (v3.26.9). 
2.7.2 DNA methylome analysis by enhanced reduced representation 
bisulfite sequencing (ERRBS) 
Genome-wide DNA methylation profiles were generated for serum, 2i and reversion 
E14 and lsh-/- mESCs using ERRBS. The integrity of the starting RNase-treated 
genomic DNA was assessed by gel electrophoresis and nanodrop 260/280 and 260/230 
readings prior to being sent for library preparation. 500 ng of genomic DNA at 20 
ng/µl was sent to the Epigenomics Core Facility of Weill Cornell Medicine (New 
York, USA) for library preparation using the protocol described in Garrett-Bakelman 
et al. (2015).  
2.7.2.1 Mapping and normalisation of ERRBS data 
ERRBS was carried out by the Epigenomics Core Facility of Weill Cornell Medicine 
(New York, USA) who provided custom data analysis. In addition, from our 
background in NGS analysis ‘in-house’, we decided to analyse the ERRBS data de 
novo. To avoid batch effects on the sequencing instrument, libraries were run over 
three individual lanes per flow cell. In Unix, these ‘triplicates’ were joined by 
catenation, and analysed as one entity. As for RNA-seq, various quality control metrics 
were assessed prior to full dataset mapping, including Trim Galore!. Data were 
mapped to a mouse genome build (Mus_musculus.NCBIM37.61.fa) using the Bismark 
tool suite (v0.16.3) with the following settings: bismark --bowtie2 
/path/to/mm9/genome/index/ -n 1 -l 32 -non_directional --un --ambiguous -o 
./output_pe --non_bs_mm -1 /path/to/1.fq.gz -2 ./path/to/2.fq.gz. Next, 
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‘bismark_methylation_extractor’ was used to extract methylation scores over CpG 
dinucleotides from the bismark output above. [Note: the methylation scores were also 
extracted using custom scripts by Dr Dunican (unpublished) which gave identical 
results]. Outputs were filtered for a minimum read-depth of 5 reads per CpG location. 
[Reads-depths of 10+ gave identical data trends, with less data]. All libraries yielded 
comparable read counts, so inter-library normalisation was deemed unnecessary. 
Changes in methylation were computed for the various cell lines concerned and 





Chapter 3. Lsh is not required to facilitate 
establishment of DNA methylation during reversion 
from the ground state of pluripotency 
3.1 Introduction 
In this chapter I discuss the optimisation of a culture system in which to dynamically 
modulate DNA methylation in mESCs. As outlined earlier, conventional mESC 
culture in which serum is included in the media (hereafter referred to as “serum” 
mESCs) results in a population of cells displaying heterogeneous colony morphology 
and expression of key pluripotency factors. Transferring mESCs into media containing 
two small molecule kinase inhibitors (hereafter referred to as “2i” mESCs) transitions 
the cells into a naïve “ground state” of pluripotency in which they more closely 
resemble cells of the ICM in vivo (Ficz et al., 2013; Habibi et al., 2013; Choi et al., 
2017). This transition of cell state coincides with more homogeneous colony 
morphology, gene expression changes and global hypomethylation. There is published 
evidence to suggest that these two culture states are interconvertible, and that the 
global hypomethylation observed in 2i mESCs can be reversed (Habibi et al., 2013; 
Leitch et al., 2013). By harnessing the interconvertibility of this system, I aimed to 
dynamically modulate global DNA methylation levels by altering mESC culture 
conditions. Specifically, I intended to use this experimental set-up to determine the 
requirement for the putative chromatin remodelling factor Lsh in re-methylation of the 
genome during the transition from 2i to serum culture. I was also able to adapt this 
culture system to investigate the involvement of other factors in re-establishment of 
DNA methylation during serum reversion, such as DNA methyltransferase co-factor 
Dnmt3l.  
At the level of DNA methylation, 2i mESCs have been proposed to be more 
representative of cells of the ICM, whereas DNA methylation levels of serum mESCs 
are more similar to that of differentiated cells (Habibi et al., 2013; Choi et al., 2017). 
Therefore, it can be reasoned that the re-establishment of DNA methylation that occurs 
during reversion from 2i could model the de novo methylation that occurs in the early 
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stages of implantation of the blastocyst in vivo. Therefore, using this culture system I 
could infer the involvement of Lsh, and other factors, in DNA methylation deposition 
during the early stages of embryonic development.  
3.2 Results 
3.2.1 Characterisation of lsh-/- mESCs 
As discussed in the introduction, extensive analysis has been undertaken in lsh-/- 
embryonic tissues and somatic cell lines. However, analysis of the impact of Lsh 
deletion in a pluripotent context has been more limited, despite Lsh expression being 
comparatively much higher in pluripotent cells (Raabe et al., 2001; Xi et al., 2009). 
Therefore, I decided to use mESCs as a model to investigate the function of Lsh in 
early embryonic development. Prior to me joining the group, Dr Donncha Dunican 
used CRISPR/Cas9 gene editing technology to generate lsh-/- mESCs. A single-guide 
RNA (sgRNA) was designed to target exon 1 of Lsh. This was transfected into E14 
mESCs along with WT Cas9. Clones were screened by XhoI restriction digest followed 
by PCR to identify mESC lines with a mutation in Lsh. The nature of the mutation was 
then assessed by Sanger sequencing. One clone was identified as having a 25 bp 
homozygous deletion in Lsh resulting in a premature stop codon in exon 1. This clone 
was subsequently shown to have no LSH protein expression by Western blot. I verified 
the homozygous mutation in this clone by Sanger sequencing and confirmed the lack 
of LSH protein expression by Western blot (Figure 3.1 A and B respectively). 
Confident that there was a homozygous deletion in this clone resulting in ablation of 





Figure 3.1. Confirmation of CRISPR-generated lsh-/- mESCs. A. Lsh exon 1 was 
targeted for CRISPR-mediated gene editing, which was assessed using Sanger  
sequencing of a region encompassing the sgRNA target site and protospacer adjacent 
motif (PAM) site, which are highlighted in the E14 sequence. The sgRNA determines 
target specificity of the Cas9 nuclease during the CRISPR gene editing process, 
whereas the PAM site is necessary for Cas9 binding and cleavage of the target DNA 
sequence. The 25 bp deletion present in lsh-/- mESCs is also highlighted. B. Western 
blot analysis of whole protein extracts from E14 and lsh-/- mESCs using an antibody 
against HELLS (human homolog of LSH) to determine LSH protein levels. An antibody 
against β-TUBULIN was used as a loading control.  
3.2.2 Derivation of mESCs from lsh-/- mouse blastocysts 
To independently verify results generated from the CRISPR-targeted lsh-/- mESCs, I 
aimed to derive lsh-/- mESC lines from an Lsh conditional knockout (KO) mouse 
model. This mouse model was generated by Dr Ian Adams and David Read using a 
genetrap construct obtained from the European Conditional Mouse Mutagenesis 
Program (EUCOMM, construct detailed in Figure 3.2 A). The ICM of the blastocyst 
was isolated by Dr Ian Adams from embryos produced by crossing two mice 
heterozygous for this conditional KO construct. The resulting mESC lines were 
derived in 2i medium on a layer of mitotically inactivated CD1 MEF feeders, following 
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the protocol described by Czechanski et al. (2014). This led to the derivation of 21 
mESC lines. PCR genotyping was performed using the primers indicated in Figure 3.2 
A and revealed that three mESC lines were homozygous for the conditional KO 
cassette, nine were heterozygous and nine were WT. An example of the PCR 
genotyping is shown in Figure 3.2 B. LSH protein levels were assessed in selected 
WT, heterozygous and homozygous mESC clones by Western blot. This revealed that 
there was residual LSH protein expression in clones shown to be homozygous for the 
genetrap cassette by PCR (Figure 3.2 C). This can be explained by so-called ‘leaky 
expression’, where the splice acceptor site in the genetrap cassette is skipped, resulting 
in full length protein production. This issue can be overcome by expressing Cre 
recombinase in the homozygous mESC lines to remove the critical exon 12 which is 
spanned by loxP sites. This, in theory, would prevent the production of any functional 
LSH protein, creating a complete Lsh knockout mESC line. However, this procedure 
could not be undertaken, as the blastocyst-derived mESC lines exhibited unstable 
growth following their recovery from cryopreservation. These mESCs grew slowly, 
with a high occurrence of cell death, and did not survive in long-term cultures. This 
was apparent for all the mESC lines generated during this derivation experiment, 
irrespective of the Lsh genotype; WT, heterozygous and homozygous mESC lines all 
exhibited unstable growth following their recovery from cryopreservation. This 
demonstrated that the absence of LSH protein did not contribute to the poor growth of 
these mESC lines in culture.  
The inability to maintain these blastocyst-derived mESC lines in long-term cultures 
meant that it was not practical to continue to use these mESCs for this study, as the 
downstream experiments required cultures to be maintained for long time periods. 





Figure 3.2. Derivation of lsh-/- mESCs from mouse blastocysts. A. Schematic 
showing design of the conditional knockout genetrap cassette received from EU COMM. 
The genetrap cassette sits between Lsh exons 11 and 12 which correspond to helicase 
domains II, III and IV. The location of the genotyping primers are indicated by the orange 
arrows for the WT band and green arrows for the KO band. B. Agarose gel showing 
genotyping by PCR of selected mESC clones derived from Lsh conditional knockout 
mice. C. Western blot of whole protein extracts from mESC lines shown in B. An antibody 
against HELLS was used to determine LSH protein levels, β-TUBULIN was used as a 
loading control. Protein Extracts from E14 mESCS and SNLP feeders on which the 







3.2.3 Optimisation of a culture system to modulate global DNA methylation 
levels in mESCs 
3.2.3.1 Experimental strategy 
To explore the requirement for Lsh in re-methylating the genome during reversion 
from 2i to serum culture, I aimed to optimise and validate a culture system using these 
culture conditions to dynamically modulate global DNA methylation. By harnessing 
the interconvertibility between these culture states, I hypothesised that I could reduce 
genome-wide DNA methylation levels by adapting mESCs to 2i culture in the presence 
of LIF, then return these mESCs to serum media to recover global DNA methylation 
levels (illustrated in Figure 3.3). As reported by Habibi et al. (2013), mESC culture in 
2i media (with LIF) for at least 12 days is required to reduce global DNA methylation 
down to steady-state levels. Similarly, a reversion period in serum culture of at least 
10 days appears to be required for re-establishment of global DNA methylation to the 
levels observed prior to 2i adaptation. Therefore, it was reasoned that a period of 15 
days (six passages) for both adaptation to 2i and reversion into serum would be 
sufficient to induce genome-wide hypomethylation and subsequent re-methylation. To 
assess whether transition between the distinct culture states had occurred, a number of 
factors and metrics would be examined, including colony morphology and expression 




Figure 3.3. Schematic depicting 2i adaptation and serum reversion experimental 
design. Key genes that show expression differences between culture states are 
highlighted, as is the change in global DNA methylation levels.  mESCs were cultured in 
either serum/LIF or 2i/LIF for 15 days (six passages) to induce transition between these 
distinct culture states.  
3.2.3.2 E14 and lsh-/- mESCs change morphologically upon adaptation to 2i 
and reversion into serum 
Morphological changes are a straightforward way to quickly assess the response of 
mESCs to the addition of 2i media. During adaptation to 2i, mESCs adopt a more 
uniform colony morphology, with individual colonies becoming more rounded and 
three-dimensional with smooth, defined colony boundaries (example shown in Marks 
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and Stunnenberg, 2014). This contrasts with the appearance of serum mESCs, which 
display a wide variety of colony morphologies, with a more flattened appearance and 
irregular colony edges. Both E14 and lsh-/- mESCs show this heterogeneous colony 
morphology whilst grown in serum (Figure 3.4, left panels). After adaptation to 2i for 
eight days (three passages), E14 mESCs had adopted the features of ‘typical’ 2i colony 
morphology described above (indicated by the arrow in Figure 3.4, middle panels). 
The appearance of lsh-/- mESCs following 2i adaptation for eight days (three passages) 
differed considerably compared to their serum counterparts. In comparison to the E14 
mESCs, lsh-/- mESC 2i colonies displayed many features of typical 2i morphology 
such as becoming more rounded and three-dimensional.  However, the colony 
boundaries did not become as smooth and defined as in E14 2i colonies, with some 
colonies exhibiting small protrusions or patches of flattened cells (indicated by the 
arrows in Figure 3.4, middle panels). Overall, although both E14 and lsh-/- mESCs 
display substantial changes in colony morphology upon adaptation to 2i, lsh-/- mESCs 
did not achieve the changes akin to typical 2i colony morphology to the same extent 
as E14 mESCs. These differences in the extent of colony morphology adaptation 
persisted to the final 15-day timepoint of the conversion to 2i (data not shown).  
 
Figure 3.4. E14 and lsh-/- mESCs show similar morphological changes after longer 
term 2i adaptation and reversion back into serum culture. E14 and lsh-/- mESCs 
cultured in media containing serum (left panels), adapted to 2i for 8 days (3 passages, 
middle panels) and reverted into media containing serum for 9 days (4 passages) 
following 15 days of 2i adaptation (right panels). Arrows indicate typical  colony 
morphology of each mESC line in 2i media. Scale bars represent 100 µm. 
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Following adaptation to 2i for 15 days, both E14 and lsh-/- mESCs were reverted into 
serum culture for 15 days. After nine days (four passages) of reversion, the 
morphology of both E14 and lsh-/- mESCs returned to the heterogeneous colony 
morphology observed prior to 2i adaptation (Figure 3.4, right panels). This 
demonstrates that both E14 and lsh-/- mESCs undergo dynamic and extensive 
morphological changes during the 2i adaptation and serum reversion process. 
However, morphological changes can only be considered as indicative of adaptation 
to 2i or serum culture. Further investigation into the expression of key genes is required 
to confirm successful transition between the cell culture states. 
3.2.3.3 Nanog and Essrb expression becomes more homogeneous upon 
adaptation to 2i  
Homogeneous Nanog expression is associated with transition to 2i and is often used 
as a marker to indicate adaptation to 2i culture. Immunofluorescence was performed 
on E14 and lsh-/- mESCs cultured in serum, adapted to 2i and reverted into serum to 
assess the uniformity of expression of Nanog and Esrrb, a downstream target of 
Nanog. In serum E14 mESCs, both Nanog and Esrrb appeared to be heterogeneously 
expressed, with some cells in the colonies exhibiting high Nanog and Esrrb expression 
and other cells displaying low expression. Upon adaptation to 2i, these factors became 
more uniformly expressed in all cells of the colony. When these 2i E14 mESCs were 
reverted into serum culture, Nanog and Esrrb expression also reverted to more 
heterogeneous expression (Figure 3.5 A and B, top panels). The same changes in 
expression patterns are evident in serum, 2i and reversion lsh-/- mESCs, however the 
increase in homogeneity of Nanog expression is not as obvious as in E14 mESCs, as 
Nanog expression already appears to be more uniform in serum lsh-/- mESCs (Figure 
3.5 A and B, bottom panels). The relevant secondary antibody-only control staining 




Figure 3.5. Nanog and Esrrb expression becomes more homogeneous upon 
adaptation to 2i and reverts to heterogeneous expression following reversion into 
serum in both E14 and lsh-/- mESCs. Immunofluorescence on E14 and lsh-/- mESCs 
cultured in serum, adapted to 2i for 15 days and reverted into serum culture for 15 days 
following 2i adaptation, using an antibody against Nanog (A) or Esrrb (B). Scale bars 




The difference in uniformity of Nanog expression between serum and 2i culture is 
more apparent when compared to a factor that is expressed homogeneously in both 
culture states. Therefore, double immunofluorescence was performed to 
simultaneously stain Nanog and Oct4 in serum, 2i and reversion E14 and lsh-/- mESCs. 
The secondary antibody-only control staining relevant to this double 
immunofluorescence analysis is presented in Appendix Figure A1. C. As observed 
previously, Nanog exhibited heterogeneous expression in serum E14 mESCs (Figure 
3.6 A). Expression of Oct4 however was more consistent, and when merged with DAPI 
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and Nanog signal it highlighted the heterogeneity of Nanog expression. Again, Nanog 
expression became more homogeneous following culture in 2i media, whereas Oct4 
expression remained uniform. This was again emphasised by the merged image, as 
most cells appeared to be similar in colour due to both factors being more uniformly 
expressed. After reversion into serum, Nanog returned to a heterogeneous expression 
pattern similar to that observed initially in serum. Oct4 expression continued to appear 
more homogeneous than Nanog.  
To add quantification and clarity to this analysis, the co-occurrence of Nanog and Oct4 
signal where DAPI signal was present was plotted using the FIJI Coloc2 plug-in. This 
software also calculated the Pearson correlation coefficient (r2), with higher r2 values 
indicating increased correlation between Nanog and Oct4 signals. These plots and 
correlation values mirrored the pattern that was implied from the immunofluorescence 
images. This is clearly demonstrated by the increase in r2 value from 0.70 in serum 
E14 mESCs to 0.93 in 2i E14 mESCs, indicating a substantial increase in the co-
occurrence of Nanog and Oct4 signal following 2i adaptation (Figure 3.6 C, left 
panels). This reinforced the initial observation that Nanog expression becomes more 
homogeneous upon adaptation to 2i, meaning that there is an increased presence of 
both Nanog and Oct4 in 2i cells compared to serum cells. Following reversion of 2i 
E14 mESCs into serum, the r2 value returned to 0.72, reflecting the loss of 










Figure 3.6. Nanog expression becomes more homogeneous upon adaptation to 2i 
and reverts to heterogeneous expression following reversion into serum in both 
E14 and lsh-/- mESCs. Immunofluorescence on E14 (A) and lsh-/- (B) mESCs cultured 
in serum, adapted to 2i for 15 days and reverted into serum culture for 15 days following 
2i adaptation, using antibodies against Nanog and Oct4. Scale bars represent 50 µm. C. 
Scatter plots showing co-occurrence of Nanog and Oct4 signal in the E14 and lsh-/- 
merge images. Generated using FIJI Coloc2 plug-in. Degree of signal correlation is 
indicated by r2 value. The secondary antibody-only control staining relevant to this 
double immunofluorescence experiment is presented in Appendix Figure A1. C. 
Double immunofluorescence to assess the uniformity of Nanog expression compared 
to Oct4 was also performed on serum, 2i and reversion lsh-/- mESCs. The expression 
patterns of Nanog and Oct4 in these cells emulated that of serum, 2i and reversion E14 
mESCs. Nanog expression increased in uniformity following conversion from serum 
92 
 
to 2i, then returned to heterogeneous expression after reversion into serum, while Oct4 
expression was fairly uniform throughout (Figure 3.6 B). The signal correlation graphs 
plotting the co-occurrence of Nanog and Oct4 signal reinforce these results. The r2 
value increased from 0.79 in serum lsh-/- mESCs to 0.93 after 2i adaptation, then 
decreased to 0.84 following reversion into serum (Figure 3.6 C, right panels). This 
further reflects the trend observed in E14 mESCs. It is notable that the r2 values of 
serum and reverted lsh-/- mESCs are slightly higher than those of E14 mESCs, adding 
strength to the observation in Figure 3.5 A that Nanog expression is already more 
homogeneous in serum lsh-/- mESCs compared to E14 mESCs. 
These analyses show that both E14 and lsh-/- mESCs exhibit increased homogeneity of 
Nanog and Esrrb expression upon adaptation to 2i, which is reversed once the cells 
are returned to serum culture. This strengthens the suggestion from the morphological 
analysis that both E14 and lsh-/- mESCs are able to successfully transition between 
serum and 2i culture. However, the information provided through analysis of Nanog, 
Esrrb and Oct4 expression by immunofluorescence is limited and largely qualitative. 
Quantitative analysis of gene expression changes was needed to add extra weight to 
the observation that E14 and lsh-/- mESCs had adapted to and reverted from 2i culture 
successfully.  
3.2.3.4 E14 and lsh-/- mESCs exhibit mRNA expression changes indicative 
of adaptation to and reversion from 2i 
Studies into the molecular basis of ground state pluripotency demonstrate that 
adaptation to 2i is accompanied by expression changes in a number of 
developmentally-relevant genes (Marks et al., 2012). The expression levels of a few 
key genes were monitored by quantitative reverse transcriptase-PCR (qRT-PCR) to 
quantitively assess whether E14 and lsh-/- mESCs had transitioned between serum and 
2i on a transcriptional level. Representative qRT-PCR analyses of three technical 
replicates from one biological replicate are shown in Figure 3.7. Previous studies have 
indicated that the expression of pluripotency factors Prdm14 and Nanog increase 
following conversion to 2i (Marks et al., 2012; Wang et al., 2014). This was found to 
be the case for both E14 and lsh-/- mESCs, with an approximate three-fold increase in 
Nanog expression and a five to eight-fold increase in Prdm14 mRNA levels upon 
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adaptation to 2i (Figure 3.7 A). The mRNA levels of these pluripotency factors 
returned to levels observed prior to 2i adaptation in reverted E14 and lsh-/- mESCs. 
Oct4 mRNA levels were also measured in serum, 2i and reversion E14 and lsh-/- 
mESCs and were found not to change between culture conditions, reinforcing the Oct4 
staining shown in Figure 3.6 and expression data from previously published literature 
(Marks et al., 2012). These results demonstrate that both E14 and lsh-/- mESCs undergo 
the expected expression changes in key pluripotency genes during adaptation to and 




Figure 3.7. Key genes undergo expression changes in E14 and lsh-/- mESCs during 
adaptation to and reversion from 2i. qRT-PCR analysis of mRNA expression levels 
for key pluripotency factors (A), DNMTs (B) and lineage commitment-associated genes 
(C). Expression of markers normalised to TATA-binding protein (TBP) expression. Error 




This analysis was extended to encompass genes associated with DNA methylation 
deposition, which have been shown to markedly decrease in expression upon 
conversion to 2i (Marks et al., 2012; Yamaji et al., 2013). The expression levels of de 
novo DNA methyltransferase Dnmt3b and de novo methylation co-factor Dnmt3l were 
checked in serum, 2i and reversion E14 and lsh-/- mESCs. Dnmt3b expression was 
reduced more than two-fold in E14 mESCs upon adaptation to 2i, and then recovered 
following reversion into serum (Figure 3.7 B). In serum lsh-/- mESCs prior to 2i 
adaptation, Dnmt3b levels are markedly lower than in serum E14 mESCs, meaning 
that the reduction in Dnmt3b expression after conversion to 2i is not as substantial. 
When these 2i lsh-/- mESCs are reverted into serum, Dnmt3b mRNA levels increase 
past those initially observed in serum and up to levels comparable to reverted E14 
mESCs.  Dnmt3l expression follows a similar pattern to Dnmt3b in both E14 and lsh-
/- mESCs. Dnmt3l mRNA levels were lower in serum lsh-/- mESCs compared to serum 
E14 mESCs, but were still reduced to almost undetectable levels in both E14 and lsh-
/- mESCs adapted to 2i. These mRNA levels then recovered following reversion into 
serum and, particularly in lsh-/- mESCs, exceeded the levels observed in serum prior 
to 2i adaptation. Expression levels of the maintenance methyltransferase Dnmt1 were 
also measured in E14 and lsh-/- mESCs and were shown to remain relatively stable 
between serum, 2i and reversion culture conditions. 
To further establish whether E14 and lsh-/- mESCs had adopted features of adaptation 
to 2i such as a reduction in lineage priming, the expression levels of early ectodermal 
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markers Fgf15 and Pax6 were assessed. Both markers followed a similar expression 
pattern in E14 and lsh-/- mESCs, with a substantial decrease in mRNA levels evident 
following 2i conversion, reflecting the reduced occurrence of lineage priming in this 
culture state (Figure 3.7 C). The expression levels of these lineage-associated genes 
then recovered after reversion into serum. Therefore, both E14 and lsh-/- mESCs 
exhibited expression changes in lineage markers associated with transitioning between 
serum and 2i culture states. However, the expression profiles of Fgf15 and Pax6 in lsh-
/- mESCs differ in some aspects from E14 mESCs and mimic some previously 
observed features of Dnmt3b and Dnmt3l expression. For example, the mRNA levels 
of these genes are markedly lower in serum lsh-/- mESCs compared to E14 mESCs. 
Also, in reverted lsh-/- mESCs, expression levels of these genes increase beyond the 
level observed initially in serum, and up to levels comparable to E14 mESCs. This 
demonstrates that key genes involved in DNA methylation and lineage commitment 
are already downregulated in serum lsh-/- mESCs before conversion to 2i, implying 
that the expression profiles of serum lsh-/- mESCs are more similar to 2i than E14 
mESCs. The downregulation of these genes in serum lsh-/- mESCs compared to E14 
mESCs however seems to be lost during reversion into serum culture, suggesting that 
conversion to 2i acts to reset the transcriptional profile of lsh-/- mESCs. These 
observations are based on one biological replicate and need to be repeated for 
confirmation. Genome-wide expression analysis is also required to investigate whether 
lsh-/- mESCs resemble 2i mESCs transcriptionally on a global scale, and whether the 
genome-wide expression profile of lsh-/- mESCs is reprogrammed following reversion 
into serum. 
Collectively, analysis of these key pluripotency, DNA methylation and lineage-
associated markers shows that in terms of transcription, E14 and lsh-/- mESCs respond 
comparably during adaptation and reversion, despite there being differences in mRNA 
levels of certain genes prior to 2i conversion. Both mESC lines exhibit gene expression 
changes expected in cells reaching ground state pluripotency, therefore this 
quantitative analysis provides further evidence that E14 and lsh-/- mESCs are 
successfully adapting to and reverting from 2i culture.  
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3.2.3.5 Global DNA methylation levels fully recover in both E14 and lsh-/- 
mESCs following 2i-associated hypomethylation 
Since I had established, using multiple experimental methods, that E14 and lsh-/- 
mESCs transition between serum and 2i culture morphologically and transcriptionally, 
I wanted to evaluate the impact of these transitions on DNA methylation levels. A few 
previous studies have described the global DNA methylation changes that occur during 
adaptation to and reversion from 2i. They demonstrate that conversion to 2i coincides 
with a two to three-fold reduction in global DNA methylation, which is subsequently 
fully recovered once cells are returned to serum culture (Ficz et al., 2013; Habibi et 
al., 2013; Leitch et al., 2013). I used two different techniques to assess whether these 
DNA methylation changes occurred in the culture system I had developed. Initially, 
methylation levels at satellite DNA were assessed using the methylation-sensitive 
restriction endonuclease MaeII that digests unmethylated ACGT sites, which are 
conveniently enriched in major satellite regions of the genome (Abdurashitov et al., 
2009). Although MaeII restriction sites are enriched mainly in satellite DNA, digestion 
using this enzyme can provide a relatively quick indication of DNA methylation 
changes occurring globally due to the large proportion of the methylated genome that 
satellite regions comprise. Using this technique, MaeII-digested DNA is separated 
using agarose gel electrophoresis. DNA hypomethylation results in increased 
restriction digestion by MaeII and the subsequent appearance of lower molecular 
weight fragments on the agarose gel (indicated by the arrow in Figure 3.8 A).  
Serum, 2i and reversion E14, WT (a wild-type clone from the CRISPR targeting) and 
lsh-/- mESCs were assayed using this method. Upon adaptation to 2i a number of low 
molecular weight bands appeared, accompanied by an overall downward shift in the 
molecular weight of the digested DNA, indicating de-methylation of satellite DNA 
(Figure 3.8 A). This de-methylation appears to be reversed following reversion into 
serum in E14, WT and lsh-/- mESCs, as demonstrated by the disappearance of low 
molecular weight fragments and the lack of downward shift in the molecular weight 
of the bulk DNA. This suggests that the absence of Lsh does not impede the re-
establishment of DNA methylation, at least at these MaeII restriction sites. Restriction 
digestion with a methylation-insensitive restriction endonuclease, MspI, was also 
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performed and gel electrophoresed as a control for digestibility of the DNA, as well as 




Figure 3.8. DNA methylation at major satellites is reduced upon 2i adaptation and 
re-established following serum reversion.  A. Agarose gel displaying digestion of DNA 
from E14, WT (wild-type clone from the Lsh CRISPR targeting) and lsh -/- mESCs 
cultured in media containing serum (Ser), adapted to 2i for 15 days (2i) and returned 
into serum-containing media for 15 days (Rev) by methylation-sensitive MaeII restriction 
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enzyme. Arrow highlights presence of lower molecular weight bands, indicating 
hypomethylation of satellite DNA sequences. B. Agarose gels showing MspI digestions 
and uncut DNA for the same samples shown in B to validate genomic digestion 
compatibility, DNA integrity and equal loading.  
Although this method can give an indication of changes in global DNA methylation, 
quantitative analysis is required to confirm the observations made from the 
methylation-sensitive digest. E14 and lsh-/- mESC DNA was digested to single 
nucleotides and 5-mC measured using liquid-chromatography mass spectrometry (LC-
MS). LC-MS was performed by Jimi Wills in the Mass Spectrometry facility at the 
IGMM, with the analysis being carried out by myself with assistance from Jimi Wills 
and David Hay. LC-MS analysis of two biological replicates for each sample is shown 
in Figure 3.9. In E14 mESCs there was more than a two-fold reduction in global 5-mC 
following adaptation to 2i, which was subsequently fully recovered after reversion into 
serum (Figure 3.9). The same trend was observed for lsh-/- mESCs, as global DNA 
methylation fully recovered to levels present prior to 2i adaptation. The global DNA 
methylation levels of serum and reverted lsh-/- mESCs appeared to be lower than those 
of E14 mESCs, however these differences were not significant. This LC-MS analysis 
supports the suggestion from the methylation-sensitive DNA digest that the absence 
of Lsh does not affect the recovery of global DNA methylation levels during reversion 





Figure 3.9. Global DNA methylation levels recover in both E14 and lsh-/- mESCs 
following 2i-associated hypomethylation. Quantitative analysis of global DNA 
methylation levels (5-mC) in serum (Ser), 2i and reversion (Rev) E14 and lsh-/- mESCs 
by LC-MS. Global 5-mC is calculated as a percentage of total cytosine levels (sum of 
LC-MS measurements for C, 5-mC and 5-hmC). Error bars represent +/- standard error 
of two biological replicates. All differences in global 5-mC levels between E14 and lsh-/- 
mESCs were found to be not significant by an unpaired two-way t-test. 
Overall, these results demonstrate that DNA methylation levels are indeed globally 
reduced following adaptation to 2i, and that they can be recovered by returning the 
cells to serum culture. These analyses also suggest that the presence of Lsh is not 
necessary for this recovery of DNA methylation to occur. Therefore it appears, perhaps 
surprisingly, that Lsh does not participate in establishment of DNA methylation in 
mESCs during transition from 2i to serum culture. 
3.2.4 Investigating the requirement for Dnmt3l in re-establishment of DNA 
methylation during reversion from 2i 
My analysis suggests that Lsh does not appear to be required for re-methylation of the 
genome following the global hypomethylation associated with adaptation to 2i. I aimed 
to explore whether other factors may be involved in the re-establishment of DNA 
methylation during reversion from 2i. The function of de novo DNA methyltransferase 
co-factor Dnmt3l in mESCs is much less well characterised than that of its catalytically 
active counterparts. Therefore, I aimed to adapt and revert dnmt3l-/- mESCs over a 15-
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day cycle to elucidate whether Dnmt3l is required for establishment of DNA 
methylation in this mESC culture system. 
3.2.4.1 WT and dnmt3l-/- mESCs morphologically and transcriptionally 
transition between serum and 2i 
To examine the effect absence of Dnmt3l has on global DNA methylation recovery 
following 2i-associated hypomethylation, a dnmt3l-/- mESC line was kindly provided 
by the Oliviero laboratory. This mESC line was generated by targeting exon 1 of 
Dnmt3l using TALEN gene editing technology, as described in Neri et al. (2013). This 
generated an 11 bp deletion, creating a premature stop codon in exon 1. I confirmed 
this deletion using Sanger sequencing (Figure 3.10). A WT mESC line from the 
TALEN-targeting procedure was also provided, and I confirmed that these cells had 
the same Dnmt3l sequence as E14 mESCs. The absence of DNMT3L protein in 
dnmt3l-/- mESCs was verified by Neri et al. (2013) using an antibody they had 
produced in-house. I endeavoured to confirm the loss of DNMT3L protein by Western 
blot, however attempts using commercially available antibodies were repeatedly 
unsuccessful (data not shown).  
 
Figure 3.10. Confirmation of WT and dnmt3l-/- mESCs. Exon 1 of the Dnmt3l gene 
was targeted for mutagenesis using TALEN gene editing technology, as described by 
Neri et al. (2013). Coding exons are shown in black. Alignment of sequences generated 
by Sanger sequencing of E14, WT and dnmt3l-/- mESCs is shown, highlighting the 11 bp 
out-of-frame deletion present in dnmt3l-/- mESCs. 
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WT and dnmt3l-/- mESCs were adapted to 2i and reverted into serum according to the 
experimental setup detailed in Section 3.2.3.1 (Figure 3.3). As with lsh-/- mESCs, 
changes in colony morphology were monitored to indicate adaptation to 2i. Both WT 
and dnmt3l-/- mESCs exhibited morphological changes reminiscent of adaptation to 2i 
(Figure 3.11). However, these mESC lines did not achieve typical 2i morphology to 
the same extent as E14 mESCs (shown in Figure 3.4), as although the colonies had 
become more three-dimensional with smoothened edges, the size and shape of the 
colonies did not become entirely homogeneous. Following reversion into serum 
culture, WT and dnmt3l-/- mESCs returned to a more flattened, heterogeneous 
appearance. Examination of colony morphology showed that both WT and dnmt3l-/- 
mESCs adopted some of the features indicative of transition between serum and 2i 
culture. However, the morphological changes observed in WT and dnmt3l-/- mESCs 
were not as obvious as those of E14 mESCs (shown in Figure 3.4). 
 
Figure 3.11. WT and dnmt3l-/- mESCs exhibit a degree of morphological transition 
between serum and 2i culture. Brightfield images of WT and dnmt3l-/- mESCs cultured 
in serum, adapted to 2i for 7 days (3 passages) and reverted into serum for 9 days (4 
passages) following 15 days of 2i adaptation. Scale bars represent 100 µm. 
To evaluate whether WT and dnmt3l-/- mESCs were adapting to and reverting from 2i 
in terms of transcription, the expression changes of a few key genes were analysed by 
qRT-PCR of three technical replicates from one biological replicate. Expression of 
pluripotency factor Prdm14 increased in 2i WT and dnmt3l-/- mESCs as expected, then 
returned to levels similar to those observed initially in serum following reversion 
(Figure 3.12 A). Dnmt3b mRNA levels followed the expected trend in dnmt3l-/- 
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mESCs, as they reduced substantially upon adaptation to 2i then increased back up to 
initial levels after reversion into serum (Figure 3.12 B). Dnmt3b expression also 
markedly reduced in 2i WT mESCs, however expression levels did not recover 
following reversion into serum, suggesting that WT mESCs did not transition between 
culture states as comprehensively as dnmt3l-/- mESCs. Expression levels of Dnmt3l 
itself were also checked in WT and dnmt3l-/- mESCs. Dnmt3l mRNA levels followed 
the expected pattern in WT mESCs, with a substantial reduction upon adaptation to 2i 
followed by a full recovery after reversion into serum (Figure 3.12 B). There appeared 
to be residual mRNA expression in dnmt3l-/- mESCs which also followed the same 
pattern, albeit on a much reduced scale. More extensive analysis is required to fully 
evaluate whether WT and dnmt3l-/- mESCs are transitioning between serum and 2i 
culture transcriptionally. However, despite a couple of irregularities, this expression 
data adds strength to the morphological analysis, suggesting that both mESC lines are 




Figure 3.12. WT and dnmt3l-/- mESCs transition between serum and 2i culture 
transcriptionally. qRT-PCR analysis of mRNA expression levels of Prdm14 (A), Dnmt3b 
and Dnmt3l (B) in serum (Ser), 2i and reversion (Rev) WT and dnmt3l-/- mESCs. 
Expression is normalised to β-actin mRNA levels. Error bars represent +/- propagated 
standard deviation of three technical replicates. 
3.2.4.2 Re-establishment of DNA methylation following reversion from 2i is 
impeded in dnmt3l-/- mESCs 
To investigate the effect of the absence of Dnmt3l on the recovery of DNA methylation 
following 2i-associated global hypomethylation, the levels of DNA methylation were 
examined in serum, 2i and reversion WT and dnmt3l-/- mESCs. Changes in DNA 
methylation levels were initially examined using a methylation-sensitive MaeII digest. 
Serum E14 mESCs were included as a comparison. WT mESCs in serum appeared to 
have similar DNA methylation levels to E14 mESCs (Figure 3.13 A). In contrast, 
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serum dnmt3l-/- mESCs exhibit noticeable hypomethylation, indicated by the 
downwards smear of the bulk DNA down the lane of the gel as well as the increased 
presence of lower molecular weight bands. Upon adaptation to 2i, there was no 
obvious change in the DNA methylation level of WT or dnmt3l-/- mESCs, at least at 
the satellite DNA regions that this technique assays. Moreover, there was no clear 
change in major satellite methylation following reversion of 2i WT and dnmt3l-/- 
mESCs into serum. This suggested that although WT and dnmt3l-/- mESCs apparently 
adapted to and reverted from 2i morphologically and transcriptionally, they did not 





Figure 3.13. Global DNA methylation levels do not recover in dnmt3l-/- mESCs 
following 2i-associated hypomethylation. A. Agarose gel showing digestion of DNA 
from WT and dnmt3l-/- (3l-/-) mESCs cultured in media containing serum (Ser), adapted 
to 2i for 15 days (2i) and returned into serum-containing media for 15 days (Rev) by 
methylation-sensitive MaeII restriction enzyme (left panel). Digestion of serum E14 
mESCs is shown for comparison. Hypomethylation of satellite DNA sequences is 
indicated by smearing of the DNA down the lane of the gel and the appearance of lower 
molecular weight fragments. MspI digests are shown as a control for digestability (left 
panel). Uncut genomic DNA is also shown as a loading control (right panel). B. 
Quantitative analysis of global DNA methylation levels (5-mC) by LC-MS. Global 5-mC 
is calculated as a percentage of total cytosine levels (sum of LC-MS measurements for 
C, 5-mC and 5-hmC). Error bars represent +/- standard deviation of three technical 
replicates.  
To corroborate this surprising result, LC-MS was performed on serum, 2i and 
reversion WT and dnmt3l-/- mESCs (three technical replicates from one biological 
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replicate for each sample) to measure global DNA methylation levels. This revealed 
that there was in fact a reduction of approximately 35% in global 5-mC levels in WT 
mESCs upon adaptation to 2i (Figure 3.13 B). This reduction was almost entirely 
recovered following reversion into serum. In dnmt3l-/- mESCs, global DNA 
methylation levels were already reduced by approximately 20% in serum compared to 
WT mESCs. Following conversion to 2i, global 5-mC levels decreased a further 30%. 
This loss of DNA methylation was not recovered after reversion of dnmt3l-/- mESCs 
back into serum.  
These results demonstrate that the expected 2i-associated global hypomethylation did 
in fact occur in WT and dnmt3l-/- mESCs, albeit not to the same extent as in E14 
mESCs. This DNA methylation reduction was not apparent in the methylation-
sensitive DNA digests, possibly due to the satellite DNA sequences assessed by this 
method remaining methylated in serum and 2i mESCs. Importantly, these results also 
highlight the complete inability of dnmt3l-/- mESCs to re-methylate the genome during 
reversion from 2i culture. This reveals, as predicted by published work (Grabole et al., 
2013; Leitch et al., 2013; Yamaji et al., 2013b), that Dnmt3l is an essential factor for 
re-establishing global DNA methylation levels in this mESC culture system. More in-
depth analysis is required to verify this interesting result and to explore what regions 
of the genome remain unmethylated in reverted dnmt3l-/- mESCs. Further investigation 
into this result may also help to uncover the exact mechanism by which DNA 
methylation is re-established during transition from 2i to serum culture.  
3.3 Discussion 
The work presented in this chapter was undertaken with two main aims in mind: to 
develop a culture system in which to modulate global DNA methylation and to 
determine whether Lsh is required for DNA methylation re-establishment in this 
system. To achieve these aims, I optimised the transition of E14 and lsh-/- mESCs 
between serum and 2i culture to modulate DNA methylation levels. This optimisation 
involved monitoring colony morphology, as well as changes in expression levels and 
uniformity of expression of a few candidate genes to assess whether the mESCs were 
transitioning between culture states. DNA methylation levels were then measured at 
satellite regions and globally to examine the genome-wide hypomethylation and 
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subsequent re-methylation. This allowed me to assess the involvement of Lsh in this 
methylation process by transitioning E14 and lsh-/- mESCs through this culture set-up. 
Furthermore, once this culture system had been optimised I was able to adopt it to 
investigate the requirement for other factors during the re-methylation process, such 
de novo methyltransferase co-factor Dnmt3l. 
3.3.1 Colony morphology and gene expression changes are good indicators 
of adaptation to and reversion from 2i 
During development of this culture system, I needed a way to assess whether the 
transition between the culture states, and therefore changes in global DNA 
methylation, had occurred. Changes in colony morphology were monitored as a quick 
and easy way to give an initial indication as to whether the mESCs were responding 
to the change in culture conditions. Both E14 and lsh-/- mESCs exhibited clear changes 
in colony morphology after adaptation to 2i and reversion into serum, albeit lsh-/- 
mESCs to a slightly lesser extent. This corresponded to the anticipated changes in 
global DNA methylation levels, as shown in Section 3.2.3.5. The morphology of WT 
and dnmt3l-/- mESCs were also assessed and were shown not to change to the same 
degree as E14 or lsh-/- mESCs. Likewise, DNA methylation levels in WT and dnmt3l-
/- mESCs were shown not to change to the same extent as in E14 and lsh-/- mESCs. 
Therefore, monitoring morphological changes could provide a straightforward and 
effective way to gauge the degree of adaptation of mESCs to the different culture states 
and perhaps predict whether the anticipated DNA methylation changes will occur. 
However, caution is required when drawing conclusions from morphological 
information, as the appearance of different mESC lines varies, which will affect their 
morphological adaptation during transitions between culture states. 
Expression analysis of a few key pluripotency, lineage-associated and DNMT genes 
was also used as an effective indicator of 2i adaptation and serum reversion in E14 and 
lsh-/- mESCs. Care is also required when rationalising expression data, as most of the 
anticipated expression changes took place in WT and dnmt3l-/- mESCs after conversion 
to 2i. However, this was not accompanied by the expected two to three-fold reduction 
in DNA methylation levels, as the global methylation change was much smaller in 
magnitude than anticipated. 
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Overall, through this set of experiments I showed that monitoring colony morphology 
and gene expression changes provides a quick and effective way to assess the degree 
of adaptation to and reversion from 2i for a particular mESC line. However, caution is 
necessary when interpreting the data from these approaches as they may not be entirely 
accurate in predicting whether genome-wide DNA methylation changes have 
occurred.  
3.3.2 Differences in colony morphology, gene expression and global DNA 
methylation levels are interconvertible between serum and 2i culture  
Previously published studies suggested that serum and 2i culture states are 
interconvertible in terms of colony morphology, gene expression differences and 
crucially, DNA methylation profiles (Marks et al., 2012; Habibi et al., 2013). This 
feature of the culture system was key to enable the investigation into the requirement 
for Lsh in DNA methylation re-establishment in a pluripotent context. During the 
optimisation of this culture system, I demonstrated that these two culture states indeed 
appeared to be interconvertible in the context of colony morphology, gene expression 
and global DNA methylation levels. Changes in DNA methylation levels followed the 
anticipated pattern of genome-wide de-methylation upon adaptation to 2i. This global 
hypomethylation was then reversed after returning mESCs to serum culture, 
highlighting the interconvertibility of DNA methylation in this culture system. This 
also confirmed that it was possible to modify global DNA methylation levels by 
altering culture conditions. However, DNA methylation changes were only examined 
on a global scale or at major satellite sequences. It would be interesting to scrutinize 
the differences in genome-wide DNA methylation profiles between serum, 2i and 
reverted mESCs to evaluate whether DNA methylation is re-established to the same 
loci during transition from 2i to serum. Similarly, it would be interesting to determine 
whether gene expression profiles of reverted mESCs were entirely comparable to their 
serum counterparts, as is suggested by previous reports (Marks et al., 2012). This 




3.3.3 Serum lsh-/- mESCs display some characteristics similar to 2i E14 
mESCs 
Whilst optimising the adaptation and reversion culture system, it became clear that 
serum lsh-/- mESCs showed some similarities to 2i E14 mESCs in terms of gene 
expression. This was most evident when examining the expression of lineage-
associated factors Pax6 and Fgf15 as well as Dnmt3b and Dnmt3l (Figure 3.7 B and 
C). For each of these genes, the expression levels in serum lsh-/- mESCs were reduced 
approximately two-fold in comparison to serum E14 mESCs, representing an 
intermediate expression level between serum and 2i E14 mESCs. Additionally, 
analysis of uniformity of Nanog expression by immunofluorescence suggested that 
Nanog expression was already fairly homogeneous prior to 2i adaptation, meaning that 
the expected increase in uniformity was not as apparent in lsh-/- mESCs compared to 
E14 mESCs following conversion to 2i (Figures 3.5 A and 3.6). These observations 
imply that transcriptionally, lsh-/- mESCs could represent an intermediate state between 
serum and 2i, although more in-depth and genome-wide expression analysis is required 
to support these observations. To address this, RNA-seq was performed on serum and 
2i E14 and lsh-/- mESCs and is discussed in Chapter 4. Furthermore, it would be 
interesting to investigate whether these similarities between serum lsh-/- mESCs and 2i 
E14 mESCs extended to the DNA methylation profiles of these mESCs. This was 
hinted to in the global DNA methylation analysis by LC-MS, as the global DNA 
methylation levels appeared to be lower in serum lsh-/- mESCs compared to serum E14 
mESCs, however this difference was not found to be significant (Figure 3.9). Higher-
resolution scrutinization of genome-wide DNA methylation profiles is necessary to 
further investigate this interesting observation. 
3.3.4 Global DNA methylation levels fully recover after reversion into serum 
in lsh-/- but not in dnmt3l-/- mESCs 
The primary aim of this chapter was to investigate the impact of absence of Lsh on the 
ability to re-establish DNA methylation following 2i-associated global 
hypomethylation. This was achieved by harnessing the interconvertibility of the 2i 
adaptation and serum reversion culture system. Using this culture system, I discovered 
that surprisingly, Lsh is not required to re-establish global levels of DNA methylation 
112 
 
during reversion from 2i to serum. Using dnmt3l-/- mESCs I then went onto show that 
Dnmt3l does appear to be required for re-methylation of the genome following 2i-
associated global hypomethylation. This strengthens the finding that Lsh is not 
required for re-establishment of DNA methylation during transition to serum by 
providing an example of a factor that is required. In this way, dnmt3l-/- mESCs can act 
as a ‘positive control’, demonstrating that it is possible for global DNA methylation 
levels not to undergo full recovery following reversion into serum. 
These findings have implications for the roles of these factors in DNA methylation 
deposition during the early stages of embryonic development. mESCs adapted to 2i 
are proposed to closely resemble cells of the ICM in terms of DNA methylation 
profiles (Habibi et al., 2013; Choi et al., 2017). In contrast, serum mESCs are proposed 
to reflect a slightly later, more ‘primed’ stage of development in terms of gene 
expression and DNA methylation levels. Therefore, the establishment of DNA 
methylation that occurs during transition from 2i to serum culture could be said to be 
representative of the de novo DNA methylation that occurs during the early stages of 
implantation of the blastocyst in vivo (Habibi et al., 2013; Choi et al., 2017). This 
implies that Lsh function is not required for DNA methylation deposition during this 
early stage of embryonic development. This finding provides new evidence to support 
a role for Lsh in establishing DNA methylation in a later developmental context. It 
also shows that although Lsh has been shown to be expressed more highly in 
pluripotent cultures, this does not translate into a role for Lsh in DNA methylation in 
these systems. In contrast, these experiments suggest that Dnmt3l is necessary for 
DNA methylation establishment in this culture model of early embryonic 
development, as had been previously suggested (Grabole et al., 2013; Leitch et al., 
2013; Yamaji et al., 2013) highlighting the role for this DNA methyltransferase co-
factor in de novo methylation during this early phase of development. 
Overall, the results discussed in this chapter provide valuable insight into the factors 
required for establishment of DNA methylation in mESCs. Further investigations are 
required to determine the stage of development where Lsh function begins to 
contribute to DNA methylation establishment. Moreover, it would be interesting to 
examine the requirement for Dnmt3l in re-methylation of the genome during reversion 
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in more detail as doing so could help to elucidate the mechanism by which DNA 





Chapter 4. Mapping genome-wide DNA 
methylation and gene expression changes during 
transition to and from the pluripotent ground state 
4.1 Introduction 
A number of previous studies have demonstrated the interconvertibility between the 
transcriptional and DNA methylation profiles of mESCs cultured in conditions 
containing serum or 2i (Marks et al., 2012; Habibi et al., 2013; Leitch et al., 2013). 
The ability to simply and effectively transition mESCs between these distinct 
pluripotent states by changing the culture conditions has provided a model in which to 
study the transcriptional and epigenetic mechanisms underlying the transitions 
between pluripotent states in early development. In particular, the extensive 
remodelling of genome-wide DNA methylation that occurs during transition between 
serum and 2i culture states is a valuable feature of this culture system, allowing 
dissection of the mechanisms involved in global de-methylation and subsequent DNA 
methylation re-establishment in a pluripotent context. 
In Chapter 3, I harnessed the interconvertibility of this culture system to examine the 
impact of absence of Lsh on DNA methylation re-establishment during transition from 
the hypomethylated 2i state to hypermethylated serum mESCs. This revealed that Lsh 
does not appear to be required for global re-establishment of DNA methylation during 
this transition. Indeed, I showed that lack of Lsh appeared to have little effect on the 
apparent interconvertibility between the serum and 2i culture states in terms of colony 
morphology, transcription of a few key pluripotency and lineage-associated factors, 
and global DNA methylation levels. However, this analysis was limited to assessing 
the transcription of a few genes and bulk 5-mC levels, which are not informative of 
changes in genome-wide patterns of transcription and DNA methylation. Therefore, I 
aimed to inspect the genome-wide changes in gene expression and DNA methylation 
of lsh-/- mESCs during transition between serum and 2i culture states to uncover any 
previously unclear roles for Lsh in influencing patterns of gene expression or DNA 
methylation. Additionally, I sought to examine transcriptional and DNA methylation 
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profiles of serum, 2i and reversion E14 mESCs to further investigate whether gene 
expression and 5-mC patterns are truly interconvertible between the serum and 2i 
culture. To enable in-depth analysis of changes in transcriptomes and DNA 
methylomes between culture states, high-resolution transcription and 5-mC profiles 
were generated for serum, 2i and reversion E14 and lsh-/- mESCs using RNA-seq and 
enhanced RRBS (ERRBS) technologies. 
4.2 Results 
4.2.1 Transcriptome analysis by RNA-seq 
RNA-seq was employed to assess the transcriptional changes that occur in E14 and 
lsh-/- mESCs during adaptation to and reversion from 2i culture. I isolated 
polyadenylated mRNA and prepared libraries from one biological replicate for each 
cell line/condition (six samples in total) for Illumina sequencing, which was performed 
by Edinburgh Genomics. All bioinformatic analysis was performed by Dr Donncha 
Dunican.  
4.2.1.1 Gene expression profiles of E14 and lsh-/- mESCs cluster based on 
culture conditions rather than genotype 
Initially, the relationship between the global transcriptomes of E14 and lsh-/- serum, 2i 
and reversion mESCs was assessed. This revealed that gene expression profiles of 
these mESCs cluster based on the conditions in which they are cultured, rather than 
the presence or absence of Lsh. As illustrated by hierarchical cluster analysis (HCA), 
the transcriptomes of E14 and lsh-/- mESCs initially branch off depending on whether 
they were cultured in conditions containing serum (including serum and reversion 
mESCs) or 2i (Figure 4.1 A). The transcriptomes of E14 and lsh-/- serum and reversion 
mESCs then differ based on whether they were always cultured in serum, or were 
adapted to 2i then reverted into serum. This analysis demonstrates that mESCs cultured 
in 2i occupy a transcriptional profile distinct from those cultured in serum. Moreover, 
it shows that when mESCs are reverted into serum culture following 2i adaptation, 
their transcriptomes return to profiles that resemble, but are not identical to, those 
observed prior to 2i conversion. Importantly, this clustering analysis emphasises that 
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within each culture condition, the gene expression profiles of E14 and lsh-/- mESCs 
are closely related.  
 
Figure 4.1. Gene expression profiles of E14 and lsh-/- mESCs cluster based on 
culture conditions rather than genotype. Analysis of the degree of similarity between 
serum, 2i and reversion E14 and lsh-/- RNA-seq datasets using hierarchical clustering 
analysis (A) and principal component analysis (B).  
These initial indications were reinforced using principal component analysis (PCA), 
which further demonstrated that the transcriptional profiles of E14 and lsh-/- mESCs 
are comparable when grown under the same conditions (Figure 4.1 B). As implied by 
the HCA, the vast majority (97.9%) of the variance between the gene expression 
profiles analysed can be accounted for by transcriptional differences between mESCs 
cultured in 2i to those cultured in serum. The differences in gene expression between 
serum and reversion mESCs explains only 2.1% of the variance observed, further 
illustrating that these expression profiles closely resemble one another. 
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Overall, these analyses clearly demonstrate that the adaptation of E14 and lsh-/- mESCs 
to 2i culture induces extensive transcriptional changes, resulting in 2i mESCs that 
adopt an entirely distinct transcriptional state compared to the serum mESCs from 
which they were derived. It also highlights that this global adaptation of gene 
expression patterns is dynamic, as when 2i mESCs are reverted into serum culture, 
their transcriptional profiles also transition back to those resembling serum mESCs 
prior to 2i adaptation. Crucially, the absence of Lsh appears to have no observable 
effect on these gross transcriptional changes that occur upon adaptation to 2i and 
reversion back into serum, as the transcriptomes of lsh-/- mESCs closely resemble those 
of E14 mESCs in each culture condition.  
4.2.1.2 Gene expression profiles of E14 and lsh-/- mESCs cultured in serum 
and 2i are generally interconvertible 
To further characterise the global transcriptional changes that occur upon adaptation 
to 2i, the expression profiles of serum and 2i E14 mESCs were compared to one 
another in a scatter plot. This supported the indication from the previous analysis that 
mESCs undergo extensive genome-wide transcriptional changes upon adaptation to 
2i, as more than 2700 genes were upregulated and more than 3000 downregulated at 
least two-fold in E14 2i mESCs compared to E14 serum (Figure 4.2 A). When serum 
E14 mESCs were plotted against reversion E14 mESCs, far fewer genes were 
differentially expressed between the two conditions, reinforcing the previous 
observation that gene expression profiles of 2i mESCs largely return to those of serum 
mESCs after reversion from 2i culture. This indicates, along with the PCA, that the 
transcriptomes of serum and 2i mESCs are largely interconvertible, dynamically 
transitioning between two states depending on culture conditions. However, there 
remain a considerable number of genes that are mis-expressed in reversion E14 mESCs 
compared to serum E14 mESCs (1262 upregulated genes and 994 downregulated 





Figure 4.2. Gene expression profiles of E14 and lsh-/- mESCs cultured in serum or 
2i are generally interconvertible. Scatter plots comparing RNA-seq profiles of serum, 
2i and reversion (rev) E14 (A) and lsh-/- (B) mESCs. Genes upregulated more than two-
fold are highlighted in blue, genes downregulated more than two-fold are shown in 
orange. Axes represent log2(read counts per 10 million) for the sample indicated on each 
axis. 
A similar trend in the transcriptional changes between serum and 2i culture is also 
apparent in lsh-/- mESCs. As observed in the equivalent comparison in E14 mESCs, a 
large number of genes are upregulated and downregulated more than two-fold when 
serum lsh-/- mESCs are compared to those adapted to 2i (2039 upregulated, 3730 
downregulated; Figure 4.2 B). Furthermore, there are far fewer differentially expressed 
genes when serum lsh-/- mESCs are compared to reverted lsh-/- mESCs (906 
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upregulated, 2297 downregulated). However, there are substantially more 
transcriptional differences between serum lsh-/- mESCs and reversion lsh-/- mESCs 
compared to the equivalent comparison in E14 mESCs, particularly evident in the 
number of downregulated genes in reverted mESCs compared to serum (2297 
downregulated genes in reversion lsh-/- mESCs compared to 994 in reversion E14 
mESCs). This suggests that although lsh-/- mESCs exhibit a degree of transcriptome 
interconvertibility between serum and 2i culture, the absence of Lsh somewhat 
hampers the upregulation of many genes during reversion into serum culture. 
Therefore, the extent of the transcriptome interconversion may not be as pronounced 
in lsh-/- mESCs as in E14 mESCs, but both mESC lines do exhibit a degree of 
interconvertibility in gene expression profiles between serum and 2i culture. 
4.2.1.3 Serum lsh-/- mESCs show similar expression of a subset of genes to 
E14 2i mESCs 
In Chapter 3, qRT-PCR and immunofluorescence analysis revealed that the expression 
of a few key pluripotency, lineage-associated and DNMT genes differed between 
serum E14 and lsh-/- mESCs, and that the expression of these factors in serum lsh-/- 
mESCs were closer to the levels observed in 2i E14 mESCs. To investigate whether 
this similarity in gene expression patterns between E14 2i and lsh-/- serum mESCs is 
applicable genome-wide, the transcriptional profiles of these mESCs obtained using 
RNA-seq were scrutinised.  
The genes that changed in expression more than two-fold in serum lsh-/- mESCs 
compared to serum E14 mESCs were defined (775 genes). A heatmap was then 
compiled displaying the expression of this refined set of genes across serum and 2i 
E14 mESCs and serum lsh-/- mESCs (Figure 4.3 A). This revealed that, based on this 
refined dataset, the expression profiles of E14 2i and lsh-/- serum mESCs cluster 
together. This contrasts with the clustering analysis of the whole transcriptomes shown 
in Figure 4.1, where E14 and lsh-/- serum mESCs cluster together. This suggests that 
the genes that are mis-expressed in serum lsh-/- mESCs compared to serum E14 mESCs 
are the same genes that change expression in E14 mESCs during transition to 2i, 
reinforcing the suggestion from the qRT-PCR data in Chapter 3 that a subset of genes 




Figure 4.3. Serum lsh-/- mESCs show similar expression of a subset of genes to 
E14 2i mESCs. A. Heatmap analysis showing the expression levels of genes mis-
expressed more than two-fold in serum lsh-/- mESCs compared to serum E14 mESCs. 
The expression levels of this defined gene set (775 genes) were then compared across 
serum and 2i E14 mESCs and serum lsh-/- mESCs. B. Gene ontology (GO) term 
enrichment analysis using the biological processes category with the GOrilla tool. The 
top ten significant terms are shown.  
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To determine whether the set of genes displayed in the heatmap are associated with 
any specific classes of genes, they were subjected to gene ontology (GO) enrichment 
analysis using the biological processes category of the GOrilla tool (http://cbl-
gorilla.cs.technion.ac.il/). This revealed a significant enrichment for GO terms 
associated with signalling processes and sensory perception (Figure 4.3 B, top ten 
significantly enriched terms are shown). This demonstrates that genes mis-expressed 
in serum lsh-/- mESCs are involved in signalling and sensory perception processes, 
suggesting that Lsh may play a role in influencing expression of these classes of genes.  
4.2.2 DNA methylome analysis by ERRBS 
To examine the changes in DNA methylation that occur during transition to and 
reversion from 2i in E14 and lsh-/- mESCs, high-resolution 5-mC profiles were 
generated using ERRBS. RRBS was originally developed to provide single-nucleotide 
resolution DNA methylation profiles of CG-rich genomic regions (Meissner et al., 
2005). This enrichment of CG-rich sequences enabled coverage of the majority of 
promoters and other genomic features of interest in the genome, while reducing the 
overall amount of sequencing required compared to techniques such as whole genome 
bisulfite sequencing (WGBS). The generation of CG-rich libraries for RRBS involves 
digestion of genomic DNA with a methylation-insensitive enzyme, such as MspI, 
followed by size selection to purify CG-rich DNA fragments (Meissner et al., 2005; 
Gu et al., 2011). These DNA fragments are then subjected to bisulfite treatment which 
distinguishes unmodified cytosine from 5-mC and 5-hmC, as the treatment deaminates 
unmodified cytosine to uracil, while methylated and hydroxymethylated cytosines are 
protected from deamination. Following the sequencing of bisulfite treated DNA, 
unmethylated cytosines can be identified as thymine residues, while methylated 
cytosines are recognised as cytosine residues. Combination of these techniques with 
next-generation sequencing strategies resulted in the generation of high-quality single-
nucleotide resolution DNA methylation profiles for a lower cost and input 
requirements compared to whole-genome based strategies (Meissner et al., 2005; Gu 
et al., 2011). However, these advantages come with the caveat of reduced genomic 
coverage that is largely restricted to CG-rich sequences. A modified RRBS protocol, 
where the size range of DNA fragments selected was increased, doubled the genomic 
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coverage of the technique and allowed examination of regions beyond CpG islands 
and promoters, such as exons, introns and other genomic regions (Akalin et al., 2012; 
Garrett-Bakelman et al., 2015). This improved method, termed enhanced RRBS 
(ERRBS) was therefore chosen for generation of DNA methylation profiles from 
serum, 2i and reversion E14 and lsh-/- mESCs. One biological replicate was sequenced 
for each cell line/condition (six samples in total). Library production and Illumina 
sequencing was performed by the Epigenomics Core Facility of Weill Cornell 
Medicine (New York, USA), while the data was analysed bioinformatically by Dr 
Donncha Dunican. 
4.2.2.1 The DNA methylomes of lsh-/- mESCs are distinct from those of E14 
mESCs 
The transcriptional profiles of serum, 2i and reversion E14 and lsh-/- mESCs were 
shown to cluster based on conditions in which the mESCs were cultured in, rather than 
on the genotype in relation to Lsh. To determine whether this was the case for the DNA 
methylation profiles of these samples, a similar HCA was performed using the ERRBS 
datasets. This revealed that E14 and lsh-/- mESC DNA methylomes initially cluster 
based on Lsh genotype, with serum and reversion lsh-/- mESCs pairing up with one 
another and serum and reversion E14 mESCs pairing up separately (Figure 4.4 A). 
This demonstrates that the DNA methylomes of serum and reversion mESCs are 
similar within each cell line, indicating that during reversion from the hypomethylated 
ground state, 5-mC patterns are generally re-established to the genomic loci that 
exhibited methylation prior to 2i adaptation. The fact that lsh-/- and E14 mESCs cluster 
separately, in contrast to the transcriptome data, suggests that the DNA methylation 
profiles of lsh-/- mESCs cultured in serum are distinct from those of the equivalent E14 
mESCs. However, although there is some degree of distinction between E14 and lsh-/- 
mESCs cultured in conditions containing serum, all these samples are present on the 
same branch of the dendogram, indicating that their 5-mC profiles remain closely 
related. As with the gene expression profiles shown in Figure 4.1 A, the DNA 
methylomes of 2i E14 and lsh-/- mESCs cluster away from those of the mESCs cultured 
in serum-containing conditions. However, 2i E14 and lsh-/- mESCs do not cluster on 
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the same branch as each other, suggesting there is also a distinction between the DNA 
methylomes of ground state mESCs in the presence and absence of Lsh.  
 
Figure 4.4. The DNA methylomes of lsh-/- mESCs are distinct from those of E14 
mESCs. Analysis of the degree of similarity between serum, 2i and reversion E14 and 
lsh-/- ERRBS datasets using HCA (A) and PCA (B).  
To further assess the differences between the DNA methylomes of serum, 2i and 
reversion E14 and lsh-/- mESCs, PCA was performed. This demonstrated that the main 
source of variation (30%) between the ERRBS datasets was due to the differences 
between mESCs cultured in conditions containing serum or 2i, indicating that the 5-
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mC profiles of E14 and lsh-/- mESCs do initially cluster based on culture conditions 
(Figure 4.4 B). However, 16% of the variation between the DNA methylation profiles 
was accounted for by dissimilarities between E14 and lsh-/- mESCs cultured in serum, 
supporting the observation from the HCA that the DNA methylomes of E14 and lsh-/- 
mESCs cultured in serum are distinct. It also reinforces the suggestion that DNA 
methylation is re-established in patterns resembling those observed prior to conversion 
to 2i during reversion from the hypomethylated 2i pluripotent state. 
In summary, these analyses illustrate that the DNA methylation profiles of mESCs 
cultured in serum or 2i are distinct, in concordance with the transcriptome analysis. 
However, unlike the analysis of gene expression profiles, evaluation of the DNA 
methylomes E14 and lsh-/- mESCs highlights differences in 5-mC profiles between 
these mESC lines, particularly when they are cultured in conditions containing serum. 
4.2.2.2 Global DNA methylation profiles of E14 and lsh-/- mESCs cultured in 
serum or 2i are interconvertible 
To further examine the genome-wide changes in DNA methylation between serum, 2i 
and reversion E14 and lsh-/- mESCs, the percentage gain or loss of methylation at 
individual CpGs between samples was calculated and collated in a violin plot to 
indicate changes in global DNA methylation levels (Figure 4.5 A). This clearly 
illustrates the substantial loss of CpG methylation that occurs in 2i mESCs compared 
to serum for both E14 and lsh-/- mESCs. However, when reversion mESCs are 
compared to serum, there is very little change in CpG methylation levels in both E14 
and lsh-/- mESCs, reinforcing the suggestions from the previous analyses that the DNA 
methylation profiles of serum and reversion mESCs are very similar in both E14 and 
lsh-/- backgrounds. The comparison of lsh-/- mESCs with E14 in a serum or 2i context 
also demonstrates that there appears to be relatively little gain or loss in overall CpG 




Figure 4.5. Global DNA methylation profiles of E14 and lsh-/- mESCs cultured in 
serum or 2i are interconvertible. Analysis of serum, 2i and reversion E14 and lsh-/- 
mESC ERRBS datasets to assess changes in methylation of individual CpGs. A. Violin 
plot showing individual CpGs that gain or lose methylation between samples indicated 
on the right hand side. The scale 0-1 represents 0-100% methylation gain/loss. Number 
of CpGs (n) that lose or gain more than or equal to 50% methylation (indicated by the 
red dotted line) are shown above and below each plot, respectively. Black bars on the 
plots show the interquartile range. B. Scatter plots comparing percentage methylation of 
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individual CpGs within the samples indicated on the axes. The scale 0-1 represents 0-
100% CpG methylation. Heatmap on each plot is generated using two-dimensional 
kernel density estimation and represents the density of data points at that percenta ge of 
CpG methylation within each sample. Black dots identify outlier data points from areas 
of lowest regional density. 
The DNA methylation profiles of serum, 2i and reversion mESCs were compared 
further using a scatter plot and a two-dimensional kernel density estimation. The line 
of best fit was determined using the linear least squares regression method. This 
provided a further clear demonstration of the global loss in DNA methylation that 
occurs following adaptation to 2i in both E14 and lsh-/- mESCs, as the higher density 
of data points along the x-axes indicates increased DNA methylation in serum E14 
(upper panels) and lsh-/- mESCs (lower panels, Figure 4.5 B). Furthermore, the line of 
best fit is skewed towards the x-axis in both scatter plots, which emphasises the 
increased density of data points along this axis, indicating a higher occurrence of 
methylated CpGs in the serum mESCs compared to 2i for both E14 and lsh-/- mESCs. 
When serum mESCs are plotted against reversion mESCs, the almost perfectly 
diagonal line of best fit demonstrates the similarity of the DNA methylation profiles 
between these samples for both E14 and lsh-/- mESCs. Along with the violin plots, this 
clearly shows that the 2i-associated global hypomethylation is recovered following 
reversion into serum, resulting in reversion mESCs with similar 5-mC profiles to those 
observed prior to 2i adaptation. This demonstrates the interconvertibility between the 
DNA methylomes of mESCs transitioned between serum and 2i culture. Furthermore, 
these analyses show no notable difference in the degree of interconvertibility between 
E14 and lsh-/- mESCs, suggesting that lack of Lsh has little impact on the ability of 
mESCs to undergo DNA methylome remodelling during transitions between in vitro 
pluripotent states. 
4.2.2.3 Ground state lsh-/- mESCs exhibit moderate changes in DNA 
methylation compared to 2i E14 mESCs 
To investigate in more detail whether there were any subtle differences in the DNA 
methylomes of E14 and lsh-/- mESCs, the 5-mC profiles of these samples were 
compared using the scatter plots described previously. In the violin plots displayed in 
Figure 4.5 A, a modest number of CpGs were shown gain and lose methylation in 
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serum lsh-/- mESCs compared to E14 (2631 and 7701, respectively). These changes 
were apparent when serum E14 mESCs were plotted against serum lsh-/- mESCs, 
manifesting in a small skew of the line of best fit towards serum E14 mESCs (Figure 
4.6 A). This indicates the presence of slightly more methylated CpGs in the serum E14 
mESC dataset.  
 
Figure 4.6. A modest number of CpGs exhibit changes in 5-mC status in serum lsh-
/- mESCs compared to serum E14 mESCs. A. Scatter plot with two-dimensional kernel 
density comparing CpG methylation of serum E14 mESCs to serum lsh-/- mESCs. B. 
Analysis of genic and non-genic regions in which CpGs that lose/gain methylation 
between serum lsh-/- and E14 mESCs (identified in Figure 4.5 A) reside.  
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To assess the genomic loci affected by loss or gain of DNA methylation in serum lsh-
/- mESCs, the regions in which the CpGs identified in the analysis shown in Figure 4.5 
A reside were determined and classified into genic and non-genic regions (using mm9 
as a reference genome). CpGs that lose methylation in serum lsh-/- mESCs compared 
to E14 are enriched in intronic regions, with exons also being affected to a lesser extent 
(Figure 4.6 B, left panels). Other genomic features such as promoters, transcription 
termination sites (TTS) and 3’ and 5’ untranslated regions (UTRs) are also affected to 
a much lesser extent. A similar pattern of affected genic regions is observed for CpGs 
that gain methylation in serum lsh-/- mESCs. The non-genic regions affected by CpG 
methylation gain or loss are also similar to one another, with intergenic sequences 
being enriched the most, followed by LINE-1 elements, then a range of other retroviral 
elements, such as ERVs, affected to a lesser extent (Figure 4.6 B, right panels). This 
suggests that Lsh modulates DNA methylation mostly at a small subset of introns, 
exons, intergenic and LINE-1 sequences in serum lsh-/- mESCs. 
To explore whether a lack of Lsh impacts the levels or genomic distribution of DNA 
methylation in the pluripotent ground state, the same analysis was performed 
comparing 2i lsh-/- mESCs to 2i E14 mESCs. Interestingly, the scatter plot showed a 
striking skew of the line of best fit towards the 2i E14 mESCs, indicating that these 
mESCs contained considerably more methylated CpGs than 2i lsh-/- mESCs (Figure 
4.7 A). Indeed, the violin plot analysis shown in Figure 4.5 A identified a moderate 
number of CpGs that gained and, in particular, lost cytosine methylation in 2i lsh-/- 
mESCs compared to E14 (8653 and 30836, respectively). Establishment of the 
genomic regions that these CpGs reside in revealed a similar pattern to the serum lsh-
/- mESCs, with introns comprising more than half of the affected genic regions, 
followed by exons constituting approximately a quarter (Figure 4.7 B, left panels). 
Non-genic regions mostly affected by CpG methylation gain in 2i lsh-/- mESCs also 
mimicked serum lsh-/- mESCs, with intergenic loci being the primary target for 
aberrant CpG methylation, followed by LINE-1 elements. Examination of the loci 
encompassing CpGs which lost cytosine methylation in 2i lsh-/- mESCs revealed 
enrichment of intergenic sequences and regions classified as ‘other’. However, it also 
showed that almost half of the non-genic regions in which the CpGs that lose 
methylation reside were LINE-1 subfamilies, suggesting that Lsh plays a role in 
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establishing or maintaining DNA methylation at these repetitive elements in the 
ground state of pluripotency.  
 
Figure 4.7. A moderate number of CpGs lose and gain methylation in 2i lsh-/- 
mESCs compared to 2i E14 mESCs. A. Scatter plot with two-dimensional kernel 
density comparing CpG methylation of 2i E14 mESCs to 2i lsh-/- mESCs. B. Analysis of 
genic and non-genic regions in which CpGs that lose/gain methylation between 2i lsh-/- 




The bioinformatic analysis of high-resolution RNA-seq and ERRBS datasets described 
in this chapter was undertaken to examine the genome-wide changes in gene 
expression and DNA methylation that occur during transition between serum and 2i 
culture in E14 and lsh-/- mESCs. These analyses demonstrated that the transcriptomes 
and, even more so, DNA methylomes of mESCs are largely interconvertible between 
the two pluripotent states. Furthermore, it showed that while the absence of Lsh may 
have a subtle effect on the transition of gene expression patterns between these two 
culture states, it does not appear to have any notable effect on the interconvertibility 
of serum and 2i mESC DNA methylation profiles. However, it was noticed that the 
DNA methylomes of lsh-/- mESCs cultured in serum are distinct from serum E14 
mESCs, and that there is a degree of DNA hypomethylation in 2i lsh-/- mESCs, a 
proportion of which occurs at LINE-1 element subfamilies. This suggests that while 
Lsh may not play a role in the global remodelling of DNA methylation patterns during 
transitions between serum and 2i culture, its absence does result in modest 
perturbations of 5-mC profiles in both serum and 2i mESCs. 
4.3.1 Transcriptional and DNA methylation profiles are generally 
interconvertible between serum and 2i culture 
In Chapter 3, I demonstrated that the serum and 2i culture states appear to be 
interconvertible in terms of colony morphology, expression of a few key genes and 
global DNA methylation levels. However, the transcriptional changes that occur 
between the two pluripotent states were only assessed for a few genes, while only total 
levels of 5-mC were measured in serum and 2i mESCs. I aimed to evaluate whether 
these smaller-scale changes were applicable genome-wide through examination of 
transcription and DNA methylation profiles of serum, 2i and reversion mESCs. Scatter 
plot analysis of gene expression profiles generated by RNA-seq demonstrate that a 
vast number of genes are upregulated and downregulated more than two-fold upon 
transition to 2i, as had been reported previously (Marks et al., 2012). Following 
reversion into serum, these expression changes are largely reversed, resulting in a 
transcriptional profile that is mostly comparable to that of serum mESCs prior to 2i 
adaptation. Some differences in gene expression profiles were apparent, suggesting 
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that transcription patterns do not completely return to those observed initially in serum. 
However, the gene expression trends generally follow the pattern demonstrated by the 
candidate genes assessed in Chapter 3 during transition between serum and 2i culture. 
PCA and scatter plot analysis also clearly showed that the DNA methylomes of 
reversion mESCs return to profiles highly similar to those observed initially in serum 
mESCs. Indeed, HCA revealed that the DNA methylomes of serum and reversion 
mESCs cluster together, indicating the high degree of similarity between the 5-mC 
profiles. This demonstrates that not only do bulk levels of 5-mC recover following 2i-
associated DNA hypomethylation, the patterns of 5-mC also return to those observed 
prior to 2i adaptation, confirming the findings from previous reports (Habibi et al., 
2013; Leitch et al., 2013; Choi et al., 2017). Together, these results provide further 
evidence for the faithful interconversion of transcription and DNA methylation 
profiles between the pluripotent serum and 2i culture states.  
4.3.2 Culture conditions have more impact on mESC transcriptomes and 
DNA methylomes than absence of Lsh 
The expression profiles and DNA methylomes of E14 and lsh-/- mESCs both undergo 
extensive changes upon adaptation to and reversion from 2i culture, as demonstrated 
by the transcription and DNA methylation profiling analyses shown in this chapter. 
This observation is further demonstrated by comparison of serum, 2i and reversion 
E14 and lsh-/- mESCs transcription and 5-mC profiles using HCA and PCA. These 
analyses showed that both E14 and lsh-/- mESCs clustered closely together depending 
on the conditions in which they were cultured, with the principal component of 
variation being the difference between serum and 2i profiles for both the gene 
expression and DNA methylation analysis. This shows that the conditions in which 
mESCs are cultured is the primary modulator of genome-wide transcription and DNA 
methylation patterns, rather than the genotype of the mESCs in relation to Lsh. The 
DNA methylome PCA did however show that the secondary contributor to the 
variation observed between ERRBS datasets was accounted for by differences 
between E14 and lsh-/- mESCs cultured in serum. This implies that the absence of Lsh 
does in fact have an impact on DNA methylation patterns in mESCs, resulting in lsh-/- 
mESC 5-mC profiles that are distinct from those of E14 mESCs, with this distinction 
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particularly evident in mESCs cultured in the presence of serum. This finding was 
alluded to in the LC-MS global DNA methylation analysis of serum, 2i and reversion 
E14 and lsh-/- mESCs in Chapter 3, in which the total 5-mC levels of serum lsh-/- 
mESCs appeared to be lower than in E14, although this difference was not found to be 
significant. 
4.3.3 Lack of Lsh results in gene expression and DNA methylation profile 
perturbations 
Although the absence of Lsh did not have any profound effects on the extensive gene 
expression changes that occur during transition to or reversion from 2i, a small subset 
of genes were found to be mis-expressed in serum lsh-/- mESCs compared to serum 
E14 mESCs. It was also noted that a large proportion of these genes exhibited a similar 
change in expression in lsh-/- mESCs to the change in expression that is observed 
during 2i adaptation in E14 mESCs, suggesting that Lsh influences the expression of 
a selection of genes involved in transition to the ground state of pluripotency. GO 
analysis of these mis-expressed genes revealed an enrichment in terms associated with 
signalling mechanisms and sensory perception, providing insight into the general 
function of genes that are mis-expressed in the absence of Lsh in a pluripotent context. 
Since PCA of DNA methylomes highlighted differences in 5-mC profiles between E14 
and lsh-/- mESCs cultured in serum, the extent of these perturbations and the genomic 
regions affected by DNA methylation gain or loss in the absence of Lsh were assessed. 
This revealed a modest number of CpGs affected by differences in cytosine 
methylation in serum lsh-/- mESCs compared to E14, and that the principal genomic 
regions affected were widespread, not concentrated in any specific genome feature. 
Comparison of the DNA methylation profiles of 2i lsh-/- mESCs with 2i E14 mESCs 
revealed a greater number of CpGs where methylation was gained or, principally, lost. 
Interestingly, a proportion of CpGs that lost methylation were located in LINE-1 
element subfamilies, suggesting that Lsh contributes to the establishment or 
maintenance of DNA methylation at these repetitive elements in ground state mESCs. 
This is consistent with previous reports demonstrating LINE-1 hypomethylation in 
Lsh-depleted mouse embryonic tissues and somatic cells (Dennis et al., 2001; Dunican 
et al., 2013; Ren et al., 2015). 
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In Chapter 3 it was noted that serum lsh-/- mESCs displayed some similar 
characteristics to 2i E14 mESCs, such as expression of a few DNMTs and lineage-
associated factors. Therefore, it was proposed that serum lsh-/- mESCs could represent 
an intermediate state between serum and 2i. Comparison of genome-wide 
transcriptional profiles of serum lsh-/- and 2i E14 mESCs did indeed identify a small 
subset of genes that exhibited similar expression between these two mESC lines 
(Figure 4.3 A). However, HCA and PCA has revealed that, generally, serum lsh-/- 
mESCs do not appear to represent an intermediate state between serum and 2i in terms 
of transcription and DNA methylation. However, there are perturbations in patterns of 
expression and, in particular, DNA methylation in serum and 2i lsh-/- mESCs compared 
to WT, suggesting that Lsh does indeed play a role in modulating DNA methylation 
patterns in a pluripotent context.  
4.3.4 Technical considerations for DNA methylome analysis by ERRBS 
The profiling of DNA methylation in E14 and lsh-/- mESCs using ERRBS revealed a 
moderate amount of changes in CpG methylation between these mESC lines cultured 
in serum and 2i. Despite the coverage of ERRBS purportedly being double that of 
RRBS, allowing the examination of exons and introns, the majority of the sequencing 
reads remain enriched in genomic regions containing high densities of CpGs, such as 
CGIs and gene promoters (Garrett-Bakelman et al., 2015). Therefore, the full extent 
of DNA methylation differences in lsh-/- mESCs compared to E14 may not be apparent 
using the ERRBS technique. In particular, the coverage of relatively CpG-poor (in 
comparison to CGIs) genomic regions such as repetitive elements is low using this 
method. Previous studies have shown repetitive regions of the genome to be the 
primary target of Lsh (Dennis et al., 2001; Huang et al., 2004; Dunican et al., 2013; 
Yu, McIntosh, et al., 2014). Therefore, further analysis of the DNA methylomes of 
lsh-/- mESCs using an unbiased method such as WGBS would be ideal for further 
elucidation of the impact of Lsh deletion on genome-wide DNA methylation patterns. 
Another caveat of the ERRBS method, and other methods using bisulfite treatment to 
identify methylated cytosines, is that bisulfite treatment cannot distinguish between 5-
mC and 5-hmC. Global levels of 5-hmC have been shown to increase during the initial 
stages of transition from serum to 2i culture (Ficz et al., 2013; Habibi et al., 2013). 
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However, these elevated 5-hmC levels decrease to a lower, more stable level after 72 
hours of 2i adaptation (Ficz et al., 2013). Therefore, although the fact that these two 
modified bases cannot be distinguished should be kept in mind, the much lower 
genomic levels of 5-hmC compared to 5-mC mean that the vast majority of each DNA 
methylation profile generated using ERRBS will accurately represent the patterns of 




Chapter 5. Lsh is required for establishment of 
DNA methylation in epiblast stem cells and embryoid 
bodies 
5.1 Introduction 
In Chapter 3 I demonstrated that Lsh does not appear to contribute to DNA methylation 
re-establishment during transition from the hypomethylated ground state of 
pluripotency (2i) to a more methylated, primed state of pluripotency (serum). 
However, Lsh has convincingly been shown to be required for DNA methylation 
globally and at specific genomic loci in mouse embryonic tissue and somatic cells 
(Dennis et al., 2001; Sun, David W. Lee, et al., 2004; Myant et al., 2011; Dunican et 
al., 2013; Yu, McIntosh, et al., 2014). This suggests that Lsh is required for 
establishment or maintenance of DNA methylation patterns during embryonic 
development. Most reports point to a role for Lsh in de novo DNA methylation through 
its association with the de novo methyltransferases Dnmt3a and Dnmt3b (Zhu et al., 
2006; Myant and Stancheva, 2008; Ren et al., 2015; Termanis et al., 2016). Therefore, 
Lsh may contribute to the wave of de novo DNA methylation that occurs in the early 
stages of development during implantation of the blastocyst (Borgel et al., 2010; Smith 
et al., 2012). However, previous investigations of Lsh function during the early stages 
of development are limited, with most studies having concentrated on the impact of 
Lsh depletion at later developmental stages, in somatic cells and tissues. 
In this chapter, I aimed to address the requirement for Lsh in establishing DNA 
methylation during transition from ground state to post-implantation development, 
beyond the ‘primed’ pluripotent state that serum mESCs supposedly reflect. I used two 
culture systems to model post-implantation development – embryoid bodies (EBs) and 
epiblast stem cells (EpiSCs) – to increasingly narrow down the developmental window 
in which Lsh acts to influence DNA methylation. I examined the impact of absence of 
Lsh on global DNA methylation in these culture models, as well as on centromeric and 
pericentromeric repetitive elements, to deduce the contribution of Lsh to de novo DNA 
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methylation globally and locally during the early stages of post-implantation 
development that these culture models represent. 
5.2 Results 
5.2.1 Differentiation of 2i mESCs to EBs 
5.2.1.1 Experimental strategy 
To dissect the requirement for Lsh in facilitating DNA methylation during the 
differentiation process in vivo, I aimed to differentiate E14 and lsh-/- mESCs to EBs in 
vitro. A report from Ren et al. (2015) demonstrates that Lsh is required for de novo 
DNA methylation of IAP, LINE-1 and minor satellite repeats during differentiation to 
EBs in the presence of RA, which directs differentiating mESCs down a neuronal 
lineage. I sought to confirm and extend this analysis to examine the contribution of 
Lsh to global DNA methylation levels in the presence and absence of RA, as well as 
evaluating the effect of Lsh deletion on DNA methylation levels locally at major and 
minor satellites. To confirm successful differentiation of E14 and lsh-/- mESCs to EBs, 
changes in cell morphology and expression of key lineage-specific genes were 
assessed (outlined in Figure 5.1). The impact of absence of Lsh on DNA methylation 
globally and at major and minor satellites was monitored in EBs differentiated in the 
presence and absence of RA to delineate whether Lsh contributes to DNA methylation 
only during differentiation down the neuronal lineage, or whether it functions more 
generally during generation of all three germ layers. 
As discussed previously, serum mESCs exhibit a high level of global DNA 
methylation similar to that of differentiated cells, while 2i mESCs are globally 
hypomethylated (Senner et al., 2012; Habibi et al., 2013; Leitch et al., 2013). 
Therefore, I reasoned that beginning the differentiation protocol with 2i mESCs would 
allow easier examination of the ability of E14 and lsh-/- mESCs to re-establish global 
DNA methylation patterns during differentiation to EBs due to the substantial 
difference in bulk 5-mC levels between these culture models. Furthermore, since the 
methylomes of 2i mESCs are proposed to more faithfully reflect those of the ICM, it 
could be argued that using ground state mESCs as a starting point represents a more 
physiologically relevant model of the DNA methylation establishment that occurs 
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during differentiation from a naïve pluripotent state to a developmentally restricted 
state. Therefore, I utilised E14 and lsh-/- mESCs that had been adapted to 2i for 15 days 
(six passages) as a starting point for the differentiation to EBs in the presence and 
absence of RA (experimental strategy depicted in Figure 5.1).  
 
Figure 5.1. Diagram depicting the experimental workflow of the differentiation of 
2i mESCs to EBs in the presence/absence of RA. Experimental procedures for 
generation of EBs are summarised, from plating out 2i mESCs in hanging drops at day 
0 to harvesting EBs at day 12. Key changes in pluripotency and lineage marker 
expression and 5-mC levels are highlighted.  
5.2.1.2 E14 and lsh-/- mESCs adapt morphologically during differentiation to 
EBs 
The morphology of differentiated cells is vastly different to that of ground state 
mESCs. As reported by Marks and Stunnenberg (2014) and demonstrated in Chapter 
3, mESCs adapted to 2i form compact, three-dimensional colonies that are rounded 
with smoothened colony boundaries (Figure 3.4). In contrast, differentiated cells adopt 
a vast array of morphologies dependent on cell type, and tend to grow in monolayers 
of flattened, irregularly-shaped cells in vitro. Following aggregation of 2i mESCs to 
form EB structures, the EBs were allowed to adhere and the outgrowth was monitored 
to assess the generation of differentiated cells displaying a range of morphologies from 
E14 and lsh-/- 2i mESCs.  
E14 and lsh-/- 2i mESCs exhibited typical 2i morphology prior to differentiation, as 
described previously (Figure 5.2, left panels). Following differentiation to EBs, a 
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monolayer of cells exhibiting a variety of morphologies was evident in E14 and lsh-/- 
cultures in the presence and absence of RA, indicating that both E14 and lsh-/- mESCs 
had successfully differentiated into a range of cell types (Figure 5.2, middle and right 
panels). As expected, cultures generated in the presence of RA exhibited less 
morphological heterogeneity and increased presence of cells displaying neuronal-like 
projections (indicated by the arrows in Figure 5.2, right panels). This suggested that 
both E14 and lsh-/- EBs supplemented with RA resulted in cell populations largely 
committed to the neuronal lineage. Although analysis of lineage-specific gene 
expression is required to confirm generation of differentiated cultures representing all 
three germ layers, these morphological changes from 2i mESCs to EBs provided an 
initial indication that both E14 and lsh-/- mESCs are able to generate differentiated 
cultures, and that the presence of RA promotes generation of neuron-like cells.  
 
Figure 5.2. E14 and lsh-/- mESCs both differentiate to EBs in the presence and 
absence of RA. Brightfield images showing morphological changes that occur during 
differentiation of E14 and lsh-/- mESCs cultured in 2i (left panels) to EBs in the absence 
and presence of RA in the middle and right panels, respectively. Arrows highlight  the 
presence of cells with neural-like projections in EBs cultured in the presence of RA. 
Scale bars represent 100 µm. 
5.2.1.3 E14 and lsh-/- mESCs transcriptionally upregulate lineage-specific 
markers following differentiation to EBs 
The differentiation of mESCs to EBs is accompanied by the upregulation of lineage-
specific genes and the downregulation of naïve pluripotency factors (Murry and Keller, 
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2008; Radzisheuskaya et al., 2013). The effective differentiation into all three germ 
layers was judged by the increased expression of markers representing all three 
embryonic lineages: ectoderm, endoderm and mesoderm. Immunofluorescence and 
qRT-PCR analysis were used to evaluate the expression of lineage-specific factors in 
E14 and lsh-/- 2i mESCs and EBs generated in the presence and absence of RA. 
An increase in the mesodermal marker α-smooth muscle actin was clearly visible in 
E14 and lsh-/- EBs in the presence and absence of RA, as demonstrated by 
immunofluorescence (Figure 5.3 A). In contrast, both E14 and lsh-/- mESCs were 
completely devoid of expression of this marker of the mesodermal lineage. 
Immunofluorescence for the neuroectodermal-specific class III β–tubulin (Tuj1) gene 
demonstrated vast upregulation of this factor in E14 and lsh-/- EBs cultured in the 
presence of RA (Figure 5.3 B). This shows that cultures differentiated in the presence 
of RA resulted in effective generation of cells committed to the neural lineage. 
Furthermore, lsh-/- EBs exhibited increased Tuj1 expression in comparison to E14 EBs, 
suggesting enhanced generation of neuronal cells in the absence of Lsh, consistent with 
a report from Yu et al. (2014) that lsh-/- iPSCs exhibit an increased propensity to 
differentiate towards the neural lineage. However, analysis of mRNA levels of the 
neuroectodermal marker Nestin by qRT-PCR did not support this finding, as although 
Nestin expression was greatly upregulated in EBs compared to 2i mESCs, Nestin 
mRNA levels were actually lower in lsh-/- EBs cultured in the presence of RA when 
compared to E14 EBs (Figure 5.4, top left panel). Nestin expression was higher in E14 
and lsh-/- EBs supplemented with RA compared to EBs without RA though, reinforcing 




Figure 5.3. E14 and lsh-/- mESCs display expression of lineage-associated markers 
following differentiation to EBs in the presence/absence of RA. 
Immunofluorescence of E14 and lsh-/- 2i mESCs and EBs +/- RA using antibodies against 





Further analysis of the expression levels of endodermal and mesodermal markers 
Gata4 and Brachyury respectively, confirmed that both E14 and lsh-/- 2i mESCs 
produced all three germ layers upon differentiation into EBs. Indeed, Gata4 mRNA 
levels substantially increased in EBs generated in the absence of RA (Figure 5.4, top 
right panel). Gata4 expression also increased in EBs in the presence of RA, but not to 
the same extent as without RA, supporting the proposal that EB cultures exhibit 
increased complexity and heterogeneity in the absence of RA. Interestingly, Gata4 
mRNA levels are notably reduced in lsh-/- EBs compared to E14, suggesting that 
absence of Lsh could influence the expression of selected lineage-associated factors. 
A difference between E14 and lsh-/- EBs was also apparent for Brachyury expression, 
which was much increased in lsh-/- EBs without RA compared to the equivalent E14 
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EBs, although a similar pattern was not evident for EBs supplemented with RA (Figure 
5.4, bottom left panel). Analysis of further markers from all three germ layers is 
required to uncover whether a trend exists towards up- or down-regulation of genes 
belonging to a specific lineage in the absence of Lsh. Furthermore, since these results 
were obtained from qRT-PCR analysis of three technical replicates from one 
biological replicate for each sample, analysis of additional biological replicates is 
required to confirm that the observed differences in expression of lineage-associated 
factors between E14 and lsh-/- EBs are reproducible. Aside from this, the vastly 
increased expression of Brachyury in E14 and lsh-/- EBs with or without RA confirms 
the generation of cells representative of the mesodermal lineage. Moreover, 
examination of Nanog mRNA levels demonstrates almost complete transcriptional 
silencing of this naïve pluripotency marker in both E14 and lsh-/- EBs generated in the 
presence or absence of RA, indicating that these cultures have effectively 




Figure 5.4. E14 and lsh-/- cells both show transcriptional changes in key genes 
following differentiation to EBs in the presence/absence of RA.  Quantification of 
mRNA expression by qRT-PCR of pluripotency or lineage-associated factors (as 
indicated on graphs), normalised to TBP expression. Error bars represent +/ - propagated 
standard deviation of three technical replicates.  
Overall, analysis of these lineage-specific and pluripotency markers by 
immunofluorescence and qRT-PCR confirmed that both E14 and lsh-/- 2i mESCs 
differentiated to EBs comprised of all three germ layers, but that, as anticipated, EBs 




5.2.1.4 Global DNA methylation levels are not fully established in lsh-/- EBs 
To examine the impact of the absence of Lsh on global DNA methylation 
establishment during differentiation of 2i mESCs to EBs, bulk 5-mC levels were 
measured by LC-MS in E14 and lsh-/- 2i mESCs and EBs cultured with and without 
RA. LC-MS analysis of three technical replicates from one biological replicate for 
each sample is presented in Figure 5.5. In contrast to the global DNA methylation LC-
MS data shown in Figure 3.9, a significant difference of approximately 16% in 5-mC 
levels between E14 and lsh-/- mESCs adapted to 2i is evident (Figure 5.5). A discussion 
into the potential explanations for the difference between these two datasets is 
presented in Section 5.3.1. Upon differentiation to EBs, global levels of DNA 
methylation more than double in both E14 and lsh-/- cultures. However, global 5-mC 
is significantly reduced by approximately 20% in lsh-/- EBs generated in the presence 
and absence of RA when compared to the equivalent E14 EB sample. This significant 
difference in global DNA methylation levels in lsh-/- EBs could be due to defective de 
novo DNA methylation during differentiation to EBs in the absence of Lsh. However, 
this reduction in global 5-mC levels in lsh-/- EBs could be accounted for by the 
difference observed prior to differentiation in 2i mESCs, a possibility that requires 






Figure 5.5. Global DNA methylation levels are not fully established in lsh-/- EBs 
differentiated in the presence of RA. Quantification of global 5-mC levels by LC-MS 
in E14 and lsh-/- 2i mESCs and EBs +/- RA. Error bars represent +/- standard deviation 
of three technical replicates. P-values indicate level of significance between E14 and 
lsh-/- cells as measured by a two-way unpaired t-test. 
5.2.1.5 DNA methylation establishment at major and minor satellites is 
impaired in the absence of Lsh during differentiation to EBs 
Lsh has convincingly been shown to be required for DNA methylation of a range of 
repeat classes in mouse embryos and somatic cells (Dennis et al., 2001; Huang et al., 
2004; Dunican et al., 2013; Yu, McIntosh, et al., 2014). Recent identification of 
mutations in the human Lsh homologue HELLS as being causative of ICF syndrome, 
a hallmark of which is hypomethylation at pericentromeric repeats, has highlighted the 
importance of HELLS in establishing DNA methylation at these repetitive regions 
(Thijssen et al., 2015). Therefore, I sought to assess the DNA methylation levels at the 
equivalent repetitive regions in my mESC and EB culture models to further elucidate 
the role of Lsh in DNA methylation of these repeats during differentiation. Initially, I 
harnessed the convenient feature of methylation-sensitive restriction endonucleases to 
indicate the cytosine methylation status of CpGs within their associated restriction site 
through differential restriction digestion, as described in Section 3.2.3.5 (Chapter 3). 
Again, the occurrence of smaller molecular weight fragments following MaeII 
digestion indicates hypomethylation at its restriction sites, which are enriched in 
pericentromeric major satellites. Restriction digestion of genomic DNA from E14 and 
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lsh-/- 2i mESCs and EBs cultured with and without RA revealed similar levels of DNA 
hypomethylation in E14 and lsh-/- 2i mESCs. Following differentiation to EBs, these 
major satellite regions appear to gain DNA methylation in E14 EBs with and without 
RA. However, a reduction in DNA methylation at MaeII sites was apparent in lsh-/- 
EBs generated in the presence and absence of RA compared to E14, demonstrated by 
the downwards smear of digested fragments along with the increased presence of lower 
molecular weight bands (indicated by the arrow in Figure 5.6 A).  
 
Figure 5.6. DNA methylation is incompletely established at major satellites during 
differentiation of lsh-/- EBs in the presence and absence of RA. A. Agarose gel of 
E14 and lsh-/- 2i, EB –RA and EB +RA MaeII restriction digests prior to Southern blot 
transfer. Arrow highlights smaller molecular weight digested fragments indicating major 
satellite DNA hypomethylation. B. Southern blot of MaeII digest following transfer and 
hybridised using a probe against major satellites.  
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To provide extra clarity into the relative levels of major satellite DNA methylation 
between samples, the analysis using methylation-sensitive digests was combined with 
a non-radioactive Southern blot using a probe specific for major satellite sequences. 
The hybridisation of the probe to low molecular weight bands in E14 and lsh-/- 2i 
mESCs indicate that most of the major satellite sequences that the probe is 
complementary to exhibit some degree of DNA hypomethylation, and are therefore 
digested by MaeII (Figure 5.6 B). The increased signal intensity in the upper portion 
of the blot in lsh-/- 2i mESCs indicates that major satellites exhibit slightly higher 5-
mC levels compared to E14. However, following differentiation to EBs in the presence 
and absence of RA, lsh-/- EBs appear to lose some DNA methylation at major satellites, 
whereas DNA methylation levels in E14 EBs greatly increase, as indicated by the 
intense staining of digestion-resistant methylated CpGs residing in the upper portion 
of the blot. This suggests that while major satellites in E14 mESCs gain DNA 
methylation during differentiation, this de novo DNA methylation is impaired in the 
absence of Lsh, which agrees with the analysis of global DNA methylation levels in 
Figure 5.5. 
For analysis of DNA methylation levels at minor satellites, another methylation-
sensitive restriction endonuclease, HpaII, was utilised as its restriction site (CCGG) is 
better represented in minor satellite sequences compared to the restriction sites of 
MaeII. HpaII digests also provide an estimation of global CpG methylation, as the 
restriction site is widespread throughout the genome, particularly in regions that are 
normally hypomethylated, such as CGIs. Digestion with the non-methylation sensitive 
isoschizomer of HpaII, MspI, was utilised as a control to demonstrate the equal 
digestibility of each genomic DNA sample. The HpaII digests generally concurred 
with the global DNA methylation analysis, showing relatively equal DNA 
hypomethylation of E14 and lsh-/- 2i mESCs, as indicated by the general downward 
shift in the molecular weight of the digested fragments (Figure 5.7 A, left panel). DNA 
methylation levels were restored following differentiation to EBs in E14 samples, 
while 5-mC levels appeared to be slightly reduced in lsh-/- 2i EBs, agreeing further 
with the LC-MS analysis. To uncover the relative DNA methylation status of minor 
satellites between E14 and lsh-/- mESCs and EBs, the HpaII digests were coupled with 
a Southern blot using a probe specific for minor satellite sequences. This revealed a 
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striking reduction of DNA methylation levels in lsh-/- 2i mESCs compared to E14 at 
minor satellite sequences (Figure 5.7 B, left panel). A similar degree of DNA 
hypomethylation was also apparent in lsh-/- EBs cultured with and without RA, 
showing that the DNA methylation loss observed at minor satellite sequences in lsh-/- 
2i mESCs is not recovered during differentiation in the absence of Lsh. The 
hybridisation of the corresponding MspI digests with the same minor satellite probe 
acted as a control for digestibility and loading of the genomic DNA samples analysed 
(Figure 5.7 A and B, right panels). The probes for analysis of both major and minor 




Figure 5.7. DNA methylation is incompletely established at minor satellites during 
differentiation of lsh-/- EBs in the presence and absence of RA. A. Agarose gels of 
E14 and lsh-/- 2i, EB –RA and EB +RA HpaII and MspI restriction digests prior to 
Southern blot transfer. B. Southern blot of HpaII and MspI digests, hybridised using a 
probe against minor satellites. 
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Southern blotting coupled with methylation-sensitive restriction digestion gave a 
strong indication of the relative levels of DNA methylation at major and minor 
satellites in E14 and lsh-/- 2i mESCs and EBs. This analysis was extended to quantify 
the DNA methylation levels at these repetitive regions using bisulfite sequencing, 
which assesses the 5-mC status of all CpGs within a specified region, rather than only 
those residing in specific restriction sites. Bisulfite-treated genomic DNA from E14 
and lsh-/- mESCs and EBs was subjected to amplification using primers specific for 
major and minor satellites (primers described in Dunican et al., 2013) to allow 
assessment and quantification of CpG methylation in these amplified sequences. 
Analysis of satellite DNA methylation in serum mESCs as well as 2i mESCs was 
included to further uncover the role of Lsh in facilitating methylation at these regions 
in different pluripotent states. This analysis revealed a relatively similar level of major 
satellite DNA methylation in E14 and lsh-/- serum mESCs of 79% and 71%, 
respectively (Figure 5.8 A). CpG methylation at major satellites was reduced equally 
to 51% and 55% upon adaptation to 2i in E14 and lsh-/- mESCs, respectively. 
Following differentiation to EBs, DNA methylation was re-established up to 75% in 
E14 EBs without RA and 80% in E14 EBs with RA, 5-mC levels which are comparable 
to those observed in serum E14 mESCs. However, this establishment of DNA 
methylation was impeded in lsh-/- EBs generated in the presence and absence of RA, 
which retained CpG methylation levels similar to those of lsh-/- 2i mESCs (55% in lsh-
/- EBs without RA and 53% in lsh-/- EBs with RA). This indicates a crucial role for Lsh 




Figure 5.8. DNA methylation quantification at major and minor satellites in E14 and 
lsh-/- EBs. Quantification of major (A) and minor (B) satellite DNA methylation in E14 
and lsh-/- EBs +/- RA by bisulfite sequencing. Filled circles represent methylated CpGs 
while unfilled circles are unmethylated CpGs. Number of CpGs assayed is shown at the 
top of each plot. Percentage of methylated CpGs is displayed under each plot.  
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At minor satellites, levels of 5-mC were comparable between E14 and lsh-/- serum 
mESCs, at 97% and 91% respectively (Figure 5.8 B). This level of CpG methylation 
was slightly reduced in E14 2i mESCs which showed 82% total DNA methylation. 
However, in accordance with the Southern blot shown in Figure 5.7 B, 5-mC at minor 
satellites was drastically reduced to just 21% in lsh-/- 2i mESCs. During differentiation 
to EBs, DNA methylation was re-established in E14 EBs cultured with and without 
RA, resulting 95% and 92% CpG methylation respectively, levels similar to those 
observed in E14 serum mESCs. In lsh-/- EBs with and without RA, partial DNA 
methylation re-establishment had occurred, although it only reached 41% and 61%, 
respectively. These results demonstrate that Lsh is required for full establishment of 
DNA methylation at minor satellites upon differentiation to EBs, while Lsh also 
appears to participate in maintenance of DNA methylation at minor satellites in the 
ground state of pluripotency. 
There are limitations of the bisulfite sequencing technique that should be taken into 
consideration when interpreting results from bisulfite sequencing data. Incomplete 
bisulfite conversion can result in incorrect interpretation of unconverted unmethylated 
cytosines as methylated cytosines. Furthermore, the presence of clonal sequences, 
which are amplified from the same template molecule in the PCR, can skew the 
calculation of percentage methylation during analysis of bisulfite sequencing data. The 
use of the BISMA online tool (Rohde et al., 2010), which has built-in algorithms for 
detection and removal of clonal sequences and sequences affected by incomplete 
conversion, reduces the impact of these limitations on the bisulfite sequencing analysis 
undertaken in this study. However, analysis of further clones for each sample is 
required to confirm the results and ensure their reproducibility.  
Another limitation of the bisulfite sequencing technique that is more difficult to 
overcome is its inability to distinguish between 5-mC and 5-hmC. However, since the 
bisulfite sequencing results mirror those of the Southern blotting analysis in respect to 
differences in DNA methylation levels between E14 and lsh-/- 2i mESCs and EBs, it 
can be reasoned that these differences in DNA methylation levels are largely due 
changes in 5-mC rather than 5-hmC. Therefore, when taken together, the findings from 
the Southern blotting and bisulfite sequencing analysis uncover the critical but 
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differential role that Lsh plays in facilitating de novo DNA methylation at major and 
minor satellites during differentiation from naïve mESCs to EBs. Furthermore, these 
results highlight the additional requirement for Lsh in preserving the hypermethylated 
status of minor satellites in the pluripotent ground state.  
5.2.2 Transition of 2i mESCs to EpiSCs 
5.2.2.1 Experimental strategy 
Analysis of lsh-/- EBs revealed a defect in de novo methylation of major and minor 
satellites and globally during differentiation from ground state mESCs. EBs are 
purported to be representative of the in vivo gastrulation process, due to the formation 
of all three germ layers, a primitive streak-like region and establishment of 
anteroposterior polarity (ten Berge et al., 2008). Therefore, Lsh appears to contribute 
to the establishment of DNA methylation during differentiation from the naïve 
pluripotent state to these gastrula-like structures in vitro.  
In Chapter 3, a culture system was used to examine the de novo DNA methylation that 
coincides with transition from 2i mESCs to serum mESCs, where 2i mESCs 
represented a naïve state of pluripotency and serum mESCs purportedly reflected a 
slightly later primed state that retains expression of naïve pluripotency markers, but 
also exhibits upregulated expression of lineage-associated factors. Investigation into 
the impact of absence of Lsh on de novo DNA methylation demonstrated that Lsh is 
not required for global establishment of DNA methylation during this transition. 
Therefore, I aimed to use a culture model that reflected an intermediate developmental 
state between serum mESCs and EBs to further deduce the exact developmental 
timepoint when Lsh is required to facilitate DNA methylation during the genome-wide 
establishment of 5-mC in the epiblast during implantation. 
EpiSCs can be isolated from the post-implantation epiblast and maintained in culture 
as an in vitro model of a truly primed pluripotent state (Brons et al., 2007; Tesar et al., 
2007; Nichols and Smith, 2009). EpiSCs can also be generated in vitro from mESCs 
continuously cultured in the presence of Activin A and FGF2 (Guo et al., 2009). 
EpiSCs represent a developmentally and functionally distinct state from mESCs. They 
retain a degree of developmental potency as they have the capacity to differentiate into 
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multiple lineages in vitro, retain expression of core pluripotency factors Oct4 and Sox2 
and are able to contribute to chimera formation when grafted into post-implantation 
embryos in culture (Guo et al., 2009; Huang et al., 2012; Kojima et al., 2014). 
However, they are unable to efficiently contribute to chimera formation at the 
blastocyst stage - considered as a benchmark of functional pluripotency. EpiSCs are 
therefore proposed to reflect a more developmentally advanced state than mESCs, 
equivalent to the post-implantation epiblast (Huang et al., 2012). 
Similar to the post-implantation epiblast, EpiSCs are globally hypermethylated 
(Senner et al., 2012; Habibi et al., 2013; Veillard et al., 2014). In vitro differentiation 
from mESCs to EpiSCs shares some epigenetic features with the equivalent process in 
vivo, such as DNA methylation establishment at one copy of the X chromosome in 
female cells (Guo et al., 2009). Therefore, I aimed to explore the impact of Lsh deletion 
on the establishment of DNA methylation that occurs during this transition in vitro. To 
achieve this, hypomethylated E14 and lsh-/- mESCs adapted to 2i for 15 days (six 
passages) were cultured continuously in the presence of Activin A and FGF2 on a 
fibronectin-coated surface to differentiate them to EpiSCs (Figure 5.9). This involved 
maintaining cultures for multiple passages until robust, stably-growing EpiSC cultures 
had been established, usually taking 4-6 weeks. Morphological changes were assessed 
to monitor the transition of 2i mESCs to EpiSCs, as well as key transcriptional changes 
involving pluripotency and lineage-specific genes that are reported to change upon 
transition to a post-implantation developmentally restricted state in vitro and in vivo 





Figure 5.9. Schematic illustrating the transition of 2i mESCs to EpiSCs following 
continuous culture in FGF2 and Activin A. Key changes in expression of naïve 
pluripotency factors and early lineage specification markers are shown, as well as 
changes in DNA methylation. 
5.2.2.2 E14 and lsh-/- 2i mESCs change morphologically during transition to 
EpiSCs 
Mouse ESCs undergo extensive morphological changes during the transition to 
EpiSCs. The morphology of EpiSCs is similar to that of differentiated cells, as they 
exhibit growth in monolayers of flattened, irregularly-shaped cells (Guo et al., 2009). 
At the start of the EpiSC transition, ground state E14 and lsh-/- mESCs exhibited typical 
2i morphology as described previously, although the lsh-/- mESCs to a slightly lesser 
extent (Figure 5.10, left panels). Both E14 and lsh-/- mESCs displayed clear 
morphological changes throughout the transition to EpiSCs that resulted in a 
population of cells displaying the morphological characteristics of differentiated cells 
– flattened, irregularly-shaped cells that grow in a monolayer rather than in colonies 
(Figure 5.10, right panels). The populations of EpiSCs display a degree of 
morphological heterogeneity, particularly well-illustrated in the brightfield image of 
E14 EpiSCs in which a variety of cell morphologies are visible including large single 
cells, three-dimensional colonies of cells and cells with neuronal-like projections 
(indicated by the arrows in Figure 5.10). This morphological variation is consistent 
with previous reports that EpiSCs in culture represent a heterogeneous population of 
cells displaying a degree of transcriptional and functional variation (Han et al., 2010; 
Kojima et al., 2014; Tsakiridis et al., 2014). Overall, both E14 and lsh-/- 2i mESCs 
display clear and widespread morphological changes during the transition to EpiSCs 
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indicative of adaptation to a culture state distinct from the naïve pluripotent ground 
state. 
 
Figure 5.10. E14 and lsh-/- mESCs both exhibit morphological changes during 
transition to EpiSCs. Brightfield images of E14 and lsh-/- mESCs cultured in 2i (left 
panels) and after addition of FGF2/Activin A for 9 passages (right panels). Arrows 
highlight morphological features indicating a heterogeneous culture – three-dimensional 
colonies, neuronal-like projections and large single cells. Scale bars represent 100 µm. 
5.2.2.3 E14 and lsh-/- mESCs exhibit mRNA expression changes indicative 
of transition to EpiSCs 
The transcriptomes of naïve mESCs and EpiSCs are distinct. Although EpiSCs retain 
expression of core pluripotency factors Oct4 and Sox2, they are devoid of expression 
of all naïve pluripotency factors, except for low levels of Nanog expression (Guo et 
al., 2009; Kojima et al., 2014). This loss of naïve pluripotency marker expression is 
accompanied by transcriptional upregulation of lineage-specific genes, resulting in an 
expression profile similar to that of the post-implantation epiblast (Guo et al., 2009; 
Huang et al., 2012; Kojima et al., 2014). Therefore, expression of key pluripotency 
and lineage markers were evaluated during the transition from 2i mESCs to EpiSCs to 
assess whether conversion to a cell state reflective of post-implantation development 
had occurred. qRT-PCR expression analysis for two biological replicates (Rep 1 and 




The mRNA expression of key naïve pluripotency factors Nanog and Klf4 was 
measured in E14 and lsh-/- 2i mESCs and EpiSCs by qRT-PCR. This demonstrated 
similarly relatively high expression of Nanog and Klf4 in both E14 and lsh-/- mESCs 
adapted to 2i, although there are differences in the Nanog and Klf4 mRNA levels 
between the two biological replicates. Upon transition to EpiSCs, Nanog expression 
was largely attenuated in both E14 and lsh-/- cells despite the initial expression level 
differences, although a slightly higher level of Nanog expression was retained in lsh-/- 
EpiSCs compared to E14 in the first biological replicate (Figure 5.11 A). Concurrently, 
mRNA levels of Klf4 were reduced to an almost undetectable level in both biological 
replicates of E14 and lsh-/- EpiSCs. Transcriptional downregulation of these two key 
naïve pluripotency markers indicate an exit from ground state pluripotency, suggesting 





Figure 5.11. E14 and lsh-/- cells display transcriptional changes in key genes 
following transition to EpiSCs. Assessment of mRNA expression by qRT-PCR of key 
pluripotency genes (A) and lineage-associated factors (B) in E14 and lsh-/- cells before 
and after transition to EpiSCs. Results from two biological replicates are shown 
independently for each cell line and culture condition and are labelled as Rep 1 and Rep 
2. All genes are normalised to TBP expression. Error bars represent +/- propagated 
standard deviation of three technical replicates. N.D. = not detected.  
Transcriptional silencing of naïve pluripotency factors upon transition of mESCs to 
EpiSCs coincides with upregulation of lineage associated genes, such as Fgf5, an 
ectodermal marker expressed in the early post-implantation epiblast, and the early 
endodermal marker Foxa2 (Tesar et al., 2007; Guo et al., 2009; Kojima et al., 2014). 
In 2i E14 and lsh-/- mESCs, levels of Fgf5 and Foxa2 mRNA are extremely low in both 
biological replicates (Figure 5.11 B). During transition to EpiSCs, expression of these 
lineage-associated factors is massively upregulated in E14 EpiSCs. Fgf5 and Foxa2 
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mRNA levels were upregulated to a similar degree in the second biological replicate 
for lsh-/- EpiSCs. However, although Fgf5 and Foxa2 expression is hugely increased 
in the first replicate of lsh-/- EpiSCs compared to the corresponding 2i mESCs, they 
are not upregulated to the same extent as in E14 EpiSCs or the other lsh-/- EpiSC 
biological replicate. Indeed, for the first biological replicate, there is a 10-fold 
difference in Fgf5 mRNA levels between E14 and lsh-/- EpiSCs and a 3.5-fold 
difference in Foxa2 expression (Figure 5.11 B, Rep 1). Coupled with the incomplete 
repression of Nanog in the first biological replicate for lsh-/- EpiSCs observed in Figure 
5.11 A, this suggests that the transition to a transcriptional state reflective of the post-
implantation epiblast was impaired in the first biological replicate.  
Despite the much reduced scale of Fgf5 and Foxa2 upregulation in lsh-/- EpiSCs 
compared to E14 in the first biological replicate, the general trend of expression 
changes in these factors is the same between the E14 and lsh-/- across both biological 
replicates. Taken together with the downregulation of Nanog and Klf4 in E14 and lsh-
/- EpiSCs, and the apparent morphological changes exhibited by both cell lines, there 
appears to be a degree of transition to an EpiSC-like state in both E14 and lsh-/- cells 
for both biological replicates.  
5.2.2.4 Global DNA methylation levels are reduced in lsh-/- 2i mESCs and 
EpiSCs compared to E14 
To examine the impact of the absence of Lsh on global DNA methylation 
establishment during transition of 2i mESCs to EpiSCs, total 5-mC levels were 
measured by LC-MS in E14 and lsh-/- 2i mESCs and EpiSCs. The average percentage 
methylation of the two biological replicates shown in Figure 5.11 is presented in Figure 
5.12. Consistent with the global DNA methylation LC-MS data shown in Figure 5.5, 
a significant difference in 5-mC levels of approximately 22% between E14 and lsh-/- 
2i mESCs is evident (Figure 5.12). Following transition to EpiSCs, there is also a 
significant difference of 18% between E14 and lsh-/- cultures. This demonstrates 
impaired establishment or maintenance of global DNA methylation in the absence of 
Lsh in 2i mESCs and EpiSCs, implying that Lsh is required for wild-type global DNA 
methylation levels in these culture states. Furthermore, the size of the error bars 
apparent in Figure 5.12, representing the standard error of the mean of the two 
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biological replicates, indicates that the global DNA methylation levels are very similar 
between biological replicates despite the differences in expression of key pluripotency 
and lineage-associated factors shown in Figure 5.11. This suggests that the changes in 
global DNA methylation levels that occur during transition of 2i lsh-/- mESCs to 
EpiSCs occur independently of the changes in expression of key pluripotency and 
lineage-associated genes. 
 
Figure 5.12. Global DNA methylation levels are not fully established in lsh-/- 
EpiSCs. Measurement of global 5-mC levels by LC-MS in E14 and lsh-/- 2i mESCs and 
EpiSCs. Error bars represent +/- standard error of two biological replicates. P-values 
indicate level of significance between 2i and EpiSC E14 and lsh-/- cells as measured by 
a two-way unpaired t-test. 
5.2.2.5 DNA methylation establishment at major and minor satellites is 
impaired in the absence of Lsh during transition to EpiSCs 
To investigate whether a similar defect in de novo methylation of major and minor 
satellites was apparent during differentiation to of lsh-/- 2i mESCs to EpiSCs, I used 
the methylation-sensitive MaeII and HpaII digests combined with Southern blotting 
as described previously, using DNA from the first biological replicate shown in Figure 
5.11. MaeII digestion of genomic DNA from E14 and lsh-/- 2i mESCs revealed similar 
levels of DNA hypomethylation in these samples, concurrent with the same digest 
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shown in Figure 5.6 A (Figure 5.13 A). However, a dramatic reduction in DNA 
methylation at MaeII sites was apparent in lsh-/- EpiSCs compared to E14, 
demonstrated by the increased presence and intensity of lower molecular weight bands 
(indicated by the arrows in Figure 5.13 A). Digestion of genomic DNA from these 
cells with HpaII, which is generally indicative of global DNA methylation, agreed 
with marked DNA hypomethylation of lsh-/- EpiSCs observed in the MaeII digest 
(Figure 5.13 A). Furthermore, the HpaII digest corroborated the LC-MS results, 
indicating that global 5-mC levels are slightly lower in lsh-/- 2i mESCs compared to 
E14.   
To provide a more comprehensive estimation of 5-mC levels at major and minor 
satellites in E14 and lsh-/- EpiSCs, the MaeII and HpaII digests were again coupled 
with Southern blotting using probes for these repetitive sequences. Hybridisation of 
MaeII digests using a probe for major satellites strengthened the observation that while 
these regions become hypermethylated in E14 EpiSCs, DNA methylation 
establishment at major satellites is severely impaired in lsh-/- EpiSCs (Figure 5.13 B). 
Analysis of the 5-mC status of minor satellites using a probe for these sequences on 
the HpaII digests revealed a similar pattern of DNA methylation of these regions as 
shown previously in Figure 5.7 B. Again, a striking hypomethylation of minor 
satellites in lsh-/- 2i mESCs was evident (Figure 5.13 C). This reduction in DNA 
methylation at minor satellites in the absence of Lsh was not recovered following 
transition to EpiSCs, which also showed substantial hypomethylation in lsh-/- cells 





Figure 5.13. Major and minor satellites are hypomethylated in lsh-/- EpiSCs. A. 
Agarose gel displaying DNA from E14 and lsh-/- 2i mESCs and EpiSCs restriction 
digested by MaeII, HpaII or MspI restriction enzyme, as indicated. B. Southern blot of 
MaeII digests displayed on agarose gel in (A) using probe against major satellite 
sequences. C. Southern blot of HpaII and MspI digests shown on gel in (A) using probe 
against minor satellite sequences. 
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The CpG methylation status of major and minor satellite repeats in E14 and lsh-/- 
EpiSCs was quantified at base pair resolution using bisulfite sequencing. The bisulfite 
sequencing plots from serum and 2i mESCs originally shown in Figure 5.8 are repeated 
here for comparative purposes. E14 EpiSCs exhibited a CpG methylation level of 76% 
at major satellites, comparable to those observed in serum E14 mESCs (Figure 5.14 
A). However, as suggested by the Southern blotting analysis, establishment of DNA 
methylation was severely impeded in lsh-/- EpiSCs, which exhibited only 24% CpG 
methylation at major satellites. This is far lower than the 55% CpG methylation 
apparent in lsh-/- 2i mESCs, indicating that not only has DNA methylation not been 
established at major satellites during differentiation to EpiSCs, it was actually lost at 
these regions in the absence of Lsh. This implies a role for Lsh beyond that of 
promoting de novo methylation at pericentromeric repeats during post-implantation 
development, suggesting that it may also contribute to maintenance of methylation at 
these regions.  
At minor satellites, E14 EpiSCs displayed very high 5-mC levels of 93%, similar to 
those of serum E14 mESCs and slightly higher than 2i E14 mESCs (Figure 5.14 B). 
In contrast, lsh-/- EpiSCs showed a markedly reduced level of DNA methylation of 
56%. This was higher than the hypomethylated minor satellite sequences in lsh-/- 2i 
mESCs, which exhibit only 21% DNA methylation, suggesting that partial DNA 
methylation establishment had occurred during differentiation to EpiSCs in the 
absence of Lsh. Therefore, these results suggest that although partial establishment of 
DNA methylation occurs during differentiation from 2i mESCs to EpiSCs in the 
absence of Lsh, full DNA methylation establishment requires the presence of Lsh. 
These bisulfite sequencing results from EpiSCs mirror the findings from EBs, 
reinforcing the proposal that Lsh is required for full establishment of DNA methylation 
at major and minor satellites during differentiation from naïve pluripotency to a more 




Figure 5.14. Lsh is required for WT levels of DNA methylation at major and minor 
satellites in EpiSCs. Quantification of major (A) and minor (B) satellite DNA methylation 
in E14 and lsh-/- serum and 2i mESCs and EpiSCs by bisulfite sequencing. Filled circles 
represent methylated CpGs while unfilled circles are unmethylated CpGs. Number of 
CpGs assayed is shown at the top of each plot. Percentage of methylated CpGs is 
displayed under each plot. 
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Collectively, these DNA methylation analyses provide further evidence for the crucial 
role that Lsh plays in facilitating DNA methylation at major and minor satellites and 
globally during the establishment of DNA methylation that occurs during 
differentiation. Furthermore, these results suggest that this critical function of Lsh is 
required during the transition to EpiSCs, prior to the gastrulation stage of development 
that EBs represent. This implies that Lsh contributes to the initial wave of de novo 
DNA methylation that occurs largely in the implanting blastocyst and the early post-
implantation epiblast during embryonic development. 
5.2.3 Transcriptome profiling of E14 and lsh-/- EpiSCs 
Since lsh-/- EpiSCs exhibit DNA hypomethylation globally and at specific repeat 
sequences, I sought to investigate whether absence of Lsh also has an effect on gene 
expression patterns in EpiSCs. Therefore, gene expression profiles of E14 and lsh-/- 
EpiSCs were generated using RNA-seq from three biological replicates for each cell 
line, with bioinformatic analysis of the RNA-seq datasets performed by Dr Donncha 
Dunican. 
5.2.3.1 The transcriptional profiles of EpiSCs are distinct from mESCs 
To examine the degree of variation between the gene expression profiles of E14 and 
lsh-/- EpiSCs and the mESCs from which they were generated, PCA was undertaken. 
The transcriptional profiles of three biological replicates for E14 and lsh-/- EpiSCs 
were compared to the single RNA-seq replicate generated for serum and 2i E14 and 
lsh-/- mESCs, which were analysed in depth in Chapter 4. This revealed that the 
principal component of variation (85%) between the transcriptional profiles of mESCs 
cultured in serum or 2i and EpiSCs, highlighting the extensive remodelling of gene 
expression patterns that occurs during transition from ground state mESCs to EpiSCs 
(Figure 5.15). Furthermore, it demonstrates that transcriptional profiles cluster based 
on cellular state rather than the genotype, as shown for the PCA of gene expression 
profiles in Chapter 4. The secondary component of variation is accounted for by the 
differences between the transcriptomes of serum and 2i mESCs, indicating that the 




Figure 5.15. The transcriptional profiles of E14 and lsh-/- mESCs and EpiSCs 
principally cluster based on cellular state. PCA of gene expression profiles for serum 
and 2i E14 and lsh-/- mESCs and EpiSCs. Each replicate for EpiSCs is plotted 
individually. 
5.2.3.2 Genes involved in developmental processes are mis-expressed in 
lsh-/- EpiSCs 
To further investigate whether there are any differences in gene expression in EpiSCs 
lacking Lsh, the transcriptional profiles of lsh-/- EpiSCs were plotted against E14 
EpiSCs and presented in a scatter plot. This uncovered over 1000 genes upregulated 
more than two-fold in lsh-/- EpiSCs and over 900 genes downregulated more than two-
fold (Figure 5.16 A). GO term analysis of the upregulated genes demonstrated a 
significant enrichment in terms associated with developmental processes (Figure 5.16 
B). Interestingly, there are also a number of terms linked with neuron development, as 
well as an enrichment in upregulated genes involved in behaviour. Many terms that 
are enriched in the GO analysis of the upregulated genes are also found in the GO 
analysis of the downregulated genes, such as “cell differentiation” and “multicellular 
organismal process” (Figure 5.16 C). GO terms associated with development dominate 
the enrichment analysis of the downregulated genes, alongside terms closely linked to 
developmental processes such as “anatomical structure morphogenesis”. These results 
reveal that genes involved in the regulation of cell and organism development are mis-
expressed in the absence of Lsh in the context of EpiSCs. However, at this level of 




Figure 5.16. Lsh influences expression of genes involved in developmental 
processes in EpiSCs. A. Scatter plot comparing transcriptional profiles of E14 and lsh-
/- EpiSCs. Genes upregulated more than two-fold are highlighted in blue, genes 
downregulated more than two-fold are shown in orange. Axes represent log2(read counts 
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per 10 million) for the sample indicated on each axis.  Genes with read counts below 5 
were excluded. B. GO term enrichment analysis of genes upregulated more than two-
fold in lsh-/- EpiSCs. C. GO term enrichment analysis of genes downregulated more than 
two-fold in lsh-/- EpiSCs. GO analysis generated using the biological processes filter of 
the GOrilla analysis tool.  Top ten significant GO terms are shown in both B and C. 
5.2.4 Summary of DNA methylation perturbations in the absence of Lsh 
Investigation into the impact of Lsh deletion on global and local DNA methylation 
levels across a variety of culture models has revealed specific requirements for Lsh in 
facilitating DNA methylation that are dependent on developmental context. The DNA 
methylation perturbations in the absence of Lsh across the culture models utilised in 
this study are summarised in Table 5.1. It highlights the specific requirement for Lsh 
in ground state mESCs to facilitate DNA methylation of minor satellites, while 
cytosine methylation of major satellites is most dependent on Lsh in EpiSCs. Overall, 
Lsh generally appears to be required to establish WT levels of DNA methylation at 
both major and minor satellites, as well as globally, following differentiation from 
ground state pluripotency. Additionally, I have explored the effect of mutation of 
human homologue HELLS in a somatic cell context and demonstrated that this results 
in global DNA hypomethylation (presented in Appendix Figure A2). This indicates 
that, as anticipated, the mouse and human homologues of Lsh share a common function 
in facilitating DNA methylation, and that the roles of Lsh in DNA methylation during 





Genomic region exhibiting DNA hypomethylation in 
an lsh-/- context 
Culture model Global Major satellites Minor satellites 
Serum mESCs No No No 
2i mESCs Yes No Yes - severe 
Reversion mESCs No No* No* 
EB -RA Yes Yes – moderate Yes - moderate 
EB +RA Yes Yes – moderate Yes - moderate 
EpiSC Yes Yes – severe Yes - moderate 
Human somatic 
cancer cell line 
Yes** - - 
Table 5.1. Table summarising DNA hypomethylated genomic regions in lsh-/- cells 
compared to the corresponding E14 sample.  
* = data that has not been presented in this thesis 
** = data shown in Appendix Figure A2 
5.2.5 Lsh is transcriptionally downregulated during differentiation  
Lsh is ubiquitously expressed at low levels throughout multiple tissues in adult mice, 
but exhibits specific enrichment in tissues with high proliferation and differentiation 
capacities, such as testis, thymus and bone marrow (Raabe et al., 2001). However, Lsh 
is more broadly expressed at high levels in multiple mouse embryonic tissues, 
suggesting a more general role for Lsh throughout the developing embryo (Geiman et 
al., 2001; Raabe et al., 2001). I sought to determine Lsh expression across the culture 
models of pluripotency and post-implantation development that I had utilised in this 
study to determine whether the apparent contribution of Lsh to DNA methylation 
establishment coincided with transcriptional upregulation of Lsh. qRT-PCR analysis 
of three technical replicates from one biological replicate for each culture condition is 
presented in Figure 5.17. In fact, Lsh expression appears to decrease following 
differentiation to EpiSCs and EBs, where its absence has the most notable effect on 
global and satellite DNA methylation levels (Figure 5.17). Lsh expression is higher in 
the pluripotent culture states, particularly so in ‘primed’ mESCs cultured in serum, 
where its mRNA levels are almost two-fold higher than in naïve 2i mESCs. The 
potential reasons and significance for the apparent enrichment of Lsh in pluripotent 




Figure 5.17. Lsh is transcriptionally downregulated upon differentiation. 
Assessment of mRNA expression by qRT-PCR of Lsh in E14 mESCs cultured in serum 
or 2i, and after differentiation to EpiSCs or EBs. All genes normalised to TBP expression. 
Error bars represent +/- propagated standard deviation of three technical replicates. 
5.3 Discussion 
In this chapter, I aimed to dissect the requirement for Lsh in facilitating DNA 
methylation during differentiation. To achieve this, I transitioned E14 and lsh-/- 2i 
mESCs to EBs and EpiSCs to examine the role of Lsh in the establishment of DNA 
methylation that accompanies the transition from the hypomethylated ground state to 
these hypermethylated, more developmentally restricted culture states. This revealed 
an apparent requirement for Lsh in establishing DNA methylation at major and minor 
satellites during differentiation. Previous reports into the function of Lsh in de novo 
DNA methylation during differentiation focused on the establishment of 5-mC at 
specific genomic loci in EBs generated in the presence of RA (Xi et al., 2009; Ren et 
al., 2015). The work presented in this chapter extended this analysis to examine global 
DNA methylation levels as well as specific repetitive regions. I also assessed 
establishment of DNA methylation in EBs generated in the absence of RA, and 
importantly, in EpiSCs following differentiation from 2i mESCs. This acted to narrow 
down the developmental window where the function of Lsh in influencing DNA 
methylation levels and patterns becomes relevant. Furthermore, exploration of DNA 
methylation patterns at centromeric and pericentromeric repeats uncovered differential 
regulation of DNA methylation by Lsh at these regions, with the genomic regions 
171 
 
affected by DNA hypomethylation in the absence of Lsh varying depending on cellular 
context. 
5.3.1 Global and local DNA methylation defects following differentiation to 
EBs and EpiSCs 
Analysis of global 5-mC levels in E14 and lsh-/- EBs and EpiSCs that had been 
differentiated from 2i mESCs revealed a significant reduction of 18-20% in global 
DNA methylation levels in the absence of Lsh. This implies that the establishment of 
de novo DNA methylation is impeded in absence of Lsh during differentiation to EBs 
and EpiSCs. Interestingly, LC-MS analysis also revealed that lsh-/- 2i mESCs exhibited 
significantly reduced global 5-mC levels (16-22%) prior to differentiation. This points 
to a previously unappreciated role for Lsh in regulating global DNA methylation levels 
in naïve pluripotency. However, it also makes it difficult to deduce whether the DNA 
hypomethylation observed in lsh-/- EpiSCs and EBs is due to a defect in de novo DNA 
methylation, or due to a pre-existing reduction in DNA methylation levels. Southern 
blotting and bisulfite sequencing analysis of DNA methylation levels at major and 
minor satellites provided further evidence to assist the interpretation of these global 
DNA methylation results. At major satellites, no DNA hypomethylation was apparent 
in lsh-/- 2i mESCs compared to E14, yet upon differentiation to EBs DNA methylation 
levels increased in E14 EBs, whereas this increase did not occur in lsh-/- EBs. Since 
there was no DNA hypomethylation at major satellites prior to differentiation in lsh-/- 
2i mESCs, this suggests that, at least at these genomic regions, attenuation of de novo 
methylation is the causative factor resulting in reduced 5-mC levels at major satellites 
in EBs. This implies that, at least at some genomic regions, the global hypomethylation 
evident in the absence of Lsh following differentiation cannot be accounted for by pre-
existing DNA hypomethylation in lsh-/- 2i mESCs.  
The significant difference in global 5-mC levels between E14 and lsh-/- 2i mESCs 
observable by LC-MS in this chapter was not evident in the LC-MS data presented in 
Chapter 3 (Figure 3.9). This inconsistency between the LC-MS datasets could be 
explained by a number of technical and biological factors. For the 5-mC measurements 
displayed in this chapter, the LC-MS protocol, spectrometry and data analysis methods 
had been improved, increasing the specificity and ability to detect more nuanced 
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differences in 5-mC content. This could account for the difference that is now apparent 
in lsh-/- 2i mESCs that was not evident previously.  
The difference in 5-mC content between E14 and lsh-/- 2i mESCs that was not observed 
initially could also be explained by the extended period of culture that the mESCs in 
this chapter had undergone compared to the mESCs used in earlier analysis. This may 
have resulted in a progressive loss in DNA methylation due to impaired maintenance 
methylation since the deletion of Lsh, a phenomenon that has been described for 
Dnmt3a/3b-/- double null mESCs (Jackson et al., 2004). This highlights a potential role 
for Lsh in maintenance of DNA methylation globally in the ground state of 
pluripotency, a concept that has been supported by the analysis of DNA methylation 
at major and minor satellites presented in this chapter. 
5.3.2 Lsh contributes to de novo DNA methylation during transition to 
EpiSCs 
The main aim of work presented in this chapter was to narrow down the developmental 
window where Lsh function becomes relevant for influencing DNA methylation 
establishment during development. Since the absence of Lsh did not affect the 
establishment of DNA methylation during transition from hypomethylated ground 
state 2i mESCs to hypermethylated primed serum mESCs, I transitioned 2i mESCs to 
culture states representing later developmental time points. First, I differentiated 2i 
mESCs to EBs, which are proposed to represent the gastrulation stage of embryonic 
development where establishment of DNA methylation is purported to influence and 
reinforce cell fate decisions during germ layer specification. Here, I demonstrated that 
Lsh was required to establish WT levels of DNA methylation globally and at satellite 
repeats in EBs generated in the presence and absence of RA. This indicated that Lsh 
facilitates establishment of DNA methylation between the naïve state of pluripotency 
and the gastrula stage of development. I then transitioned 2i mESCs to EpiSCs to 
determine whether this failure to establish DNA methylation was apparent at the earlier 
post-implantation stage of development that EpiSCs are purported to reflect. Indeed, a 
similar degree of global and local satellite hypomethylation was evident in lsh-/- 
mESCs, suggesting that Lsh primarily acts during this earlier developmental stage 
where genome-wide patterns of DNA methylation are being deposited and cell potency 
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restriction is being established following implantation of the blastocyst. This indicates 
a previously uncharacterised role for Lsh is contributing to global DNA methylation 
patterns during the early post-implantation stages of development.  
5.3.3 Differential regulation of DNA methylation at satellite repeats is 
dependent on developmental context 
The analysis of the 5-mC status of major and minor satellites revealed that DNA 
methylation of these repetitive elements is differentially regulated by Lsh in different 
cellular contexts. In the absence of Lsh in 2i mESCs, minor satellites were severely 
hypomethylated, whereas there was no effect on DNA methylation levels at major 
satellites. Conversely, DNA methylation levels were drastically reduced at major 
satellites in lsh-/- EpiSCs compared to E14, and moderately reduced in EBs. This 
uncovers an interesting feature of Lsh function in differentially influencing DNA 
methylation at specific genomic loci in different developmental contexts, shedding 
light on the mechanisms underlying repeat methylation during the early stages of 
development.   
5.3.4 Role for Lsh in maintenance methylation? 
The extent of DNA hypomethylation at major and minor satellites in the absence of 
Lsh is too considerable to be explained by defective de novo DNA methylation alone. 
Indeed, the level of 5-mC at major satellites in lsh-/- EpiSCs is far below that of the 2i 
mESCs from which they were differentiated, suggesting that not only has there been a 
lack of de novo methylation at these sequences during differentiation to EpiSCs, DNA 
methylation has actually been lost from these regions during this transition. 
Furthermore, the severe hypomethylation observed at minor satellites in the absence 
of Lsh is specific to 2i mESCs, where de novo DNA methylation is largely attenuated 
due to transcriptional downregulation of the de novo DNMTs. This leads to the 
assumption that the DNA hypomethylation observed at these repetitive elements arises 
due to impaired maintenance methylation and progressive loss of 5-mC over 
subsequent cell divisions. Therefore, these analyses provide further insights into the 




5.3.5 Lsh influences expression of developmental genes in EpiSCs 
Comparative analysis of E14 and lsh-/- EpiSC transcriptional profiles uncovered nearly 
2000 genes that are up or down-regulated more than two-fold in the absence of Lsh. 
GO term analysis of the biological processes in which these genes are involved 
revealed an enrichment in terms associated with cell and organism development for 
both up- and down-regulated genes. In particular, there was an enrichment in terms 
associated with the specification, differentiation and development of neurons in the 
GO analysis of upregulated genes. This demonstrates the de-regulation of pathways 
involved in neuronal development in the absence of Lsh, implicating Lsh in the 
processes of neuron lineage specification and development. Indeed, absence of Lsh has 
been previously reported to affect expression of neuron lineage-associated markers 
during differentiation, influencing the propensity of lsh-/- iPSCs and ESCs to 
differentiate towards this lineage (Yu, Briones, et al., 2014; Han et al., 2017). 
These results indicate that the function of Lsh influences expression of developmental 
genes in this culture model of post-implantation development. This could have 
implications for the specification and establishment of germ layers in the 
developmental stages subsequent to the post-implantation epiblast. This analysis 
highlights an intriguing possible function for Lsh, however further investigation is 
required to deduce the effect that Lsh has on lineage-specific factor expression and 
developmental progression. 
5.3.6 Lsh expression is enriched in pluripotent cell states 
Expression analysis of Lsh across the various pluripotent and differentiated culture 
models used in this study revealed that Lsh is most highly expressed in pluripotent 
culture states, is transcriptionally downregulated upon transition to EpiSCs, and is 
further reduced following differentiation to EBs. Lsh is most highly expressed in serum 
E14 mESCs, where it is almost two-fold upregulated compared to 2i mESCs. This 
appears to be counter-intuitive, as absence of Lsh had no apparent effect on global or 
local satellite DNA methylation levels in serum mESCs. One possible explanation for 
this is that the low levels of Lsh present in differentiated cells are sufficient to influence 
DNA methylation levels in these cellular contexts, and that the higher expression of 
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Lsh observed in pluripotent cells is related to an alternative function for Lsh in these 
systems. An alternative explanation is that Lsh acts indirectly to influence DNA 
methylation levels in differentiated EpiSCs and EBs. In this case, the higher Lsh 
expression observed in 2i mESCs, and particularly in serum mESCs which supposedly 
represent a slightly later developmental state, could act to prepare genomic regions 
that will subsequently become cytosine methylated upon transition to post-
implantation stages of development. This preparation could involve a mechanism 
whereby chromatin state is altered, potentially through the putative chromatin helicase 
activity of Lsh, or through modification of histone modifications. This altered 
chromatin state in the epiblast prior to implantation could subsequently influence the 
genomic regions that acquire 5-mC during the wave of de novo DNA methylation 
during implantation of the blastocyst. This potential function of Lsh will be discussed 





Chapter 6. General discussion 
The overarching purpose of the work undertaken in this thesis was to provide insight 
into the fundamental, yet not fully understood, epigenetic mechanisms involved in the 
transition from a pluripotent to a more developmentally primed cellular state during 
the early stages of murine embryonic development. Specifically, I aimed to evaluate 
the involvement of selected factors in the establishment of DNA methylation during 
the cellular transitions that accompany the progression towards lineage commitment 
during early embryogenesis. I predominantly focussed on the function of DNA 
methylation co-factor and putative chromatin remodelling helicase Lsh in these 
cellular transitions, utilising in vitro culture systems to model the developmental stages 
encompassing the reduction in cellular potential and the concomitant increase in global 
DNA methylation establishment. Using these culture models that represented 
pluripotent and developmentally primed states enabled investigation into the impact 
of absence of Lsh on transitions between cellular states and, importantly, the effect on 
the genome-wide establishment of DNA methylation that accompanies these 
transitions.  
Firstly, I optimised a culture system in which to study the establishment of de novo 
DNA methylation during the transition of E14 and lsh-/- mESCs between two 
pluripotent culture states. The analysis of expression changes of a few key 
pluripotency and lineage-associated genes, alongside the quantification of global DNA 
methylation levels, suggested that both E14 and lsh-/- mESCs can effectively transition 
between the hypomethylated ground state of pluripotency (2i) and the 
hypermethylated, primed state of pluripotency (serum). This indication was reinforced 
by analysis of genome-wide transcription and DNA methylation profiles which further 
demonstrated the ability of both E14 and lsh-/- mESCs to interconvert between the 
pluripotent serum and 2i culture states. Crucially, and somewhat surprisingly, these 
global and local analyses revealed that the absence of Lsh does not affect the re-
establishment of DNA methylation patterns during reversion from the pluripotent 
ground state, suggesting that Lsh does not contribute to de novo DNA methylation in 
a pluripotent context. 
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To further investigate the role of Lsh in the establishment of DNA methylation that 
occurs during the restriction of cell fate potential associated with differentiation and 
germ layer specification, I used culture models representing later developmental 
stages. E14 and lsh-/- 2i mESCs were differentiated to EpiSCs and EBs, which revealed 
a critical requirement for Lsh in contributing to DNA methylation during transition to 
these cell types, as DNA methylation levels were significantly reduced globally and at 
major and minor satellites in lsh-/- EpiSCs and EBs. A particularly striking decrease in 
DNA methylation was evident at the pericentromeric major satellites in lsh-/- EpiSCs, 
highlighting an important function for Lsh in contributing to DNA methylation at these 
repetitive regions in a culture model of post-implantation development. This is 
consistent with the observation of DNA hypomethylation of satellite repeats first 
described in mutant lsh-/- mouse models and subsequently HELLS-dependent ICF 
syndrome (Dennis et al., 2001; Sun, David W Lee, et al., 2004; De La Fuente et al., 
2006; Dunican et al., 2013; Ren et al., 2015; Thijssen et al., 2015). 
These investigations into DNA methylation levels globally and at satellite repeats in 
the absence of Lsh also revealed a reduction in DNA methylation globally and at minor 
satellites in 2i lsh-/- mESCs, where de novo DNMT activity is low. This provides 
evidence for a relatively uncharacterised role for Lsh in maintenance of DNA 
methylation at specific genomic loci, dependent on the cellular context. Overall, the 
findings presented in this thesis have resulted in the following main conclusions (also 
summarised in Figure 6.1): 
• Lsh contributes to DNA methylation globally and at satellite repeats in 
culture models representing ground state pluripotency and post-implantation 
development 
• Lsh differentially regulates DNA methylation at major and minor satellites 




Figure 6.1. Schematic summarising the main findings of this thesis. The methylation 
status of major and minor satellites in lsh-/- serum and 2i mESCs, EpiSCs and EBs is 
depicted diagrammatically, with the orange arrows indicating DNA hypomethylation at 
these sequences when compared to the equivalent E14 cells.  One arrow indicates 
moderate DNA hypomethylation, while two arrows indicates severe hypomethylation. A  
reduction of global DNA methylation in lsh-/- cultures compared to E14 is also indicated 
in each culture state. The possible involvement of Lsh in de novo or maintenance 
methylation within culture states or during transition to EBs or EpiSCs is also indic ated. 
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6.1 Technical considerations 
The lsh-/- mESC line used throughout this study was generated using the first iteration 
of CRISPR/Cas9 gene editing methodology. This involves targeting WT Cas9 
nuclease to the desired genomic locus using a sgRNA, which is engineered to contain 
an approximately 20-base sequence complementary to the genomic DNA target, next 
to a PAM site. This induces a double strand break at the intended locus, which is 
repaired by non-homologous end-joining (NHEJ). This error-prone repair process 
leads to the introduction of insertion/deletion mutations (indels), which can disrupt the 
translational reading frame of a coding sequence, resulting in loss of gene function 
(Ran et al., 2013; reviewed by Sander and Joung, 2014). This technique has provided 
a valuable tool to quickly and effectively edit the genome of a range of eukaryotic cell 
culture systems. However, CRISPR/Cas9 gene editing using this method is also 
associated with the occurrence of off-target mutations, where Cas9 is directed to 
unintended genomic targets that show high sequence similarity to the desired target 
(Tsai and Joung, 2016). 
Towards the end of the study presented in this thesis, an off-target mutation was 
discovered in the CRISPR-generated lsh-/- mESCs. The top two genic and top two 
intergenic off-target sites (as predicted by the CRISPR sgRNA design software and 
outlined in Table 6.1) were inspected for off-target mutations using Sanger 
sequencing. I found no mutations in the top two intergenic sites and the Myh7b gene 
(data not shown). However, a 17 bp deletion at the site of the Tbkbp1 gene was 
uncovered (Figure 6.2 A). This mutation was an out-of-frame deletion in exon 3 of the 
gene, resulting in a premature stop codon. This gene, also known as Sintbad, encodes 
an adaptor protein which is proposed to be involved in interferon signalling during the 
innate immune response to viral infection (Ryzhakov and Randow, 2007). I checked 
the expression of this gene in serum and 2i mESCs and EpiSCs using the RNA-seq 
datasets generated from these samples. Compared to Lsh expression as a reference, 
Tbkbp1 is very lowly expressed in the culture models utilised throughout this study 




Chromosomal region Gene 
No. of mismatches 
compared to guide 
chr11:97,010,011-97,010,033 Tbkbp1 2 
chr11:107,604,794-107,604,816 N/A 2 
chr16:98,203,202-98,203,224 N/A 4 
chr2:155,454,888-155,454,910 Myh7b 3 
Table 6.1. Details of genomic regions predicted to be the most likely unintended 
targets of the Lsh sgRNA used to generate lsh-/- mESCs. 
 
Figure 6.2. Off-target mutation in CRISPR-generated lsh-/- mESCs. A. Sanger 
sequencing analysis showing alignment of Tbkbp1 exon 3 in E14 and lsh-/- mESCs, 
revealing a 17 bp deletion in lsh-/- mESCs. Highlighted region indicates the 20 bp 
sequence showing similarity to the intended target of the sgRNA in Lsh exon 1. B. RNA-
seq data showing mRNA expression levels of Lsh and Tbkbp1 in serum and 2i E14 
mESCs and EpiSCs. 
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Since the Tbkbp1 gene is not thought to be involved in any DNA methylation 
mechanisms and is lowly expressed in the mESC culture models used in this study, the 
off-target mutation in this gene should not have impacted any of the results generated 
in this study. Furthermore, the global and repeat DNA hypomethylation that I have 
uncovered using the CRISPR-generated lsh-/- mESCs has been previously reported in 
Lsh-depleted murine embryonic tissues and somatic cells, validating the findings 
presented in this thesis. However, further experiments should also be performed in the 
future to confirm that this off-target mutation did not affect any of the results generated 
throughout this project. A rescue experiment where Lsh is re-expressed in lsh-/- mESCs 
prior to 2i adaptation and differentiation to EpiSCs and EBs would verify that the 
observed DNA hypomethylation and gene mis-expression is caused by the ablation of 
Lsh. These findings could be further validated using an independently generated lsh-/- 
mESC line, as was intended by the derivation of mESCs from lsh-/- mouse blastocysts 
described in Chapter 3, Section 3.2.2. Overall, although further experiments could 
corroborate the findings presented in this thesis and fully mitigate the uncertainties 
associated with the presence of an off-target mutation in the CRISPR-generated lsh-/- 
mESCs, the fact that Tbkbp1 is very lowly expressed in the culture models I use and 
is reported to function in an entirely different cellular process to DNA methylation 
establishment suggests that a mutation in this gene does not appear to contribute to the 
results generated throughout this study. However, it serves as a warning that CRISPR 
technology can produce unintentional off-target gene editing that can complicate 
mutational analysis. 
6.2 Lsh contribution to DNA methylation during early development 
Lsh has been convincingly demonstrated to contribute to DNA methylation during 
development, as its deletion in mice results in substantial DNA hypomethylation 
globally and at specific genomic loci in embryonic tissues and somatic cells (Dennis 
et al., 2001; Sun, David W Lee, et al., 2004; Zhu et al., 2006; Tao et al., 2011; Yu, 
Briones, et al., 2014). Due to the high expression of Lsh in pluripotent cells and its 
proposed function in de novo DNA methylation, I hypothesised that Lsh contributes to 
the wave of de novo DNA methylation that occurs in the early stages of development 
during implantation of the blastocyst (Zhu et al., 2006; Xi et al., 2009; Termanis et al., 
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2016). Initially, I used the genome-wide re-establishment of DNA methylation that 
occurs during reversion from the hypomethylated ground state to investigate the role 
of Lsh in de novo DNA methylation in a pluripotent context reminiscent of pre-
implantation development. It was surprising to discover that the absence of Lsh had no 
impact on the global re-establishment of DNA methylation that occurs during 
reversion from the pluripotent ground state. Genome-wide analysis of serum and 
reversion E14 and lsh-/- mESC DNA methylation profiles further revealed that lack of 
Lsh did not affect the distribution of DNA methylation following reversion, but rather 
emphasised the high degree of similarity of 5-mC profiles between reverted and serum 
mESCs in both E14 and lsh-/- backgrounds. These experiments lead to the initial 
conclusion that, despite its high expression in pluripotent cells, Lsh does not contribute 
to DNA methylation establishment in a pluripotent context. This also implies that Lsh 
does not partake in the early stages of de novo DNA methylation establishment in the 
implanting blastocyst.  
The adoption of this culture system to examine the involvement of other epigenetic 
factors in the de novo re-methylation of the genome revealed that Dnmt3l is required 
for DNA methylation establishment during transition from 2i to serum culture. This 
indicates that Dnmt3l is required for de novo methylation initiating from the 
pluripotent ground state, consistent with its essential function in de novo DNA 
methylation and silencing of genomic imprints and retrotransposons (Bourc’his et al., 
2001; Hata et al., 2002; Bourc’his and Bestor, 2004; Kaneda et al., 2004). However, 
although the DNA hypomethylation apparent in Lsh-depleted embryos indicates that 
Lsh contributes to DNA methylation during development, it appears not to be required 
for the de novo DNA methylation that initiates from this early developmental stage. 
This highlights the distinct signatures of epigenetic factors that are required for DNA 
methylation establishment in different cellular contexts. 
To determine whether Lsh facilitates DNA methylation establishment during transition 
to culture models representing later developmental stages, 2i E14 and lsh-/- mESCs 
were differentiated to EBs and EpiSCs. Global DNA methylation analysis by LC-MS 
revealed a failure to establish WT levels of DNA methylation in the absence of Lsh in 
both EBs and EpiSCs, indicating the involvement of Lsh in de novo DNA methylation 
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establishment that occurs during differentiation of 2i mESCs to culture models 
reflective of post-implantation stages of development. However, this LC-MS analysis 
also revealed a significant difference in global 5-mC levels between 2i E14 and lsh-/- 
mESCs prior to differentiation. Indeed, comparison of genome-wide DNA methylation 
profiles of 2i E14 and lsh-/- mESCs highlighted the loss of methylation at more than 
30,000 CpGs, most of which reside in intronic and intergenic genomic regions, 
although a proportion are located within LINE-1 subfamilies. This is consistent with 
many studies which demonstrate DNA methylation loss at LINE-1 elements in lsh-/- 
embryonic tissues and somatic cells (Dennis et al., 2001; Dunican et al., 2013; Yu, 
McIntosh, et al., 2014; Ren et al., 2015). However, analysis of the 5-mC profiles of 2i 
lsh-/- mESCs has revealed that hypomethylation of LINE-1 repeats observed in somatic 
tissues and cells may have persisted from the pre-implantation stage of development. 
Similarly, analysis of the CpG methylation status of minor satellites by bisulfite 
sequencing and methylation-sensitive restriction digestion coupled with Southern 
blotting uncovered a striking loss of 5-mC at these repeats in 2i lsh-/- mESCs compared 
to E14. This minor satellite hypomethylation was partially maintained following 
differentiation to EpiSCs and EBs, providing further evidence that some of the 
hypomethylation observed in later developmental stages could have originated from 
the pre-implantation epiblast.  
Although interesting, the reduced level of 5-mC observed globally and at specific 
genomic regions in 2i lsh-/- mESCs made it more difficult to delineate whether the 
global DNA hypomethylation observed in lsh-/- EBs and EpiSCs is a result of a defect 
in de novo DNA methylation in the absence of Lsh, or is due to the reduced 5-mC level 
evident in 2i lsh-/- mESCs prior to differentiation. However, bisulfite sequencing and 
methylation-sensitive Southern blotting analysis of CpG methylation at major 
satellites showed a similar level of 5-mC at these sequences in 2i E14 and lsh-/- mESCs, 
whereas a striking reduction in major satellite DNA methylation was evident in the 
absence of Lsh following transition to EpiSCs. This demonstrates that, at least at some 
genomic loci, the DNA hypomethylation observed at later developmental stages is not 
due to a pre-existing lack of DNA methylation at these regions earlier in development. 
To further deduce to what extent the global DNA hypomethylation observed in lsh-/- 
EBs and EpiSCs is caused by impaired de novo methylation in the absence of Lsh, a 
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regulatable expression vector could be used to rescue Lsh expression in 2i lsh-/- 
mESCs. This would presumably also rescue the DNA hypomethylation observed in 2i 
lsh-/- mESCs, meaning that global DNA methylation levels would be comparable 
between 2i E14 and lsh-/- mESCs prior to differentiation. Lsh expression could then be 
down-regulated during differentiation to EpiSCs and EBs, meaning that any DNA 
hypomethylation observed in lsh-/- EpiSCs and EBs could be attributed specifically to 
the function of Lsh in DNA methylation establishment during differentiation.  
Overall, the results presented throughout this thesis demonstrate a previously 
uncharacterised role for Lsh in modulating DNA methylation in pre-implantation and 
post-implantation development. These analyses provide the first characterisation of 
Lsh contribution to DNA methylation in the pluripotent ground state and in an EpiSC 
culture model. More in-depth analysis of DNA methylation profiles using a technique 
with increased genome coverage compared to ERRBS would provide further insight 
into the genomic regions at which DNA methylation is regulated by Lsh during early 
development. Furthermore, temporal regulation of Lsh expression using a regulatable 
expression system would allow dissection of the contribution of Lsh to DNA 
methylation in culture models representing distinct developmental stages.  
6.3 A role for Lsh in maintenance methylation during 
development? 
Lsh is proposed to predominantly contribute to de novo DNA methylation rather than 
maintenance methylation. Lsh was shown to be required for DNA methylation 
establishment on episomal vectors introduced into MEFs, while it was not required for 
methylation maintenance of already methylated episomes (Zhu et al., 2006). Lsh is 
thought to facilitate de novo DNA methylation primarily through its interaction with 
Dnmt3b. This has been demonstrated during differentiation of mESCs to EBs, where 
depletion of Lsh has been reported to reduce the association of Dnmt3b with certain 
genomic targets such as the Oct4 gene promoter as well as specific repeat elements, 
resulting in impaired de novo methylation at these regions during differentiation (Xi 
et al., 2009; Ren et al., 2015). The role of Lsh in maintenance methylation is less well 
characterised. Lsh has been shown to interact directly with Dnmt1 and facilitate its 
association with chromatin (Myant and Stancheva, 2008; Dunican, Pennings and 
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Meehan, 2015). However, Lsh was also shown to be dispensable for the recruitment 
of Dnmt1 to replication foci during S phase (Yan et al., 2003).  
The analysis of major and minor satellite DNA methylation in mESCs and EpiSCs has 
provided further evidence for a role for Lsh in maintenance methylation during 
development. There is a dramatic reduction of 5-mC at minor satellites in 2i lsh-/- 
mESCs compared to E14. Furthermore, the percentage CpG methylation at major 
satellites in lsh-/- EpiSCs is less than half of that of 2i lsh-/- mESCs, indicating that not 
only is there a failure to establish DNA methylation at these repeats during transition 
to EpiSCs, DNA methylation is lost from these regions during the transition. This 
suggests that Lsh is required for maintenance methylation at these repetitive sequences, 
although this function is dependent on cellular context. Therefore, it would be 
interesting to assess the association of Dnmt1 with these satellite repeats in these 
different cellular contexts in the presence and absence of Lsh. This would provide 
further insights into the mechanism by which Lsh promotes maintenance of DNA 
methylation at these regions during development. 
6.4 Influence of Lsh on gene expression during development 
Expression analysis of a few key lineage-associated and DNMT genes by qRT-PCR 
demonstrated that the mRNA levels of these genes in serum lsh-/- mESCs represent an 
intermediate expression level between those observed in serum and 2i E14 mESCs. 
Further analysis and comparison of the transcriptomes of these three mESC cultures 
discovered a larger (775) subset of genes that exhibit this intermediate expression level 
in serum lsh-/- mESCs between that of E14 serum and 2i mESCs, with GO term 
enrichment analysis demonstrating that many of these genes are involved in signalling 
and sensory perception. This indicates that Lsh may act to influence expression of 
genes associated with developmentally-related processes in a pluripotent context. 
Indeed, depletion of Lsh has been reported to result in de-repression of selected Hox 
genes and stem cell-associated factors in MEFs and EBs (Xi et al., 2007, 2009; Tao et 
al., 2010).  
This initial indication that Lsh influences the transcriptional regulation of genes 
involved in developmental processes was reinforced by GO analysis of the genes that 
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are mis-expressed in lsh-/- EpiSCs compared to E14. This revealed an enrichment in 
genes involved in cellular differentiation and development as well as genes associated 
with morphogenetic transformations that occur during development. Interestingly, 
although Lsh is generally associated with transcriptional repression due to its 
contribution to de novo methylation of selected gene promoters (Myant and Stancheva, 
2008; Ren et al., 2017), a relatively similar number of genes are downregulated as 
there are upregulated in lsh-/- EpiSCs compared to E14 (904 vs 1017, respectively). Of 
the genes that were upregulated more than two-fold in lsh-/- EpiSCs, there was a 
significant enrichment of genes involved in neuron fate specification and 
differentiation, suggesting a skew in differentiation towards the neuronal lineage could 
occur at later developmental stages. This is consistent with a previous report 
demonstrating an increased propensity of lsh-/- iPSCs to differentiate towards the 
neuronal lineage, which is accompanied by increased expression of some neuronal 
genes in lsh-/- iPSCs (Yu, Briones, et al., 2014). Therefore, it appears that Lsh could 
contribute to the regulation of key genes involved in development and cell fate 
decisions, influencing the cellular plasticity and differentiation potential of cells during 
early development. The generation and analysis of DNA methylation profiles of lsh-/- 
EpiSCs would uncover whether the aberrant transcription patterns evident in these 
cells are a result of gene promoter or enhancer DNA hypomethylation, or whether Lsh 
influences gene expression through an uncharacterised indirect or DNA methylation-
independent mechanism.  
The primary target of Lsh is repetitive elements, and depletion of Lsh has been shown 
to result in transcriptional reactivation primarily of IAP elements, although de-
repression of other repetitive sequences such as minor and major satellites is also 
reported in embryonic tissues and somatic cells (Sun, David W Lee, et al., 2004; 
Dunican et al., 2013; Yu, McIntosh, et al., 2014). It would therefore be interesting to 
assess whether there is transcriptional de-repression of repetitive elements during 
earlier developmental stages through transcriptome analysis of lsh-/- mESCs and 
EpiSCs. Evaluation of major and minor satellite expression in these contexts would 
uncover whether a substantial loss of DNA methylation at these repeats results in 
reactivation of gene expression, or whether redundant silencing mechanisms exist, as 
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has been described for some repeat sequences such as LINE-1 elements in lsh-/- MEFs 
(Dunican et al., 2013). 
6.5 Lsh expression during development 
The analysis of Lsh expression in the culture models I utilised throughout this study 
demonstrated that Lsh is most highly expressed in mESCs, and is downregulated upon 
transition to EpiSCs, and even more so in EBs. This result was unsurprising, as Lsh 
has been previously reported to be highly expressed in pluripotent cells and 
downregulated during development, leading to a reduced but ubiquitous expression 
pattern throughout the mouse embryo and somatic tissues (Raabe et al., 2001; Xi et 
al., 2009). The human homologue of Lsh, HELLS, was also identified as one of 40 
genes that is consistently highly expressed across 38 human ESC transcriptome 
datasets, suggesting that the elevated expression of Lsh in a pluripotent context is 
conserved and is in fact characteristic of ESCs (Assou et al., 2007). This may seem 
counter-intuitive, as the effect of absence of Lsh on global DNA methylation appears 
to be more prominent at later stages of embryonic development, as a 50% decrease in 
global 5-mC is evident in lsh-/- embryos, compared to the approximate 20% reduction 
in global DNA methylation levels that I show in lsh-/- 2i mESCs, EpiSCs and EBs (Tao 
et al., 2011; Yu, Briones, et al., 2014). This apparent enhanced DNA hypomethylation 
at later developmental stages could be explained by impaired maintenance methylation 
in the absence of Lsh. In this scenario, high levels of Lsh in WT pluripotent cells could 
act to facilitate de novo DNA methylation during exit from pluripotency, before being 
down-regulated during differentiation. The lower expression levels apparent in 
differentiated cells could be sufficient to assist maintenance of DNA methylation 
throughout subsequent cell divisions. Indeed, the majority of genes identified as 
drivers and facilitators of exit from pluripotency from a number of large-scale screens 
have been shown to be more highly expressed in the pluripotent ground state, and are 
then down-regulated upon exit from pluripotency (Kalkan and Smith, 2014). Another 
possibility is that the high expression of Lsh in a pluripotent context is due to a DNA 
methylation-independent function of Lsh, perhaps linked to the high rate of 
proliferation of pluripotent cells, as the expression of Lsh has been shown to be most 
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prominent in highly proliferative cells such as T and B lymphocytes (Jarvis et al., 
1996; Raabe et al., 2001). 
6.6 Lsh function in DNA methylation and chromatin formation at 
repetitive elements 
The main genomic regions affected by DNA methylation loss in the absence of Lsh 
are satellite DNA and dispersed repeat elements, to the extent that Lsh has been 
referred to as an ‘epigenetic guardian’ of repetitive elements (Huang et al., 2004). One 
of the proposed mechanisms of the regulation of DNA methylation at repeats by Lsh 
involve its putative chromatin remodelling activity (Geiman et al., 2001; Meehan, 
Pennings and Stancheva, 2001). Lsh has been proposed to promote heterochromatin 
formation through its ATP-dependent nucleosome remodelling activity, acting to 
regulate access of DNMTs to certain genomic loci (Meehan, Pennings and Stancheva, 
2001; Ren et al., 2015, 2017). Recent reports have suggested that the nucleosome 
remodelling activity of Lsh is the primary mechanism by which it functions to 
influence DNA methylation patterns. Ren et al. (2015) demonstrated reduced 
nucleosome occupancy at IAP and LINE-1 elements following differentiation to EBs 
in the absence of Lsh, which coincides with impaired de novo DNA methylation of 
these sequences during differentiation. A further study from Ren et al. (2017) 
demonstrated the reduction in active histone marks and chromatin accessibility at an 
engineered Oct4 promoter upon Lsh binding in mESCs. Upon differentiation, the Oct4 
promoter acquires repressive H3K9me3 and DNA methylation and is subsequently 
transcriptionally silenced. This elucidates a potentially crucial mechanism by which 
Lsh alters DNA methylation establishment during differentiation, by modulating 
chromatin accessibility in order to prime certain loci for acquisition of a silent 
heterochromatin environment. It would be intriguing to assess whether this mechanism 
is applicable generally to endogenous loci in mESCs during differentiation, and to 
deduce whether this function of Lsh accounts for the DNA methylation perturbations 
observed in EpiSCs in the absence of Lsh. 
Furthermore, it would be interesting to assess the nucleosome occupancy, as well as 
the histone modification signature of the major and minor satellites that exhibit striking 
DNA hypomethylation in lsh-/- 2i mESCs and EpiSCs, as this would provide 
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mechanistic insights into the regulation of these repetitive elements in different 
developmental contexts, as well as how this acts to influence DNA methylation levels 
of these repeats. This could have implications for the disease mechanisms underlying 
ICF syndrome, in which mutations in HELLS have recently been identified as 
causative of the disease (Thijssen et al., 2015). A hallmark of ICF syndrome is 
pericentromeric chromosomal instability due to DNA methylation loss and 
decondensation of these regions, leading to characteristic rearrangements of 
chromosomes 1, 9 and 16 (Jeanpierre et al., 1993; Hagleitner et al., 2007). Dnmt3b is 
also known to account for 50% of ICF cases, indicating a common mechanism of 
action at pericentromeric repeats alongside Lsh (Hansen et al., 1999; Xu et al., 1999; 
Ehrlich et al., 2008). Investigation of the regulation of chromatin structure and DNA 
methylation by Lsh and Dnmt3b in early development using the culture models 
described in this thesis could add mechanistic understanding into the origination and 
progression of the genomic instability observed in ICF syndrome in the context of 
early murine embryonic development.  
6.7 Concluding remarks 
In this study, I have uncovered a role for Lsh in modulating DNA methylation in 
culture models reflective of early developmental stages. However, the mechanism by 
which Lsh acts to facilitate establishment or maintenance of DNA methylation in these 
culture models remains unclear. This would be the primary focus for future work, with 
emphasis on further characterisation of the role of Lsh in maintenance methylation, 
and investigation into whether the mechanism by which Lsh functions involves 
chromatin remodelling activities. Finally, evaluation of the impact of epigenetic 
regulation by Lsh on gene expression patterns during early development would provide 
insight into the influence of Lsh on developmental progression. This should add 
understanding into the mechanisms underlying the multiple physiological defects and 
postnatal lethality apparent in Lsh-deficient mouse models, which highlight the crucial 
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Figure A1. Secondary antibody-only staining. Immunofluorescence on serum E14 
and lsh-/- mESCs using secondary antibodies only. Each secondary antibody used for 
immunofluorescence analysis was assessed by secondary antibody-only staining to 
determine the level of non-specific binding and background fluorescence. The secondary 
antibody used for Nanog staining is shown in (A), the antibody for Esrrb staining is shown 
in (B), and the antibodies used for Nanog and Oct4 co-staining are shown in (C). Scale 








Figure A2. A HELLS mutant human somatic cancer cell line displays substantial 
global hypomethylation. Analysis of global 5-mC levels in a HELLS mutant human 
somatic haploid cancer-derived cell line (HAP1) (A) confirmation of HELLS mutation by 
Sanger sequencing, showing insertion of a single A (indicated by arrow) in exon 3 which 
creates a premature stop codon. (B) LC-MS analysis of global DNA methylation in WT 
and HELLS mutant HAP1 cells. Error bars represent +/- standard error of three biological 
replicates. 
 
 
